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Abstract 
 
Background:  
Antiretroviral (ARV) treatment of HIV infection is associated with 
disturbances in body fat distribution,  dyslipidaemia , insulin resistance 
and diabetes. The exact mechanisms of these changes have not been fully 
understood.  
Fat redistribution with loss or accumulation of excess fat in different 
regions can be associated with changes in adipocytokines. The 
adipocytokines also play key roles in glucose and fat metabolism. 
 
Objective:  
To investigate the effect of HIV infection and ARV on apolipoprotein-B 
(apo-B) metabolism and body fat distribution. 
To investigate the effect of adiponectin and other cytokines on apo-B 
metabolism, lipid changes, insulin resistance and body fat distribution. 
 
Methods                                                                                                                                            
We performed a cross sectional study on 67 subjects who were HIV 
positive (n=55), or presumed HIV negative controls (n=12). The subjects 
were treatment naïve (n=15) or taking two nucleoside analogues plus 
either a protease inhibitor (PI, n=15), or a non-nucleoside reverse 
transcriptase inhibitor (NNRTI, n=25) for between 1 – 6 years.  
Apo-B kinetics and lipid composition were measured following an infusion 
of a stable isotope 13C leucine after an overnight fast. Body fat distribution 
was measured by whole body dual energy X-ray absorptiometry (DEXA) 
scan and expressed in terms of lean body mass (LBM). Plasma adiponectin 
and leptin were measured by radioimmunoassay and cytokines levels 
were measured in a multiplex bead sandwich immunoassay. 
Insulin Resistance was calculated using the Homeostasis Assessment 
Model (HOMA IR).. The apo-B kinetics were calculated using a 
multicompartmental model with an intrahepatic delay function. 
  
Results 
1. Apo-B kinetics: The very low density lipoprotein (VLDL), Intermediate 
density lipoprotein (IDL) and low density lipoprotein (LDL) apo-B fractional 
clearance rate (FCR) was reduced (p=0.005)  with longer circulating 
residence time of the different apo-B containing particles  in the three 
lipoprotein compartments in all the HIV positive groups compared to HIV 
negative controls (p=0.05). The HIV positive treatment groups had mild 
dyslipidaemia. The treatment naïve group and the HIV-negative control 
group did not have any difference in serum triglyceride (TG) and total 
cholesterol (TC). Compared to the control subjects, PI-treated patients 
exhibited raised serum TG, LDL cholesterol (LDL-C) and IDL cholesterol 
(IDL-C) that was not exhibited by nevirapine (NVP) or efavirenz (EFV) 
treatment groups. The delay in the clearance of apo-B was more marked 
in patients taking PI containing ritonavir.   
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2. Body fat distribution, insulin resistance and apo-B kinetics: Trunk fat, 
VLDL apoB absolute secretion rate (ASR), and insulin resistance were not 
different between groups. Peripheral fat was lower in the treated patients 
(P < 0.05) and correlated with duration of therapy (r = –0.55; P <0.001). 
There was a positive correlation between peripheral fat and VLDL apo-B 
FCR (P= 0.002) and IDL apo-B FCR (P=0.002) and a negative correlation 
with VLDL apo-B pool size, VLDL cholesterol (VLDL-C), and triglyceride (P 
=0.03; P = 0.01; P = 0.002). 
3. Effect of adiponectin and cytokines on apo-B metabolism, body fat 
distribution: Adiponectin (median [interquartile range]) was reduced in 
treatment naïve (5.4 µg/ml, [4.7-8.5]), PI (5.0 µg/ml [3.3-6.4]) and 
NNRTI (5.0 µg/ml, [3.1-6.7]) groups compared to controls (9.7 µg/ml 
[6.9-13.3], p<0.05). In all subjects adiponectin correlated positively with 
high density lipoprotein-cholesterol (HDL-C), VLDL, IDL and LDL apo-B 
FCR and limb fat/lean body mass (all p<0.01) and correlated negatively 
with plasma TG and HOMA (p<0.001).  In a linear regression model which 
included HOMA, adiponectin level but not HOMA was predictive of VLDL, 
IDL and LDL apoB FCR and HDL cholesterol (all p<0.05). Other cytokines 
including TNF-alpha (α), IL-6, IL-8, and leptin did not have any effect on 
apo-B metabolism.   
 
Conclusion  
This thesis highlights that in patients with mild dyslipidaemia reduced 
VLDL, IDL and LDL apoB FCR and consequently an increased circulating 
residence time of apo-B containing lipoproteins may be a primary 
abnormality in lipoprotein kinetics in HIV infection, possibly consequent to 
body fat redistribution. The same abnormalities were also found in 
patients treated with either a PI, or NNRTI containing HAART regimens. 
The association of apo-B FCR with regional fat distribution suggests a 
common mechanism for lipodystrophy and abnormal VLDL, IDL and LDL 
metabolism. The latter may be due to a decrease in lipoprotein lipase, 
down regulation of the LDL receptor or a combination of all these. 
Adiponectin may have a direct effect on lipoprotein metabolism, 
independent of insulin action. The increased residence time of apo-B 
conatining lipoproteins will lead to increased LDL oxidation and 
atherogenesis thus contributing to the increased risk for cardiovascular 
disease (CVD) reported in these patient populations.   
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Chapter 1 
General Introduction 
 
Section 1: HIV, AIDS and treatment 
1.1.1 HIV overview 
Incidence of Human Immunodeficiency Virus (HIV) infection had grown to 
pandemic proportions soon after the first cases of acquired 
immunodeficiency syndrome (AIDS) were reported in 1981. Over 33 
million people are now living with HIV in the world and in 2007 there were 
2.7 million new HIV infections and 2 million HIV-related deaths world  
wide [1].  
The estimated number of people living with HIV in the UK has increased 
from just over 16,000 in 1990 to over 77,000 in 2007with more than a 
quarter (28 per cent) unaware of their infection [2]. HIV continues to be 
one of the most important communicable diseases in the UK. It is an 
infection associated with serious morbidity, high costs of treatment and 
care, significant mortality and number of potential years of life lost. 
1.1.2 Basic virology 
Human retroviruses HIV-1 and HIV-2 are members of the family of human 
retroviruses (Retroviridae) [3, 4]. They present as RNA viruses whose 
hallmark is the reverse transcription of genomic RNA to DNA by the 
enzyme reverse transcriptase. HIV-1 is the most common cause of AIDS 
worldwide. HIV-2 has been identified predominantly in western Africa[5]. 
It has around 40% sequence homology with HIV-1 type, but the prognosis 
of HIV-2 infection is much better than HIV-1.  
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Like any virus, HIV must use the cells of another organism – its host – to 
survive and reproduce.  
 
1.1.3 Viral replication cycle                                                                             
Human immunodeficiency virus (HIV) is adapted to use the cells of the 
human immune system. The life cycle inside the host cells, CD-4 and 
macrophages has been summarised in the figure (figure 1.1)[6].   
The virions enter the blood stream of a new host. A protein on the surface 
of the virus called gp120[7], has a high affinity for the CD4 receptor found 
on cells circulating in the blood called CD4+ or T helper cells. The virion 
attaches to the host cell. This binding is strengthened further by a co-
receptor on the cell surface, called chemokine co-receptor type-5 (CCR-5) 
and CXC chemokine receptor type-4 (CXR-4)[8].                                                                                                    
Once the virion has been bound to the host cell surface, its next task is to 
get inside. This is achieved through the fusion of the virus coat and the 
cell membrane.                                                                                            
Following fusion, the genetic material of the virus, which is RNA, is 
released into the cell, along with the viral enzymes, reverse transcriptase 
and integrase [9-11]. Reverse transcriptase reads the viral RNA and builds 
the corresponding DNA strands. The DNA copy is known as a provirus. 
Viral DNA then moves to the cell nucleus, where the cell’s own genes, also 
made of DNA, are present. The viral enzyme, integrase, splices the 
strands of DNA into the host cell genome and helps the integration of the 
virion into the host genome [12-14].                                                                                                         
The proviral DNA can persist for many years in a latent state. When the 
host cell is activated as during cell division, the proviral DNA transcribes 
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into RNA, which is then translated into viral proteins and polyproteins. 
Together, the RNA and these proteins then migrate to the inside of the 
host cell membrane, where they assemble into new virions.                                                     
Among the viral proteins is the enzyme, protease, which cleaves the 
polyproteins into smaller, functional proteins, thereby, allowing the new 
viral particles to mature [11]. Following assembly, the newly formed 
virions bud from the host cell surface, entering the bloodstream where 
they encounter uninfected CD4+ cells and begin another cycle.  
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Figure 1.1: The replication cycle of HIV [6] (Adapted from Fauci et al, 1996) 
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1.1.4. Pathophysiology and natural history of the disease  
(figure 1.2)                                                    
The most common mode of transmission of HIV involves deposition of HIV 
on mucosal surfaces, especially the genital mucosa [15, 16]. Direct 
inoculation into the blood through intravenous (IV) needle sharing is also 
a common mode of HIV transmission [17]. Vertical transmission from 
mother to child is another mode of transmission [18, 19]. Following 
successful transmission of HIV from one individual to another, the course 
of subsequent infection is quite variable and dependent on a number of 
factors.  
Throughout the course of HIV disease the virus replicates continuously. Up 
to 10 billion virions are produced and cleared every day. The half-life of an 
HIV-infected CD4 cell is about 1.3 days [20]. Most CD4 cells turn over 
rapidly, but some belong to a latent pool with a long half-life and the virus 
can remain there in a latent phase. Virus-specific CD4 cells, which are 
critical in maintaining an effective host immune response in chronic viral 
infections, are present early in HIV infection but are generally lost over 
time [21]. The patient's immune system keeps pace with this activity 
during the relatively clinical latent period. However, in the absence of 
effective antiretroviral treatment, the immune system ultimately reaches a 
point at which viral replication exceeds its ability to produce CD4 cells. 
The viral replication rates reach such a magnitude that lymphoid tissues 
are completely destroyed or nearly destroyed and this leads to a decline in 
immunologic function and the development of clinical disease 
manifestations, including opportunistic infections and neoplasms [20]. The 
rate of viral replication is thought to stabilize after primary infection at a 
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particular level or "set point"; this level may be maintained within a ten-
fold range over months and possibly years.  
Viruses or virus populations that can use only the chemokine co-receptor 
(CCR) -5 are termed R5 viruses and viruses or virus populations that can 
use only the CXCR4 chemokine co-receptor are termed X-4 viruses [22, 
23]. Viruses using both populations are termed as dual type and the viral 
population containing both R5 and X4 or dual type are called mixed type. 
During the early stage of HIV-1 infection (as determined in subtype B 
HIV-1 infections), the R5 virus predominates. Over 80% of individuals 
with early stage HIV-1 infection have R5 virus. However, as HIV-1 disease 
progresses, the prevalence of CXCR4-utilizing viruses gradually increases. 
About 50% of people with HIV-1 that progress to AIDS demonstrate only 
R5 virus throughout the entire course of HIV-1 disease. The presence of 
X4 viruses has been associated with accelerated disease progression and a 
decrease in CD4 cells, but despite descriptions of in vitro cyto-
pathogenicity of X4 viruses, no causal in vivo relationship or mechanism 
for this association has been proven. The role of different population of 
CD-4 cells either R5 or X4 or mixed type may have effect on metabolic 
changes, but has not been described yet.  
Throughout the disease huge amounts of cytokines are liberated and the 
types and nature of the cytokines can vary at different stages. These 
cytokines may have effects on the different vital functions including the 
metabolic changes in the body. 
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Figure 1.2: Typical course of an untreated HIV-infected individual[24].  
 
         :   HIV RNA level             :  CD-4 count 
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1.1.5. Treatment of HIV 
The treatment of HIV infection is complex and changes rapidly as 
advances are made in basic science and clinical experience. Understanding 
of the different stages of viral replication and different enzymes used by 
the virus for their replication have helped to identify different agents that 
can block the function of the enzymes and therby stopping the viral 
replication inside host cells. Various events in the HIV life cycle have been 
identified as potential targets for antiretroviral therapy [11].The 
complexity of treatment regimens against HIV infection increases further 
with the rising number of available compounds and the growth in new 
information about their use [25-27].  
Drugs of five different classes (table 1.1) are currently available in the UK, 
with several others close to release [25]. Inhibitors of HIV reverse 
transcriptase and of HIV protease are so far the most developed and most 
used in clinical practice in developed countries. Newer agents of these 
classes with better efficacy against the virus and activity against 
resistance virii are in the pipeline of development. Drugs of longer half life 
with penetration in to different body compartments with less systemic side 
effects to the host are coming into production. Drugs of higher antiviral 
potency with less side effects and less number of tablets could help 
improve patiets long needed adherence to treatment and longer survival.  
 
1.1.5.1. Reverse transcriptase inhibitors [9, 10]:  
These are of three types: nucleoside analogues (nucleoside reverse 
transcription inhibitors, NRTIs), nucleotide analogues (nucleotide reverse 
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transcriptase inhibitors, NtRTIs) and non-nucleoside analogues (non-
nucleoside reverse transcriptase inhibitors, NNRTIs).  
Nucleoside analogues (NRTIs) inhibit reverse transcription by binding to 
viral DNA and also act as DNA chain terminators. NRTIs need to be 
phosphorylated intracellularly for activity to occur. These were the first 
group of agents to be used against HIV, initially as monotherapy and later 
as dual drug combinations. Usually two drugs of this class are combined to 
provide the 'backbone' of a triple or combined regimen.                               
Nucleotide analogues (NtRTIs) have a similar mechanism of action but do 
not require intracellular phosphorylation for activity. Tenofovir, a 
monophosphorylated thymidine derivative, is the only licensed compound 
of this group. 
Table 1.1: Antiretroviral drugs available in the UK [25] 
Reverse Transcriptase Inhibitors 
Nucleoside 
Reverse 
Transcriptase 
Inhibitors 
(NRTIs) 
Non-
Nucleoside 
Reverse 
Transcriptase 
Inhibitors 
(NNRTIs) 
Protease Inhibitors 
(PI) 
Entry 
Inhibitors 
Integrase 
inhibitors 
Zidovudine 
(AZT) 
Lamivudine 
(3TC) 
Didanosine (ddI) 
Stavudine (d4T) 
Abacavir (ABC) 
**Tenofovir* 
(TDF) 
**Emtricitabine 
(FTC) 
Nevirapine 
(NVP) 
Efavirenz 
(EFV) 
Delavardine 
**Etravirin 
(ETR) 
Saquinavir (SQV) 
Ritonavir(RTV) 
Nelfinavir(NFV) 
Indinavir(IDV) 
Lopinavir(LPV) 
Amprenavir(APV) 
**Atazanavir(ATV) 
**Fos-
amprenavir(FPV) 
**Daurunavir(DAV) 
**Tipranavir(TPV) 
**Enfuvirtide 
(T20) 
**Maraviroc 
**Raltegravir 
 
*NtRTI 
** These drugs were not available in the UK or licensed to use in the UK 
at the time of the study 
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1.1.5.2. Non-nucleoside analogues (NNRTIs)                                         
These drugs interfere with reverse transcriptase by direct binding to the 
enzyme and are considered as a separate class because of an entirely 
different cross-resistance pattern and different mechanism of action [28]. 
They are generally small molecules that are widely disseminated 
throughout the body and have a long half-life.  
1.1.5.3. Protease inhibitors (PIs)  
These drugs act competitively on the HIV aspartyl protease enzyme, 
which is involved in the production of functional viral proteins and 
enzymes. In consequence, viral maturation is impaired and immature 
dysfunctional viral particles are produced. There are marked differences in 
toxicity, pharmacokinetics and resistance patterns which influence 
prescribing. Cross-resistance that means development of resitance 
occurring for more than one drug at the same time is common across the 
PI group, which makes it difficult to use the drugs sequentially. There 
appears to be no activity against human aspartyl proteases (e.g. renin), 
although there are clinically significant interactions with the cytochrome P-
450 system. This is used to therapeutic advantage by using small doses of 
a PI, ritonavir that blocks the metabolism of other PIs and boosts the 
blood level of those drugs [27, 28].  
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1.1.5.4. Entry inhibitors 
Chemokine co-receptor (CCR-5) blocker: It blocks the attachment of CCR-
5 co-rectors and inhibits the virus to enter the CD-4 cells [22]. Currently 
maraviroc is a member of this class and licenced to be used in the UK. 
Enfurvitide (T20). It is a peptide derived from HIV protein, GP41 that 
inhibits GP41-mediated fusion of HIV with the target cell [28].  
1.1.5.5. Integrase inhibitors 
Raltegravir: It is an integrase inhibitor [14]. Initial results appear to be 
very much effective and are now licensed to be used in treatment 
experienced patients [25]. Recent trials in treatment naïve patients [29] 
for using in treatment of naïve patients appear to be very encouraging.  
1.1.5.6. Newer drugs [30, 31] 
Newer NRTIs include Alovudine (MIV-310), and SPD-756 which appear to 
have activity against NRTI-resistant strains.  
New NNRTIs [30-32] include TMC-278[33], RDEA 427, RDEA640[34] 
appear to have efficacy against NNRTI resistant virus and TMC -278 is 
expected to be licenced in UK by the end of 2010.  
PRO 140, a monoclonal antibody with ability work when administered 
intravenously every 3 to 4 weeks has created lot of interest in phase II 
trial [35]. 
1.1.6. Principles of treatment  
The ongoing HIV replication leads to damage of the immune system and 
progression to AIDS. The plasma HIV RNA levels reflect the magnitude of 
HIV replication. The CD4+ T-cell counts indicate the current level of 
competence of the immune system. The rates of disease progression differ 
among patients, and treatment decisions should be individualized based 
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on plasma HIV RNA levels and CD4+ T-cell counts. Maximal suppression 
of viral replication is a goal of therapy; the greater the suppression, the 
less likely the appearance of drug-resistance variants (quasispecies). The 
most effective therapeutic strategies involve simultaneous initiation of 
combinations of anti-HIV drugs active against the virus present in the 
patient’s blood. This prevents the development of any specific mutation 
leading to resitance to any particular class and helps to achieve a sutained 
viral suppression. The combinations of drugs usually of two or more 
different classes are called Highly Active Anti-Retroviral Therapy (HAART) 
or Combination Anti-Retroviral Therapy (CART). In the UK, the treatment 
is usually considered when CD-4 count drops below 350 cells per dl of 
blood [25, 26]. 
1.1.7. Toxicities of HAART  
It is well recognised that despite significant improvements in morbidity 
introduced by HAART [36], all classes of antiretroviral agents have 
multiple side effects (Table 1.2), some of which can be life threatening 
[37]. Specifically, the NRTI class has been implicated in peripheral 
neuropathy and lactic acidosis [38]. In addition, abacavir is associated 
with potentially fatal hypersensitivity reactions in ~5% of treated patients 
[39] and didanosine is associated with pancreatitis [40]. 
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Table 1.2: Adverse events of drugs [28, 37]. Bold Words:  Relatively 
common side effects 
Drug Side effects 
Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTI) 
Abacavir Hypersensitivity reaction, fever, rash, vomiting.  
Association with mitochondrial dysfunction and lactic acidosis 
Didanosine/ddI Nausea, diarrhoea, peripheral neuropathy, pancreatitis. Association 
with mitochondrial dysfunction and lactic acidosis, lipoatrophy. 
Emtricitabine (FTC) Headache, nausea, skin pigmentation 
Lamivudine (3TC) Nausea, headache, rash, peripheral neuropathy, myelosuppression, 
mitochondrial dysfunction & lactic acidosis 
Stavudine/d4T Polyneuropathy. Megaloblastic changes, mitochondrial dysfunction 
and lactic acidosis, lipoatrophy 
Zidovudine/AZT Nausea, headache, insomnia, skin and nail pigmentation, 
myelosuppression, megaloblastic changes. Association with 
mitochondrial dysfunction and lactic acidosis, lipoatrophy 
Tenofovir Hypophosphataemia, renal toxicity, osteopaenia 
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI) 
Efavirenz Rash, Stevens-Johnson syndrome, central nervous system effects 
(vivid dreams, agitation, hallucinations, and depression amongst 
others), fat re-distribution. 
Nevirapine Rash, Stevens-Johnson syndrome, hepatic toxicity 
Etravirin Rash 
Protease Inhibitors (PI) 
Atazanavir Hyperbilirubinaemia, nephrolithiasis 
Indinavir Nephrolithiasis and crystalluria, dry skin, nail dystrophy, alopecia, 
hyperbilirubinaemia, fat redistribution, raised plasma lipids, 
hyperglycaemia 
Nelfinavir Diarrhoea, fat redistribution, abnormal plasma lipids, 
hyperglycaemia 
Ritonavir Nausea/vomiting, diarrhoea, taste distortion, perioral paraesthesia, 
fat redistribution, hepatotoxicity, abnormal plasma lipids 
hyperglycaemia, pancreatitis 
Saquinavir (soft gel) Nausea, diarrhoea, abdominal pain, fat redistribution, abnormal 
plasma lipids, hyperglycaemia 
Lopinavir  Diarrhoea, nausea, fat redistribution,  abnormal plasma lipids 
Fosamprenavir Similar to amprenavir 
Daurunavir As ritonavir and indinavir with less severity 
Tipranavir Nausea, abnormal LFT, dyslipidemia 
Entry Inhibitors 
Enfurvitide (T20) Reaction at the injection site, bacterial septicaemia 
CCR-5 inhibitor 
(Maraviroc) 
Rash, abnormal liver function test 
Integrase Inhibitors 
Raltegravir Rash, abnormal liver function test 
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1.1.8 Changing spectrum of HIV disease (figure 1.3)                                                                                    
The continuous exposure of antivirals of different class with different side 
effect profile has led to a new trend of problems. Toxicity related problems 
have become an important threat to the morbidity and even mortality in 
HIV patients. Drug related serious toxicity has been found to be more 
common than AIDS or AIDS related morbidity in the era of HAART.  In a 
large multicenter randomized treatment trial setting in the USA [41], 675 
patients (11.4 per 100 person-years) developed drug related serious side 
effect described as grade 4 events and only 332 patients (5.6 per 100 
person-years) developed an AIDS events (figure 1.3). Grade-4 events, 
were defined as non-AIDS related events considered to be severe or life 
threatening[42]. Of the 272 deaths, 153 (56.2%) developed grade-4 
events, prior to death and cardiovascular disease (CVD) events were 
associated with greatest risk of death (figure 1.3). Besides cardiovascular 
disease, problems in disturbances of other organs have been recognised 
as well.  While HIV associated nephropathy (HIVAN) has become less 
common with HAART some antiretrovirals have been associated with 
significant nephrotoxicity[43]. A protease inhibitor called Indinavir [44] 
has been reported to cause kidney stones in up to 43% of HIV-infected 
patients, and tenofovir [45, 46], a reverse transcriptase inhibitor has been 
reported to be associated with Fanconi-like renal tubular injury. Liver 
disorders have been found to be more common in patients who are co-
infected with hepatitis B and C infections [47]. Mitochondrial dysfunction 
leading to pancreatitis, neuropathy and lactic acidaemia has been found to 
be more common with some nucleoside analogues like stavudine and 
didanosine [48].  There is a greater incidence of osteoporosis in HIV-
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infected women, both pre- and post-menopausal [49-53]. In a review of 
20 cross-sectional studies, there was a 3.7 fold increased risk of 
osteoporosis in HIV positive individuals compared to HIV-ve population. 
Some reports suggest that effect in bone mineral density is more 
commonly associated with PI use [49, 51]. Skin rash and liver toxicity is 
more common with nevirapine [28].  
 
Figure 1.3: Spectrum of HIV related serious illness: incidence of grade 4 
events is higher than that of AIDS defining illnesses. CVD events were 
associated with greatest risk of death [41].  
 
 
 
1.1.9. Risk of cardiovascular disease (CVD) in HIV (table 1.3, figure 
1.4) 
There is a significant body of evidence suggesting that exposure to 
HAART, primarily Protease Inhibitors (PI)s [54-56], may be associated 
with a measurable increase in cardiovascular events (table 1.3). The 
French Hospital Database on HIV found that patients who are treated with 
PI for more than 30 months had twice the risk of developing MI than 
those with less drug exposure [56].  A review of claims for more than 
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28,000 HIV patients of younger age group (18-33 years) who were 
exposed to anti retroviral agents had twice the risk of CVD seen among 
age-matched, treatment naïve patients [57]. Klein et al [58] reported that 
the rate of hospitalisation for coronary artery disease among HIV patients 
regardless of whether on HAART or not was more than twice among their 
uninfected counterparts. The Data Collection on Adverse Events of Anti-
HIV Drugs (D:A:D) Study Group recently reported outcomes 
demonstrating an increased incidence of myocardial infarction (MI) that 
was proportional to the cumulative duration of HAART(figure 1.4a), 
particularly PIs [54].  After adjusting for conventional risk factors, low 
HDL-cholesterol, total cholesterol and duration of exposure of HAART were 
associated with increased risk of CVD (figure 1.4b). There was a 16% 
increased risk of MI per additional year of HAART exposure over the first 
seven years of use [54].  The study very recently has suggested that 
recent use of abacavir and didanosine is associated with a higher risk of 
developing myocardial infarction, but not with stroke (figure 1.4c)[59]. 
The Frankfurt HIV-cohort study [60] showed increased incidence of 
myocardial infarctions in HIV-infected patients after HAART was 
introduced. However, there was no specific association with any particular 
class of drugs.  
In a study conducted at Johns Hopkins University, cardiovascular event 
rates in a cohort of 2671 HIV-infected patients were approximately three 
times higher than expected compared with national coronary heart disese 
(CHD) and CVD event rates [61]. The traditional risk factors including age, 
hypertension and diabetes played an important role.The recently 
presented SMART (Strategies for Management of Anti-Retroviral Therapy) 
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study has shown excess risk of cardiovascular disease (CVD) among 
patients receiving intermittent antiretroviral therapy [62].  Sub analysis of 
the same study [63, 64] has shown that treatment interruptions were 
associated with lowering of all lipids including both total and HDL 
cholesterol levels, but rise of inflammatory and coagulation markers to a 
high magnitude which correlated with increase in HIV RNA level [65].  This 
leaves the reasons for observed elevated risk of cardiovascular events still 
uncertain, but inflammatory and atherogenic factors, such as pro-
inflammatory cytokines driven by uncontrolled viral replication, may play 
an important role [66]. 
Uncontrolled viral replication may have effects as well. Further evidence of 
a pro-inflammatory role for HIV may be found in the results of the ACTG 
(AIDS Clinical Trials Group) A5102 study, which found that although 
interrupting antiretroviral therapy (ART) resulted in rapid improvements in 
lipid profiles, the risk of CVD increases [67]. In contrast some studies did 
not provide evidence of an association between ART and increased CVD 
events or mortality. The HIV Out Patient Study (HOPS) [68] found no 
association of CVD with specific antiretroviral (ARV) agents or classes but 
found a significantly increased association with the traditional risk factors. 
In a retrospective study [69] of CVD risk in 36,766 HIV-infected patients 
comprising a database of the Department of Veterans Affairs (VA), the 
rates of CVD hospital admissions and death did not increase with exposure 
to ART over 8.5 years. However, initiation of ART was correlated with a 
decline in overall morbidity and mortality. 
Taken together, these data and some other data suggest that a small but 
significant and increasing risk exists for cardiovascular disease related to 
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HIV infection with or without antiretroviral use. The actual number of 
cardiovascular events remains small and must be placed in the overall 
perspective of the benefit of antiretroviral (ARV) therapies on immune 
function. However, the risk may rise with aging of the HIV population and 
longer duration of ARV exposure and metabolic abnormalities. 
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Table 1.3 Antiretroviral therapy and risk of CVD (CVD= cardiovascular disease; CHD=coronary heart disease;MI=myocardial 
infarction; HTN=hypertension;DM= diabetes mellitus; TC=total cholesterol; MI=myocardial infarction, P=prospective; 
R=retrospective) [54-56, 58, 60, 63, 69-72]  
Study Number Study Event ARV Effect Traditional Risk Factors 
D:A:D [54, 55] 23,490 P 345 MI cART and PI Yes Smoking, age, gender, HTN, DM 
French [56]  34,976 R 49 MI PI Yes Age 
Medi-Cal [57] 28,513 R NA ART Risk with ART in 
18-33 year olds 
Not evaluated 
Kaiser [58]  4408 R 86 MI PIs Risk of HIV+ vs 
HIV- 
No risk on PI 
Not evaluated 
Frankfurt [60] 4993 R 29 MI ART Yes Age < 40 y 
SMART [62] 54472 P 63 CHD Intermittent ART No – stopping 
therapy led to 
complication 
Age 
John Hopkins 
[61]  
2671 Case 
Control 
43 CHD HIV+ vs HIV- Yes Age, HTN, DM 
HOPS [68] 1807 P 84 CV 
events 
Specific ARVs No Age >40 y, diabetes, HTN 
VA [69] 36,766 R 1,207 
CHD 
ART or PI No Not evaluated 
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Figure 1.4a: Incidence of myocardial infarction relative to duration of HAART in the D:A:D 
Study [54]. A small increase in incident CVD is associated with duration of HAART 
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Figure 1.4 b: Influence of HAART and lipids on CVD events (adapted from     
D:A:D study [54]) 
 
 
Figure 1.4c: Association of CVD with recent use of abacavir and 
didanosine (adapted from D:A:D study) [27, 59]  
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Section 2: Metabolic complications of the disease and treatment 
  
1.2.1. Methodology 
A Medline search from 1985 though March 2009 was performed using the 
key works “HIV,” “antiretroviral therapy”, “toxicities”,  “dyslipidaemia”, 
“lipodystrophy”, “insulin resistance”, “adipocytokines”, “cytokines”, 
“lipoproteins”, “apolipoprotein-B”. Further search was performed 
combining key words “HIV and dyslipidaemia”, “HIV and lipodystrophy”, 
“HIV and insulin resistance”, “HIV and adipocytokines”, “HIV and 
cytokines”, “HIV and lipoproteins” “HIV and apolipoprotein-B”, “HIV and 
toxicities”, “antiretroviral therapy and toxicities”.  
A total of 668 articles were found with the combination of “HIV and 
dyslipidaemia,” and the search was limited to the English language, 
resulting in 568 articles. In the similar way “HIV and lipodystrophy”, 
resulted 1587 articles, “HIV and adipocytokines” resulted 108 articles, 
“HIV and insulin resistance” resulted 752 articles and “HIV and 
apolipoprotein-b” resulted 24 articles. Other sources included peer 
reviewed abstracts from recent HIV-related conferences that presented 
data pertinent to metabolic and toxicology issues.  
The articles included were those reported primary data on lipid 
abnormalities and related topics in patients with HIV infection. The search 
was further focused on articles dealing with pathogenesis of dyslipidaemia 
and lipodystrophy in HIV infection. In addition the bibliographies of eligible 
studies as well as those of relevant review articles were reviewed to 
identify additional studies not captured by the database searches. 
Chapter 1 
 23 
Because this is a rapidly evolving field and, for many clinical questions, 
the evidence is limited to case series or small observational studies, the 
articles were initially not excluded on methodological grounds. Finally 
studies were selected based on their impact on our understanding of HIV 
infection and its treatment and complication. In general more emphasis 
was given on differentiating clearly between randomized controlled trials 
and observational studies. 
  
1.2.2. Overview (figure 1.5) 
The widespread use of different antiretroviral regimens has coincided with 
increasing reports of metabolic abnormalities including lipid disorders, 
impaired glucose metabolism and insulin resistance, lactic acidosis [73, 
74] and osteopenia [75]. Distressing morphologic changes in body habitus 
associated with these metabolic abnormalities are characterized by 
accumulation of fat in the abdomen (visceral fat compartment) and in the 
dorsocervical area of the neck, breast enlargement as well as by the 
depletion of fat in the face, buttocks, and extremities [76]. A single 
pathogenic mechanism linking peripheral lipoatrophy and central 
lipohypertrophy may not exist. Increasing evidence suggests these 
disorders, have distinct pathologic pathways and can occur independently 
of each other [77]. However, the morphologic changes and the metabolic 
changes may have a close link between them.    
The causes of the metabolic disturbances and morphologic changes 
related to ART are not understood completely. The etiology is likely to 
involve the effect of HIV per se as well as the direct and indirect effects of 
ART superimposed on individual characteristics such as genetic 
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predisposition, gender, and age. There are likely to be both drug class-
specific as well as drug-specific differences in the tendency of 
antiretroviral medications to cause these effects [73]. Although some of 
the metabolic disturbances may be linked to one another, the 
interconnections among these metabolic abnormalities have yet to be 
elucidated.
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Figure 1.5 Cluster of metabolic complications associated with HIV infection 
(Adapted from Wohl D et al Contemporary Views of Metabolic 
Complications and Cardiovascular Risk in HIV-Infected Patients 
http://www.clinicaloptions.com/HIV/Resources/CME) 
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1.2.3. Basic physiology of lipid metabolism  
1.2.3.1. Plasma lipoproteins: structure, nomenclature and 
occurrence  
Plasma lipoproteins are complexes of lipids and proteins, called 
apolipoproteins. With the exception of free cholesterol, the lipoprotein 
lipids are of different lipid types that include cholesterylesters (CE), 
triglycerides (TG) and phospholipids [78]. The lipoproteins comprise a 
continuum of particles differeing gradually in density, volume and in lipid 
and protein content. Various methods can isolate different relatively 
distinct subclasses and are operationally classified according to their 
densities and electrophoretic motilities. In order of decreasing densities, 
they are high density lipoprotein (HDL), low density lipoprotein (LDL), 
intermediate density lipoprotein (IDL), very low density lipoprotein 
(VLDL), and chylomicron. The plasma lipoproteins can be altered in 
structure and composition by various types of hyperlipidaemia depending 
upon the content of triglyceride or cholesterol [79].  
1.2.3.2. Apolipoproteins 
Apolipoproteins (apoproteins) are a specialised group of proteins that 
associate with lipids and mediate several biochemical steps associated 
with plasma lipid metabolism. The apolipoproteins are designated by 
Roman letters and numerals (as example apo A-1 and apo C-2) [78, 80]. 
Apolipoproteins act as the vehicles for solubilisation and transport of lipids 
in the plasma compartment. Many of the apolipoproteins contain 
determinants that regulate several activities essential to normal lipid 
metabolism. Some apolipoproteins stimulate enzymes that degrade 
plasma lipids. Others contain the ligands that mediate the binding of 
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lipoproteins to cell surface receptors, binding is succeeded by the 
internalisation of all or part of a lipoprotein and the regulation of 
intracellular lipid synthesis [81]. 
1.2.3.3. Intracellular lipid synthesis and lipoprotein assembly: 
very low density lipoproteins (VLDL) 
The major secreted lipoproteins are VLDL, assembled in the liver, and the 
chylomicron, derived from the intestine. Both lipoproteins undergo 
substantial remodelling in the plasma compartment, thus remnants or 
mature forms or circulating particles are found under fasting conditions 
[80, 82].   
The assembly of lipoproteins containing apo-B is a complex process that 
occurs in the lumen of the endoplasmic reticulum (ER) [83, 84]. The VLDL 
secretion appears to be driven by the availability of plasma free fatty acids 
(FFA) that act as fuel for lipid synthesis. Before being secreted in the 
blood the VLDL particle acquire other proteins and undergo massive 
remodelling by plasma lipid transfer proteins and lipases [85]. 
1.2.3.4. Lipase family 
Lipase family consists of different enzymes [85-90] which cause hydrolysis 
of glycerides present in different lipid fractions, resulting in formation of 
free fatty acid and different relatively smaller lipid fractions. 
a. Lipoprotein lipase (LPL) is a protein secreted primarily by adipocytes 
and muscle cells into the circulation where it is bound to the luminal 
surface of capillary endothelial cells [86, 88]. In the presence of its 
cofactor, apo C-II [91-93], lipoprotein lipase hydrolyzes triglycerides 
present in chylomicrons and very low density lipoproteins to free fatty 
acids (FFA) which can be utilized as sources of energy or re-esterified for 
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storage. During the hydrolytic process LPL is intimately involved in the 
initial remodelling of the triglyceride-rich lipoprotein particles and thus 
plays a key role in both normal triglyceride and lipoprotein metabolism.  
b. Hepatic lipase (HL) is synthesized in hepatocytes and transported to 
hepatic endothelial cells where it is bound by means of heparin sulphate 
[85, 94]. The major role of HL appears to be hydrolysis of triglycerides 
and phosphoglycerides of HDL and IDL with the help of apo-C II and also 
LDL.  
It also acts sequentially to lipoprotein lipase on TG rich lipoproteins 
catalysing the hydrolysis of intermediate density lipoprotein glycerides to 
produce chylomicron remnants and low density lipoproteins.  
c. Hormone sensitive lipase [95] is an intracellular enzyme. It hydrolyses 
adipose tissue store of triglycerides which is the major source of FFA in 
the fasting state. 
d. Endothelial lipase (EL) [96-98] is synthesized by endothelial cells and is 
expressed in organs including liver, lung, kidney and placenta, but not in 
skeletal muscle. It has a considerable molecular homology with lipoprotein 
lipase (LPL) and hepatic lipase (HL). As a lipase, EL has primarily 
phospholipase A1 activity, playing a role in HDL metabolism. However, 
recent study has shown that EL have role in metabolism of apo-B 
containing lipoproteins [96]. 
 
1.2.3.5. Lipoprotein transport (figure 1.6a, 1.6b, 1.6c) 
There are two major pathways of lipoprotein transport [78, 81, 99]. The 
exogenous pathway transports dietary lipids to the periphery and the liver 
and the endogenous pathway transports hepatic lipids to the periphery. 
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In the exogenous pathway [78], cholesterol and fatty acids after intestinal 
absorption, are re-esterified to form triglyceride (TG) and cholesteryl ester 
(CE) in intestinal mucosal cells. These lipids are then packaged together 
with apo-B 48, phospholipids, unesterified cholesterol and several 
apolipoproteins including apo-C and apo-E into nascent chylomicrons, 
secreted into the lacteals and transported via the thoracic duct into the 
blood. During transport in the circulation chylomicrons are degraded to 
smaller chylomicron remnants which are recognised by the apo-E 
receptors on hepatic parenchymal cells and rapidly removed from the 
blood stream[100]. 
In the endogenous pathway [78], triglycerides and cholesterol are 
transported to different tissues in the form of VLDL, IDl and LDL. The liver 
assmbles and secretes apo-B contatining lipoproteins, mainly VLDL. Fatty 
acids surplus to oxidative requirements in the liver are esterified to form 
triglyceride in a manner similar to chylomicron formation and are packed 
together with cholesterol, phospholipid apolipoprotein B-100 (apo-B), 
apolipoprotein-C (apo-C) and apolipoprotein-E (apo-E) and secreted into 
the blood as VLDL. During transport the VLDL undergoes delipidation and 
becomes smaller and denser resulting in the formation of IDL and 
subsequently LDL. In contrast to chylomicron remnants, VLDL remnants 
and IDL can either be taken up by LDL receptors on the liver or undergo 
further delipidation and loose apo-E to form LDL. The LDL is removd from 
the circulation by LDL receptors present in the liver and to a small extent 
by extr hepatic tissues including macrophages. The main structural protein 
that remains associated with VLDL, IDL and LDL is apo-B 100. Hence 
apoB-100 is a suitable marker for tracing the metabolic pathway of these 
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lipoprotein particles (figure 1.6b). This is the fundamental principle 
employed in studies of the metabolism of apoB-containing lipoproteins 
based on the use of stable isotopically labelled amino acid precursors 
[101-103]. 
 
Excess cholesterol from the periphery is transported back to the liver for 
excretion in the bile by a process called reverse cholesterol transport 
(figure 1.6 c). Both intestine and liver secrete individual apolipoproteins 
with a small amount of phospholipid. These cholesterol-poor proteins can 
absorb free cholesterol on the surface from different cell membranes and 
become nascent HDL and considered to be the initial step in reverse 
cholesterol transport. These particles can continue to adsorb more free 
cholesterol and with the help of lecithin-cholesterol acyltransferase (LCAT) 
esterifies free cholesterol into cholesteryl esters (CE); forming mature 
HDLs that can be selectively taken up by the liver via scavenger receptor 
class BI (SR-BI). Formation of CE increases the capacity of HDLs to accept 
more cholesterol, because the core of the molecules can accommodate 
more CE molecules. These lager sized cholesterol rich HDL transfer CE to 
other TG rich lipoproteins with the help of CETP resulting in formation of 
CE rich apo-B containing lipoproteins VLDL, IDL or LDL and TG rich HDL 
which then is further modified by hepatic lipase (HL) into smaller HDL and 
cleared from circulation [104]. The CE rich VLDL and chylomicrons can be 
either taken up by the liver or further hydrolysed to smaller IDL and LDL 
[105, 106]. 
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Figure 1.6a: Lipid transport.  
The exogenous and endogenous lipoprotein metabolic pathways [107] . 
(adapted from Fauci AS et al, Harrison’s principles of internal medicine, 
17th edition). LPL, lipoprotein lipase; FFA, free fatty acid; VLDL, very low 
density lipoprotein; IDL, intermediate-density lipoprotein; LDL, low-
density lipoprotein; LDLR, low-density lipoprotein receptor. 
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Figure 1.6b: Apo-B 100 in endogenous transport (adapted from Gibbons 
et al [108]). 13C Leucine: stable tracer isotope 
 
 
 
Figure 1.6c: Reverse cholesterol transport  [107](adapted from Fauci AS 
et al, Harrison’s principles of internal medicine, 17th edition). LCAT, 
lecithin-cholesterol acyltransferase; CETP, cholesteryl ester transfer 
protein; VLDL, very low density lipoprotein; IDL, intermediate-density 
lipoprotein; LDL, low-density lipoprotein; HDL, high-density lipoprotein; 
LDLR, low-density lipoprotein receptor; TG, triglyceride. 
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Section 3: Lipid disorders in HIV infection 
1.3.1. Overview and prevalence  
The lipid disorders seen in individuals with HIV infection include elevated 
triglycerides (TG) and total cholesterol (TC), a decrease in high-density 
lipoprotein (HDL) cholesterol, and variable effects on low-density 
lipoprotein (LDL) cholesterol [55] (figure 1.7, 1.9). The exact mechanism 
is still not clear and the cause could be multifactorial. The individual 
contributions of HIV infection, specific antiretroviral agents, host genetics 
and changes in body composition, all should be considered (table 1.4) .  
Figure 1.7: Pattern of dyslipidaemia (Total cholesterol > 6.2 mmol/l, 
Triglyceride >2.5 mmol/l and HDL-cholesterol <0.9mmol/l), in HIV 
infected adults according to current antiretroviral regimen, from D:A:D 
cohort [55]. 
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Table 1.4: Overview of studies on effect of HIV infection and HAART and different antiretrovirals (ARV) on lipid changes 
 
TC: total cholesterol, TG: triglyceride, LDL: Low density lipoprotein, HDL: high density lipoprotein 
d4T: stavudine, ddI: didanosine, AZT: zidovudine, 3TC: lamivudine, FTC: emtricitabine, ABC: abacavir, TDF: tenofovir,  
CBV: Combivir (AZT + 3TC), TVD: truvada (TDF+FTC), TA: thymidine analogue, IDV: indinavir, LPV: lopinavir, RTV: 
ritonavir, ATV: atazanavir, NFV: nelfinavir, SQV: saquinavir, FPV: fosamprenavir, TPV: tipranavir, DRV: daurunavir, r: small 
dose (100mg) of ritonavir, NRTI: nucleoside reverse transcriptase inhibitor, NNRTI: non-nucleoside reverse transcriptase 
inhibitor, EFV: efavirenz, NVP: nevirapine 
  
1.4.1. Effect of HIV and HAART 
 
Study (name) Number Design Comparing arms Changes in lipid 
El-Sadr et al[73]. 419 Retrospective HIV infection and 
AIDS 
Decrease in TC and HDL but 
increase in TG in advanced HIV 
infection 
 
Grunfeld et al[109]. 75 Cross-sectional HIV infection and 
AIDS 
 
Increase in TG  
  
MACS[110] 50 Prospective HIV and HAART Decrease in TC, LDL and HDL after 
HIV infection. Increase in TC and 
LDL after HAART 
 
DAD[55] 17852  Observational 
cohort 
HAART Increase in TG, TC, LDL and 
decrease of HDL 
 
SMART[65] 5472 Observational 
cohort 
Stopping HAART  Reduction in TC, TG and LDL, but 
not HDL 
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1.4.2. Effect of NRTI on lipid changes 
 
1.4.2a. Studies switching to TDF or ABC 
Switching to TDF 
Study name (Ref) Number Design Comparing arms Changes in lipids 
Lipo-Rec sub-study 
(Llibre et al[70])  
352 Prospective 48 week switch 
d4T to TDF  
Decrease in TC, LDL, TG but not 
HDL in TVD arm 
COMET  
(Schmid et al [111]). 
402 Prospective 24 week switch 
CBV to TVD  
Decrease in TC, LDL, TG and HDL 
In TVD arm 
Gilead 903extension 
(Gallant et al[112]).  
173 Randomized 144 week switch 
d4T to TDF 
Decrease in TC, LDL, TG and HDL 
in TVD arm 
RAVE  
(Moyle et al[113])  
105 Randomized 48 week switch 
d4T/AZT to TDF [or 
ABC] 
Decrease in TC, LDL, TG and HDL 
In TVD but not in ABC arm  
SWEET 
(Moyle et al [111]) 
234 Randomized CBV to TVD Decrease in TC, LDL and TG in 
TVD arm 
BICOMBO 
(Martinez et al [112]) 
333 Randomized TA to TDF or ABC More decrease in TC, TG, LDL and 
HDL in TVD arm 
Switching to ABC 
RAVE  
(Moyle et al [113]).  
105 Randomized 48 week switch 
d4T/AZT to ABC [or 
TDF] 
 Increase in TC,LDL,TG and HDL in 
ABC arm 
MITOX 
( Carr et al [116]). 
111 Randomized 24 week data 
TA to ABC 
 Increase in TC and HDL in ABC 
arm 
MITOX extension 
(Carr et al [117])  
85 Randomized 104 week data 
TA to ABC 
 Increase in TC,LDL,TG and HDL in 
ABC arm  
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1.4.2. Effect of NRTI on lipid changes 
 
1.4.2b. Non-switch studies 
Study (Ref) Number Design Comparing arms Change in lipids 
Gilead 903  
(Gallant et 
al[112, 118]).
                                                   
602 Randomized 
double blind 
prospective 
d4T versus TDF in 
ART 
TC, LDL and TG were higher in d4T 
group 
Gilead 934 
(Gallant et al 
[119])  
487 Randomized  CBV + EFV versus 
TDF/FTC + EFV 
TC, LDL higher and HDL lower in 
TDF group 
CNA30024 
(DeJesus et al 
[113]).  
649 Randomized  AZT Vs. ABC No difference  
ABCDE 
(Podzamczer et 
al [114]).  
237 Randomized  d4T versus ABC More rise in TG in d4T, more rise in 
HDL in ABC arm 
HEAT[115]  
Smith et al  
564  Randomized 
double blind 
TDF/FTC vs. 
ABC/3TC  
More rise in TC and TG in ABC/3TC 
ESS40002 
(Kumar et 
al[116]).  
254 Randomized ABC/AZT/3TC vs. 
d4T/3TC/NFV 
More increase in TC, LDL and TG in 
d4T/3TC/NFV 
START II  
(Eron et al[90]). 
205 Randomized ddI/d4T/IDV vs. 
AZT/3TC/IDV 
More rise in TG in ddI,/d4T/IDV 
TOKEN 
(Das et 
al[117]). 
195 Prospective ABC/3TC vs. 
TDF/FTC 
More rise in TC in ABC 
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Table 1.4.3: Effect of PI and NNRTI on lipid changes 
Study name (Ref) Number Design Comparing arms Change in lipids 
GEMINI (Walmsley et al 
[118])  
337 Randomized SAQ/r vs. LPV/r More rise in TC, LDL and TG in LPV/r 
ARTEMIS (DeJesus et al 
[92])  
689 Randomized DRV/r vs. LPV/r More rise in TC, LDL and TG in LPV/r 
ALERT  
(Smith et al [119])  
106 Randomized ATV/r vs. FPV/r More rise in TG in FPV/r 
CASTLE 
 (Molina et al [120]). 
883 Randomized ATV/r vs. LPV/r More rise in TC and TG in LPV/r 
KLEAN 
(Eron et al[96]).  
878 Randomized LPV/r vs FPV/r No difference 
BMS 045[95] 
Johnson et al. 
334 Randomized ATV/r OR ATV/SQV 
vs LPV/r 
Reduction of TC, TG in ATV/r or 
ATV/SQV  
ATAZIP  
(Martinez et al[121]). 
248 Randomized ATV/r vs. LPV/r Reduction of TC, TG in ATV/r  
SWAN 
Gatell et al[122]. 
419 Prospective Switch to ATV or 
ATV/r from other PI 
Reduction of TC and TG in ATV or 
ATV/r 
ACTG 5142 
(Haubrich et al[123]). 
757 Randomized LPV/r vs. EFV More rise in TG in LPV/r 
613 substudy (Cameron 
et al [98]). 
155 Randomized LPV/r vs. EFV More rise TC and TG in LPV/r 
2NN 
(Van Leth et al [124]).  
706 Randomized NVP vs. EFV Increase in HDL in NVP 
Swiss HIV cohort 
(Young et al [125]).  
1065 Prospective PI vs. NNRTI Decrease in TG and increase in HDL 
in NNRTI 
Negredo et al[100]. 34 Randomized NVP vs. PI Increase in HDL in NVP 
Shafran et al[126]. 20 Prospective Immediate effect of 
RTV and LPV in 
heathy volunteers 
Low dose RTV increased TC, TG, LDL 
and lowered HDL. Addition of LPV 
increased HDL 
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Table 1.4.4. Lipid metabolism in HIV infection 
Study  Number Design Changes 
Stein et al[101]. 65 Cross-sectional Delayed clearance of postprandial VLDL in HIV patients. 
Delay in clearance of IDL and LDL , but not VLDL in 
patients taking PIs 
Rimland et al[127]. 271 Cross-sectional Higher CIII and TG in patients treated with PI or NNRTI 
Ouguerram et 
al[128].  
14 Cross-sectional 
Apo-B kinetic 
study 
Increased production and delayed clearance of apo-B in 
HIV patients, more with lipodystrophy 
Petit et al[104].  11 Cross-sectional 
Apo-B kinetic 
study 
VLDL and IDL apo-B production rate was higher in PI group 
Mauss et al[105] 187 Cross-sectional High serum VLDL and increase in size of VLDL particles but 
not numbers  
Reeds et al[101]. 12 Cross-sectional 
Tracer kinetic 
study 
Increased VLDL-TG secretion and delayed clearance in 
fasting and non-fasting state leads to increase in serum TG 
Carpentier et 
al[129] 
13 Prospective Elevation VLDL early in the course of HAART caused by the 
combination of impaired VLDL clearance already present in 
HAART-naive HIV patients and HAART-mediated increase in 
VLDL secretion 
Schmitz et al[130]. 11 Cross-sectional Patient on HAART showed increased serum TG due to 
increased apo-B synthesis and diminished rate of VLDL 
transfer to IDL and LDL  
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1.3.2. Effect of HIV infection                                                                                                               
Abnormalities of lipid metabolism in HIV-infected patients were described 
before the use of HAART [109, 131-134] (figure 1.8). Increased serum 
triglyceride and reduced total cholesterol concentrations were observed in 
advanced HIV infection [73]. Patients with advanced HIV infection or with 
AIDS have also had lower levels of HDL-C and LDL-C, increased TG level 
and a predominance of small, dense LDL particles, compared with HIV 
negative individuals [73]. In the early 1990s a number of investigators 
described the lipid abnormalities associated with HIV infection. A 
consistent finding from these studies was that patients with advanced HIV 
infection or AIDS had high levels of circulating triglycerides and low levels 
of HDL cholesterol [109, 133]. El-Saadar et al [73] using data from HIV 
treatment naive patients have shown that the higher HIV RNA level was 
independently associated with lower LDL cholesterol and higher VLDL 
cholesterol and triglyceride levels, while a history of AIDS-defining events 
was associated with higher total cholesterol, VLDL cholesterol and 
triglyceride levels. The lipid changes were found to be restricted to 
patients with a history of P. jiroveci pneumonia (PCP) and were related to 
recent diagnosis of this condition. This data thus demonstrated that low 
CD4 lymphocyte count, high HIV RNA level and a history of AIDS-defining 
events, all markers of more advanced HIV disease, were all associated 
with higher concentrations of VLDL cholesterol and triglycerides.  
Even among subjects with HIV infection and relatively preserved CD4+ 
cell counts, the levels of triglycerides appeared to be higher than among 
HIV-uninfected subjects and were thought to be due to increased levels of 
very low density lipoprotein (VLDL) cholesterol in the circulation[109]. 
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These changes in triglycerides were accompanied by reduced levels of 
total and LDL cholesterol. Thus, in a study of 63 patients with HIV 
infection, Zangerle and colleagues [135] reported decreased levels of total 
cholesterol, HDL cholesterol, and LDL cholesterol in 3.2%, 48%, and 56% 
of the subjects respectively. Triglycerides were elevated in 32% of the 
patients in this cohort. The prevalence of lipid abnormalities was higher 
among those with lower CD4+ cell counts.  
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Figure 1.8 Timeline of development in antiretroviral treatment and ‘lipodystrophy syndrome(s)’ (adapted from Nolan) [77] 
AZT= zidovudine; 3TC = lamivudine; d4T = stavudine; ddl = didanosine; HAART = Highly active antiretroviral therapy; 
HDL = high density lipoprotein; LDL = low density lipoprotein; NRTI = nucleoside reverse transcriptase inhibitor; PI = 
Protease Inhibitor; VLDL = very low density lipoprotein; 
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A prospective analysis of HIV seroconverters (the Multicenter AIDS Cohort 
Study) has helped to illuminate the role of HIV infection in the 
pathogenesis of lipid disorders (figure 1.9). MACS investigators examined 
data on lipids among a subgroup of participants with known dates of 
seroconversion and stored samples, making it possible to compare their 
lipid levels before they became infected, after they seroconverted, and 
after they started antiretroviral therapy [110].  
 
Figure 1.9: HIV acquisition associated with lipid reductions, with reversion 
on HAART (Multicenter AIDS Cohort Study) [110]  
NCEP: National cholesterol education programme 
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After seroconversion, patients experienced reductions in total cholesterol, 
LDL cholesterol, and HDL cholesterol, compared with their pre-
seroconversion levels [110]. When they started antiviral therapy, their 
total cholesterol, LDL cholesterol and triglyceride levels but not their HDL 
cholesterol levels promptly returned toward their pre-seroconversion 
levels (figure 1.8).  
Of great interest was the observation that HDL cholesterol levels 
decreased at or soon after seroconversion, and remained low even after 
antiretroviral therapy was initiated. 
The recently presented SMART study has shown that treatment 
interruption improved TC, LDL-C, TG but not HDL-C [65]. Whether this 
change is due to the withdrawal effect of HAART or the effect of viral 
replication is not clear. 
 
1.3.3. Effect of Antiretrovirals                                                                  
1.3.3.1. Protease inhibitors (PIs)      
Hyperlipidaemia associated with PI use is more common and more severe 
than what was observed before HAART was used. In patients who receive 
a PI-containing antiretroviral regimen, the prevalence of hyperlipidaemia 
ranges from 28% to 80% [136-138], and it includes hypertriglyceridaemia 
in the majority of cases (40–80%), followed by hypercholesterolaemia 
(10–50%) [44, 136, 139-144].  
In a cohort of 212 HIV-positive patients who started a new PI-based 
antiretroviral regimen, the incidence of hypertriglyceridaemia and 
hypercholesterolaemia was 38.2% and 25%, respectively, after a 12 
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month follow-up [145]. Sixty-two (47%) of 133 PI recipients at one study 
had lipid abnormalities [146] that met the previous National Cholesterol 
Education Programme (NCEP), 1994 intervention criteria [147]. In the 
Swiss HIV Cohort [148], hypercholesterolemia and hypertriglyceridaemia 
were 1.7 2.3 times more common among individuals receiving PI-
containing HAART regimen. Hypercholesterolemia (cholesterol level, 
>6.2mmol/l) and severe hypertriglyceridaemia (triglyceride level, 
>5mmol/dl) occurred in 60% and 75% of subjects, respectively, receiving 
PIs at one centre [149].  
In the large survey of the Data Collection on Adverse Events of Anti-HIV 
Drugs (D:A:D) study [55], hypercholesterolemia (defined as total 
cholesterol 6.2 mmol/L]) was found in 27% of subjects receiving HAART 
including a PI, compared with 8% in treatment-naïve subjects (figure 
1.7). Raised LDL-C (above 3.4mmol/L) in 58% of patients, compared to 
31% in treatment naïve patients, triglyceride levels higher than 2.3 
mmol/L were seen in 40%, compared 15% in naïve subjects, and low 
levels of HDL-C [0.9 mmol/L] were in 27%, compared to 26% in 
treatment naïve subjects. There was a much higher rise in TC, TG and 
LDL-C and lowering of HDL-C, when antivirals of three different classes 
were used (figure 1.9). 
The effect of PIs on the lipoprotein fractions appear to be different [138, 
150]. Hyperlipidaemia associated with PI-uses often includes the increase 
in the level of VLDLs [150, 151] and, to a lesser extent, IDLs [152]. 
Increased LDL-C levels have been reported in some studies but not others 
[153-155]. The HDL-C levels tends not to change or to increase, but 
inconsistent changes in small and large HDL particles have been described 
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as well [156, 157]. A small lowering of HDL-C has been observed with 
atazanavir which tend not to have any effect on the other lipid parameters 
[158]. Increased triglyceride concentrations, found in all lipoprotein 
fractions, were accompanied by rise in apo-B concentration.  The changes 
in apo-B and apo-A in plasma with PI use did not always correspond with 
the rise of the different lipoprotein fractions. While lopinavir/r use showed 
significant rise in TG and TC with little change in HDL-C and rise in 
TC/HDL, the apo-B/ apo-A1 did not show significant changes [153].  
There are very few systematic comparisons of the lipid effects of different 
PIs. Amongst them, lipid abnormalities tend to be most marked with 
ritonavir and lopinavir-ritonavir[159]. Amprenavir and nelfinavir tend to 
have intermediate effects, whereas indinavir and saquinavir tend to have 
the fewest effects. Amongst the newer PIs, atazanavir [160] and 
daurunavir [161] appears to have little effect on lipid concentrations, as 
determined on the basis of preliminary reports. Severity of lipid elevations 
particularly TC, TG and LDL-C are most likely to be dependent on the dose 
of ritonavir used as booster of the PI [160-162].  
1.3.3.2. Nucleoside reverse-transcriptase inhibitors (NRTIs)      
Subjects in MITOX (Mitochondrial Toxicity) study have failed to show 
differences in nonfasting cholesterol and triglyceride levels associated with 
receipt of stavudine- compared with zidovudine-containing regimens 
[163]. However, in a prospective, randomized study, antiretroviral-naive 
subjects who initiated therapy with stavudine-lamivudine-nelfinavir had 
significant increases in TC, LDL-C, and TG levels, compared with subjects 
receiving zidovudine-lamivudine-nelfinavir [116]. In another randomized 
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study elevations in nonfasting TG levels were more common in association 
with stavudine-didanosine-indinavir than with zidovudine-lamivudine-
indinavir [164]. The NRTI tenofovir was associated with lesser increases in 
cholesterol and triglyceride levels than was stavudine [165] and 
zidovudine [166, 167]. Tenofovir containing regimens have better lipid 
profiles compared to AZT and d4T. Abacavir containing regimens are 
associated with rise in TC, LDL-C and TG along with rise HDL-C [168, 
169]. Switch studies have shown better total cholesterol (TC), LDL 
cholesterol (LDL) and triglyceride (TG) but not HDL profile in the tenofovir 
group compared to the abacavir group [166, 168, 170]. Additional data 
are needed before any firm conclusions can be drawn regarding the 
relative tendencies of individual nucleoside analogues to alter lipid profiles.  
1.3.3.3. Nonnucleoside reverse-transcriptase inhibitors 
(NNRTIs)      
The NNRTIs cause alterations in the lipid profiles, although generally to a 
lesser degree than has been observed with PIs. In the D:A:D cohort 
(figure 1.7), raised cholesterol was seen in 23% receiving an NNRTI but 
no PI, and in 10% receiving NRTIs only [55]. Raised TGs were seen in 
32% of NNRTI use compared to 15% of NRTI use only and low HDL-C was 
less common in 19% of NNRTI use compared to 25% in NRTI use [55, 
171]. In the recently presented ACTG 5142 study [172], efavirenz 
containing regimen had similar rise of TC compared to ritonavir boosted 
lopinavir (LPV/r), but  TG were significantly higher with LPV/r. Increases in 
HDL cholesterol were not different. 
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ACTG 5142 was a prospective, randomized, open-label trial evaluating the 
effects of an NRTI-sparing regimen on lipids [172]. Treatment-naive 
subjects received one of three treatment regimens: the NRTI-sparing 
regimen lopinavir boosted with riotonavir (LPV/r) + efavirenz (EFV), LPV/r 
+ two NRTIs, or EFV + two NRTIs. The NRTIs were selected before 
randomization from zidovudine, satvudine or tenofovir (each plus 
lamivudine). At week 96 of treatment, the differences in the change from 
baseline in lipoprotein levels between EFV and LPV/r when either was 
combined with NRTIs were minimal, although statistically greater 
increases in TG levels were observed with the PI. Increases in HDL-C were 
almost the same in these two groups. In contrast, the NRTI-sparing 
regimen of LPV/r + EFV increased lipids significantly more than either 
LPV/r or EFV + two NRTIs. 
On the contrary NNRTI use, particularly nevirapine is associated with 
substantial increases in HDL-C levels to a degree not generally seen with 
PIs or NRTI [173-175]. In the 2NN study [176], the TC/HDL ratio 
improved significantly with nevirapine but remained unchanged with 
efavirenz. Efavirenz did show some improvement initially but the effect 
disappeared with time which was not the case with nevirapine.  
Since pre-treatment TC usually remains lower in HIV patients, the rise 
from baseline after treatment could initially be correction of the initial 
defect. This needs to be taken into consideration when looking at the 
cohort studies.   
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1.3.3.4. Effect of other agents 
The early data indicates that the recently licensed fusion inhibitors, CCR-5 
inhibitors and integrase inhibitors do not appear to be associated with 
dyslipidaemia and hence considered to be lipid neutral [177, 178]. 
1.3.4. Mechanism of Lipid disorders  
The mechanism of dyslipidaemia is not fully understood, but is probably 
multifactorial. Whether plasma lipid alterations are a direct consequence 
of antiretroviral therapy or reflect an HIV-associated metabolic defect that 
is exacerbated by the drug remains unclear. A recent study [179] has 
shown that HIV replication alone without any influence of antiretroviral 
drugs enhances production of free fatty acids, lipoproteins and many key 
proteins associated in lipid synthesis, transport and metabolism.   
A key question is whether elevations in lipids are associated with 
increased production or decreased clearance apo-B containing 
lipoproteins. Several theories have been proposed to explain the 
mechanism of dyslipidaemia, particularly the role of PIs (table 1.5). 
 
 
1.3.4.1. Increased lipoprotein (hepatic cholesterol and 
triglyceride) synthesis  
1.3.4.1.1. Cytoplasmic retinoic acid binding protein type- 1    
(CRABP-1) and Lipoprotein receptor related protein (LRP)                                                                     
An early hypothesis developed by Carr and Cooper suggested that the PIs 
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might bind to several proteins involved in lipid and adipocyte metabolism 
after similarities between the HIV protease enzyme and regions of 
Table 1.5: Possible Mechanisms for Dyslipidemia 
 
 
 
 
 
 
 
 
 
 
 
cytoplasmic retinoic acid binding protein type-1 (CRABP-1) and lipoprotein 
receptor related protein were identified [180, 181]. However, to date 
direct inhibition of CRABP-1 and LRP inhibition as a causative mechanism 
for increased TG levels has not been demonstrated [76, 182]. 
Furthermore, the concept of a class based effect for PIs [183] has 
subsequently been shown to be outdated [76]. Specific agents have been 
implicated in the development of lipid abnormalities, but these effects do 
Increased lipoprotein (hepatic cholesterol and triglyceride) 
synthesis 
• Impaired CRABP-1and inhibition of LRP  
• Decreased proteasome activity 
• Increased hepatocyte accumulation of SREBP-lc  
• Improved nutritional status and increased hepatic 
substrate delivery  
Impaired lipoprotein clearance 
• Downregulation of low density lipoprotein receptor 
expression  
• Inhibition of lipoprotein lipase  
• Impaired lipoprotein cell-surface interaction 
• Impaired CRABP-1 
Genetic Predisposition 
• Heterozygous or homozygous apolipoprotein E2 
phenotype  
• Abnormal regulation of apolipoprotein C-III  
Effect of Cytokines  
• Tumour Necrosis Factor (TNF)-α 
• Interleukin-6 
• Interleukin-8 
Other  
 
CRAPB-1: cytoplasmic retinoic acid binding protein ; LRP: 
low density lipoprotein receptor-related protein; SREBP-1: 
sterol regulatory element binding protein 
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not appear to be class specific with individual PIs having differential 
effects on both lipid and glucose metabolism [184]. 
1.3.4.1.2. Decreased proteosomal activity: Impaired apo-B 
degradation                                                                      
Apo-B is a key protein involved in the metabolism of lipoproteins [78, 
100]. Increased synthesis or decreased clearance of this protein can be 
associated with raised TG in blood. Liang et al [185] reported that 
ritonavir inhibited the normal proteasomal degradation of apolipoprotein B 
(apoB) in HepG2 cells leading to increased intracellular accumulation of 
apoB. Riddle et al [186] also found ritonavir to increase VLDL cholesterol 
production in mice when fed a high fat western diet, an effect which 
corresponded to higher levels of hepatic apoB accumulation.  
1.3.4.1.3. Sterol regulatory element binding protein-1(SREBP-1)  
Some studies indicate that PIs may directly suppress adipocyte 
differentiation in vitro at an early step involving impaired sterol-
regulatory-element-binding-protein-1 (SREBP-1) which actively promotes 
lipogenesis and adipocyte differentiation [187-189]. Therefore, an 
increase in SREBP-1 activity will increase both the size of the adipocyte as 
well as increasing production of VLDL cholesterol. 
Riddle et al [186] found an increase in VLDL cholesterol production in mice 
when treated ritonavir. They found no effect of ritonavir on lipoprotein 
clearance from the circulation. These investigators observed a significantly 
higher level of hepatic apo-B secretion in the ritonavir-treated animals. 
This led them to hypothesize that the hypertriglyceridemic effects of 
ritonavir were due to an increase in hepatic lipoprotein production by the 
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inhibition of proteasome-mediated degradation of apo-B and SREBP-1 in 
the liver.  
Caron et al [190] reported that indinavir in-vitro reduced the translocation 
of SREBP-1 from the endoplasmic reticulum to the nucleus in addition to 
abnormal phosphorylation of its active form [191]. Increased and altered 
form of SREBP-1 can activate lipogenic genes responsible for increased 
synthesis of fatty acids and lipids.  
1.3.4.1.5. Improved nutritional status and increased hepatic 
substrate delivery 
The nutritional status and fat content of the diet can increase apo-B 
synthesis. The activity of SREBP-1 in the liver is also affected by 
nutritional status and by levels of insulin as well as by other nuclear 
receptors. Several of the PIs appear to increase fasting insulin levels over 
time. Indirect effects of PI therapy on circulating insulin levels could 
further stimulate an increase in SREBP-1. The lipid effects of ritonavir 
described in the studies by Riddle et al [186],
 
were greatly influenced by 
the fat content of the diet fed to the mice. While it is not likely that diet 
alone will change the lipid abnormalities observed among patients, it may 
play an indirect role.  
1.3.4.2. Impaired lipoprotein clearance 
 
1.3.4.2.1. Down regulation of low density lipoprotein receptor 
expression 
 
LDL receptor expression [192] may be impaired in HIV patients. In a small 
cross-sectional study Petit et al [193] showed that in HIV-infected 
subjects, LDL receptor expression was lower in those on antiviral 
treatment, particularly in those with lipodystrophy compared to those 
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without, and inversely proportional to total cholesterol and LDL blood 
levels.  
1.3.4.2.2. Inhibition of lipoprotein lipase 
 
The Lipoprotein lipase (LPL) family plays an important role in the 
clearance of lipoproteins and inhibition of LPL can increase the lipid levels 
[82, 85]. Lipoprotein lipase and hepatic lipase levels were negatively 
correlated with triglyceride levels, suggesting that reduced levels of these 
enzymes may contribute to the PI-associated hyperlipidaemia[80]. 
1.4.4.2.3. Impaired lipoprotein cell-surface interaction 
 
The interaction of lipoproteins with specific receptors depends on the 
lipoprotein composition and structures. Smaller CE rich LDL may have less 
affinity for LDL hepatic receptors and can remain in the circulation for 
long. Similarly CE rich larger HDL particles has less affinity for hepatic 
receptors and can remain in the circulation for longr time, but their role in 
cardioprotective action is doubtful. 
1.4.4.2.4. Cytoplasmic retinoic acid binding protein type- 1   
(CRABP-1) 
The interaction between PIs and CRABP-1 was thought to reduce the 
activity of 9-cis-retinoic acid, which was postulated to have downstream 
effects on fat cell differentiation [181]. The interaction between PIs and 
LRP would impair hepatic chylomicron uptake and triglyceride clearance. 
This hypothesis has not been confirmed, as pointed out in a [182] 
subsequent review by Mooser and Carr [182] . In a mouse model, 
inhibition of LRP in a manner similar to that proposed by Carr et al earlier 
[181] did not result in hyperlipidemia. In addition, more recent studies 
[194] found that mice treated with PIs did not exhibit decreased clearance 
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of triglycerides. Finally, data from healthy volunteers treated with ritonavir 
do not show inhibition of lipoprotein lipase. 
1.3.4.3. Genetic Predisposition 
Genetic predisposition may explain the variability between patients in 
respect of the lipid effects of PIs. The observation that some patients 
experience increases in triglycerides to over 10 mmol/l during therapy 
with ritonavir, while others sustain no changes, indicates a role for genetic 
predisposition.   
1.3.4.3.1. Apolipoprotein E2  
Apolipoprotein E2 (apo E2) is involved in the clearance of triglycerides 
[78]. HIV-negative people who are homozygous for the E2 phenotype are 
predisposed to develop a form of hyperlipidaemia similar to that observed 
with PI therapy. HIV-infected patients who are heterozygous or 
homozygous for the E2 genotype have been reported to have dramatic 
increases in cholesterol and triglyceride levels when receiving PI therapy 
[138]. However, the prevalence of the E2 phenotype does not explain all 
cases of hyperlipidaemia on PI therapy [136]. 
1.3.4.3.1. Apolipoprotein C-III  
Apolipoprotein C-III (apo C-III) may also play a role in the 
hyperlipidaemia associated with PI therapy. Apo C-III is the major 
lipoprotein of hepatic VLDL, and specific polymorphisms in the apo C-III 
gene are associated with certain types of hypertriglyceridaemia in the 
general population [195]. Fauvel et al [196] examined the prevalence of 
specific apolipoprotein C-III polymorphisms on PI induced lipid increases 
following 3 months of treatment in sixty consecutively treatment naive 
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males. Carriers of the -455c variant had 30% lower HDL levels than those 
without the variant as well as increased levels of triglycerides [196].  
These results in combination indicate that genetic factors can clearly 
interact with both HAART as well as the severity of metabolic changes; 
however, the design of all these studies was based on small non-ethnically 
diverse populations, and thus need to be confirmed in larger groups.  
 
1.3.4.4. Effect of cytokines 
Previous studies [197, 198] have shown that lipoprotein changes in 
patients with HIV-infection were related with humoral and cellular immune 
markers. Interferon (IFN)-α, beta2-microglobulin and tumor necrosis 
factor (TNF)-α were correlated positively with total and VLDL-triglycerides 
and negatively with HDL-cholesterol [199]. As an ongoing chronic 
infection, the inflammatory cytokines including TNF-α, IL-6 and  
interferon- α  may remain abnormal in different stages of HIV infection 
and may be responsible for the lipid abnormalities seen in patients with 
HIV infection [200]. 
 
The mechanism of dyslipidaemia with NRTI use appears to be different 
and most of the actions may be mediated indirectly through impaired 
adipogensis. Increased lipolysis may generate excess FFA that in turn act 
as a fuel for increased synthesis of triglycerides. Increased fat loss can 
also cause lack of plasma adiponectin which may have role on lipid 
metabolism. 
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1.3.4.5. Role of HIV 
Proteonomic studies[179, 201] have shown effect of different viral 
proteins on lipid metabolism. Expression of HIV Nef protein that enhances 
HIV replication and infectivity can inhibit ATP binding cassette transporter 
(ABCA-1) dependent cholesterol efflux from macrophages [201]. While 
Nef transfected cells exhibit increased binding of Apo-A1, but 
internalisation of Apo-A1 was blocked, suggesting that Nef at plasma 
membrane prevents lipidation of Apo-A1 and thereby reduce serum HDL-
cholesterol. Further study has shown that the Nef protein can enhance 
synthesis of several lipoproteins either by upregulating or down regulating 
several key proteins responsible for lipid metabolism [179]. However, 
their role in clinical studies has yet to establish.  
 
 
Section 4: Abnormalities of Fat distribution 
1.4.1. Overview                                                                                                        
HIV patients are at higher risk of development of fat redistribution and the 
condition was first described as lipodystrophy syndrome by Carr et al in 
1998 [180]. Lipodystrophy syndrome is a common term in the literature 
traditionally used to describe several morphologic (fat atrophy and fat 
hypertrophy) and metabolic disturbances including dyslipidemia and 
insulin resistance found in patients with HIV infection. Increasing evidence 
suggests these disorders, though commonly clustering in a syndromal 
pattern, have distinct pathologic pathways and can occur independently of 
each other (table 1.6).                                  
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Table 1.6a: Over view of key studies describing fat redistribution (lipodystrophy), HIV and HAART 
 
d4T: stavudine, ddI: didanosine, AZT: zidovudine, 3TC: lamivudine, FTC: emtricitabine, ABC: abacavir, TDF: tenofovir,  
CBV: Combivir (AZT + 3TC), TVD: truvada (TDF+FTC), TA: thymidine analogue, IDV: indinavir, LPV: lopinavir, RTV:ritonavir, 
ATV: atazanavir, NFV: nelfinavir, SQV: saquinavir, FPV: fosamprenavir, TPV: tipranavir, DRV: daurunavir, r: small dose 
(100mg) of ritonavir, NRTI: nucleoside reverse transcriptase inhibitor, NNRTI: non-nucleoside reverse transcriptase inhibitor, 
EFV: efavirenz, NVP: nevirapine  
Risk factor Study (Ref) Number Design 
(comparing arm) Lipoatrophy Lipohypertrophy 
ACTG 5142 
(Haubrich et[202]) 
753 Randomized 
(TA/EFV or TA/LPV/r or EFV/LPV/r) 
More in PI sparing arm No difference in trunk 
fat, but more gain in 
peripheral fat in PI 
containing arm 
613 sub-study 
(Cameron et 
al[203]). 
155 Randomized 
(CBV/EFV vs. LPV/r monotherapy) 
More in AZT/3TC/EFV  No difference 
5005 sub study 
(Dube et al[204]). 
157 Randomized 
(AZT/3TC vs. d4T/DDI with EFV or 
NFV) 
More in d4T/ddI No difference 
Mallon et al[205]. 40 Prospective observational 
(Effect of HAART) 
d4T use Increase in CD-4 count 
and drop in VL  
ABCDE study 
(Podzamczer et 
al[114]). 
57 Randomized 
(d4T vs. ABC) 
More in d4T compared to 
ABC 
No difference 
Gilead 903 
(Gallant et al[206]). 
232 Randomized 
(d4T vs. TDF) 
More in d4T compared to 
TDF 
No difference 
Gilead 934 
(Gallant et al[207]). 
93 Randomized 
(CBV vs. TVD) 
More in AZT/3TC compared 
to TVD 
No difference 
MITOX extension 
(Carr et al[208]). 
85 Prospective 
(TA switched to ABC) 
Thymidine analogue use  
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Table 1.6a (cont.): Over view of key studies describing fat redistribution (lipodystrophy), HIV and HAART 
Risk factor Study (Ref) Number Design 
                  (comparing arm) Lipoatrophy Lipohypertrophy 
PIILR  
(Martin et 
al[209]). 
 
45 Randomized 
(Switching from PI d4T and AZT) 
d4T use  
Boyd et al[210]. 60 Prospective 
(Switching from NRTI to PI and EFV) 
 
NRTI use Fat gain in 
IDV/RTV/EFV use 
RAVE  
(Moyle et al 
[166]). 
105 Randomized 
48 week switch 
(d4T/AZT → TDF [or ABC]) 
 
d4T and AZT use  
SWEET 
(Moyle et al 
[111]). 
234 Randomized 
(CBV to TVD) 
AZT use  
Walmsley et 
al[211]. 
 
68 Prospective 
(Different PIs and NNRTIs) 
No difference amongst 
different PI and NNRTI 
No difference amongst 
different PI and NNRTI  
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able 1.6b: Over view of key epidemiological studies describing fat redistribution (lipodystrophy), HIV and HAART 
Risk factor Study [Ref] Number Design 
(comparing arm) Lipoatrophy Lipohypertrophy 
Miller et  al[212]. 1348 Cross-sectional Older age, CDC stage, 
baseline viral load (VL), 
NRTI use, d4T, ddI, AZT, 
PI use 
Older age, CDC stage 
baseline VL, 
Lichtenstein et 
al[213]. 
1244 Prospective White race, Low CD-4 
count, low BMI 
 
Lichtenstein et 
al[214]. 
1077 Cross-sectional White race, older age, low 
CD-4 count, d4T use, IDV 
use 
Older age, BMI gain, 
duration treatment 
Heath et al[215]. 745 Cross-sectional d4T use, AIDS diagnosis d4T, PI use 
Saves et al[216]. 614 Cross-sectional d4T use, male sex, older 
age 
CD-4 increase, SQV, 
3TC 
Thiebaut et 
al[217]. 
581 Cross-sectional Duration of treatment, 
male sex, older age 
Higher BMI, Increased 
waist/hip ratio 
Martinez et 
al[218]. 
494 Prospective Duration of treatment, 
d4T use 
Female, duration of 
treatment 
Joly et al[219]. 170 Prospective d4T and ddI use, lower 
CD-4 count 
Female, older age 
Bogner et 
al[220]. 
115 Prospective Older age, white race, 
duration of treatment, 
high baseline VL 
Duration of treatment, 
PI use 
Bonfanti et 
al[221]. 
1480 Observational 
cohort 
Older age, duration of 
treatment, homosexuality 
RTV use, female sex 
Johnson et 
al[222]. 
55 Cross-sectional Serum IL-6 and TNF- R2 
and increased TNF-alfa 
secretion from adipose 
tissue 
Serum IL-6 and TNF- R2 
and increased TNF-alfa 
secretion from adipose 
tissue 
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There are two major phenotypes described in HIV infected patients.   
Lipohypertrophy is characterised by the presence of a hypertrophied pad 
of fat accumulated in various parts of the body.  The anatomical sites of 
fat deposits are abdominal (visceral and abdominal wall), breast tissue, 
and head-neck region (dorsocervical, submandibular, trapezio-occipital, 
mastoid)[77].                                                                              
Lipoatrophy is characterised by peripheral fat wasting with loss of 
subcutaneous tissue in the face, arms, legs, and buttocks, producing an 
emaciated appearance [223] and prominence of the superficial veins in 
these sites (pseudovenomegaly). Patients starting antiretroviral treatment 
for the first time may demonstrate initial increases in limb fat during the 
first few months of therapy, followed by a progressive decline during the 
ensuing years. In contrast, truncal fat increases initially and then remains 
stable during the ensuing years, resulting in relative central adiposity 
(figure 1.10). Changes in limb and central fat masses may become 
clinically evident in 20 to 35 percent of patients after approximately 12 to 
24 months of combination antiretroviral therapy [205]. 
Fat accumulation or lipohypertrophy is more common with PI use and fat 
loss or lipoatrophy with thymidine analogues. 
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Figure 1.10: HAART induces initial fat gain followed by limb fat loss 
(Adapted from Mallon PWG et al. [205]) 
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1.4.2. Prevalence                                                                                                        
The prevalence of fat redistribution amongst HIV patients can vary from        
11- 80% [220, 224-239]. One 5-year retrospective cohort study of 
patients with HIV infection who were treated with PIs demonstrated a 
13% prevalence of lipodystrophy. In untreated patients with HIV infection, 
a 4% prevalence rate has been reported [149]. On the other hand, 
prospective cohort study demonstrated a 17% prevalence rate after an 
18-month follow-up [240]. The variance in prevalence estimates probably 
arises from the use of different diagnostic criteria, differences in 
demographic factors, HIV treatment practices, disparities between patient 
and physician assessments and lack of a universally accepted definition of 
lipodystrophy or fat redistribution syndrome.   
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1.4.3. Definition of Lipodystrophy                                                                            
It has been a long debate between the different study groups and no 
consensus has been reached regarding a unifying definition of 
lipodystrophy. Definition of lipodystrophy by Lipodystrophy Case Definition 
Study Group was based on a case-control study of patients with or without 
features of fat redistribution [241]. A series of tests (table 1.5) provided 
an objective definition with sensitivity and specificity of less than 80%.  
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Table 1.7: HIV lipodystrophy case definition and scoring system[241]. The 
model has a sensitivity of 79% (95% CI, 70–85%) and specificity of 80% 
(95% CI, 71–87%). A total lipodystrophy score is derived by adding the 
relevant individual score for each parameter and then subtracting 43 (the 
constant). A final score for a given patient of >=0 constitutes presence of 
lipodystrophy and a score <0 constitutes no lipodystrophy. CDC. Centres 
for Disease Control and Prevention; HDL, high-density lipoprotein; VAT, 
intra-abdominal adipose tissue (visceral fat); SAT, subcutaneous adipose 
tissue. 
 
 
                                                                               
The other definition introduced by the FRAM study group (Fat 
Redistribution And Metabolic change) considered lipoatrophy (LA) as a 
distinguishing trait of HIV lipodystrophy [242]. It was initially thought that 
a decrease in peripheral fat occurred in tandem with an increase in central 
adiposity. However, preliminary data reported by Gripshover et al [243]  
Parameter Unit OR 95% CI p-value Lipodystrophy 
score 
Gender Male 
Female 
1.0 
9.33 
 
3.86-22.52 
<0.001 0 
22 
Age <40 years 
>40 years 
1.0 
2.02 
 
1.20-3.40 
0.008 0 
7 
Duration of 
HIV 
<4 years 
>4 years 
1.0 
3.11 
 
1.69-5.71 
<0.001 0 
11 
CDC stage A 
B 
C 
1.0 
1.32 
1.92 
 
0.73-2.39 
 
0.361 
0.043 
0 
3 
7 
Waist/hip 
ratio 
<1.0 1.34 1.06-1.69 0.014 Multiply by 29 
HDL-
cholesterol 
mmol/l 0.87 0.81-0.94 <0.001 Multiply by  
-14 
Anion gap mmol/l 1.01 1.04-1.16 0.001 Multiply by 1 
VAT/Sat 
ratio 
<0.45 
0.45-0.83 
0.83-1.59 
>1.59 
1.0 
0.82 
1.40 
3.70 
 
0.38-1.76 
0.62-3.18 
1.44-9.55 
 
0.613 
0.416 
0.007 
 0 
-2 
 3 
13 
Trunk/limb 
fat 
1.0 1.72 1.12-2.66 0.014 Multiply by 5 
Leg fat 
percent 
>21.4 
14.5-21.4 
8.8-14.5 
<8.8 
1.0 
1.27 
2.32 
5.04 
 
0.57-2.87 
1.00-5.40 
1.90-13.35 
 
0.559 
0.051 
0.001 
-16 
-14 
-8 
 0 
Chapter 1 
 63 
raised questions about this perception and suggest that a single 
pathogenic mechanism linking peripheral lipoatrophy and central 
lipohypertrophy may not exist. The FRAM group further showed no 
association between lipoatrophy and visceral adiposity [242]. Loss of fat in 
the periphery was however associated with loss of subcutaneous fat from 
the abdominal wall, suggesting that fat loss is a general phenomenon that 
occurs in the arms, legs, face and trunk and that central accumulation of 
fat is not necessarily associated. The FRAM study further showed that 
patients tend to lose more fat in the legs compared to arms, with relative 
sparing of fat in the trunk [244]. This further suggested that abnormal 
body shape is a relative rather than an absolute phenomenon. FRAM study 
however, included more Caucasian patients [242] and results could be 
different in black or other ethnic groups.                                                                          
Currently peripheral lipoatrophy is described as localized fat wasting in the 
face, arms, legs, and buttocks; Central lipohypertrophy, is described as 
fat accumulation in the abdomen, breasts, or dorsocervical region (buffalo 
hump) [25]; Fat redistribution is described comprising both conditions 
either present alone or together. Lipoatrophy should be distinguished from 
HIV wasting, which is a generalized loss of body fat and lean body mass. 
A number of host factors (table 1.6) [221, 223, 245], in addition to type 
and duration of antiretroviral drug exposure, have been associated with 
fat distribution abnormalities. These include older age [212], baseline 
body mass index or change in body mass index [246], duration of HIV-1 
infection [223], effectiveness of viral suppression, baseline degree of 
immunodeficiency and subsequent immune restoration with therapy, and 
white race [213, 214, 223, 247]. The risk of lipoatrophy is increased in 
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whites (5.4 odds ratio) compared with blacks [213]. Gender-based 
differences in presentation have been reported. Women are more likely to 
report fat accumulation in the abdomen and breasts, whereas men are 
more likely to describe fat depletion from the face and extremities [212]. 
These findings may reflect differences in baseline body composition. 
Although older age is a consistently reported risk factor, body fat changes 
occur naturally with aging and body fat distribution abnormalities have 
also been reported in HIV-infected children [248, 249].  
1.4.4. Effect of HIV                                                                                                  
Abnormalities of fat distribution has been reported in individuals with HIV 
infection who have never been treated with antiretrovirals [250-252]. It is 
not clear whether this is due to the direct effect of the virus or due to the 
effect of cytokines liberated by chronic infection [251, 252].                                             
Several studies suggested a link between immune or inflammatory factors 
and fat redistribution. Pro-inflammatory cytokines are known to stimulate 
lipolysis and inhibit adipose tissue lipogenesis [74, 222, 253, 254]. Some 
risk factors for fat distribution apart from ART have been identified within 
cohort studies and potentially in prospective studies that include host and 
genetic factors. In the HIV Out-patient Study (HOPS), patients who had 
low CD-4 count that did not recover in the survey period of 23 months 
had a 10 fold increased risk of lipoatrophy independent of drug treatment 
[213]. Other Studies have found associations between the development of 
lipodystrophy and nadir CD4+ cell count as well as the rise in CD4+ cell 
count during HAART, independent of specific antiretroviral agents [213, 
214]. Data from Western Australia [255, 256] showed doubling of the risk 
of LA in association with a polymorphism of TNF alpha gene. 
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 1.4.5. Effect of PI                                                                                                     
Several studies have now shown that PI use is associated with 
lipohypertrophy [215, 218]. The median time from the use of protease 
inhibitors to the development of lipodystrophy is 18 months [215, 218]. 
Prior reports had shown that ritonavir/saquinavir combinations had a 
stronger association with lipodystrophy than indinavir or nelfinavir [212, 
221]. One study revealed that switching from other protease inhibitors to 
nelfinavir led to an improvement in lipodystrophy symptoms [257]; 
however, recent findings suggest that the incidence of lipodystrophy does 
not vary significantly across different protease inhibitors [25, 211, 258]. 
On the other hand other studies suggest that risk of lipoatrophy with 
ritonavir boosted PI is less compared to NNRTI or unboosted PI. The 
effects of ritonavir boosted lopinavir (LPV/r) with zidovudine and 
lamivudine (AZT/3TC) combination therapy followed by LPV/r 
monotherapy on lipoatrophy and lipohypertrophy were evaluated in a 96-
week  sub analysis of 613 study [203]. Treatment-naive patients (n=155) 
were randomly assigned to treatment with LPV/r + AZT/3TC for up to 48 
weeks, followed by LPV/r monotherapy or efavirenz (EFV) with AZT/3TC or 
LPV with AZT/3TC combination. Lipoatrophy and lipohypertrophy were 
defined as >20% limb fat loss and gain, respectively, on DEXA scans. 
Only 5% of patients receiving LPV/r monotherapy exhibited lipoatrophy 
compared with 34% in the EFV treatment arm (P<0.001). Between LPV/r 
monotherapy and AZT/3TC/EFV combination group lipohypertrophy 
occurred in similar percentages of both groups (45% and 44% of the 
LPV/r and EFV groups, respectively; P<0.99), and lipohypertrophy and 
lipoatrophy occurred together in 0% and 16% of the groups, respectively 
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(P=0.002). These results indicate that treatment with LPV/r is significantly 
associated with a sparing of peripheral lipoatrophy when compared with 
an NNRTI-containing regimen. However, there was no difference in 
peripheral fat loss between AZT/3TC/LPV/r arm and AZT/3TC/EFV arm, 
suggesting that lipoatrophy observed in this study was mostly due to AZT 
use in both arms. Further randomized control prospective study might 
give more light in to the effect of boosted PI on fat loss.  
1.4.6. Effect of NRTI                                                                                         
Although several early cross-sectional studies suggested association of fat 
distribution abnormalities with protease inhibitor use, other studies 
provided clear evidence that these could occur in PI- naive subjects [259]. 
Specific roles for each class of drugs have not been defined, but an 
association between lipoatrophy and NRTIs have been shown in other 
studies [260, 261]. 
Several studies assessing lipoatrophy, the most common statistically 
significant risk factors were exposure to and duration of thymidine 
analogues, most commonly stavudine (d4T). A prospective, randomized, 
controlled trial (ACTG-384) after 80 weeks of follow up, demonstrated 
more rapid and severe fat loss in d4T-ddI arm compared to AZT-3TC 
[262].  Data from the mitochondrial toxicity (MITOX) study demonstrated 
that peripheral (limb) fat, as assessed by DEXA and CT scans, increased 
over long-term follow-up after switching from thymidine analogue-based 
therapy to abacavir-based therapy [163]. At week 104, patients who 
switched to abacavir showed a 1.26-kg mean increase in limb fat, relative 
to baseline. Multivariate analysis demonstrated that the increase in limb 
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fat was associated with less exposure to the thymidine analogues before 
the study [208]. The effect of thymidine analogues on lipoatrophy has 
been further exemplified in various other switch studies. Protease Inhibitor 
Induced Lipodystrophy Reversal Study (PIILR) after 120 weeks [209] 
revealed a statistically significant association with switching to thymidine 
analogue and limb fat mass reduction (d4T: 0.72 kg/y, P = 0.004; 
zidovudine [AZT]: 0.29 kg/y, P = 0.019). On the other hand, Boyd et al 
[210] reported preliminary results on the impact of replacing an NRTI 
regimen with an NRTI-sparing regimen (indinavir-ritonavir-efavirenz) in a 
48-week observational study of 61 patients. DEXA scans showed 
statistically significant increases in limb fat after 96 weeks of the NRTI-
sparing regimen. The recently presented RAVE (Randomized Abacavir 
versus Viread Evaluation) study [166]  and SWEET (Simplification With 
Easier Emtricitabine and Tenofovir ) study  demonstrated improvement in 
fat gain after switching patients from d4T and or AZT containing regiment 
to tenofovir or abacavir containing regime [263]. 
1.4.7. Effect of NNRTI                                                                                                
Current data indicates that some NNRTIs may also be associated with 
lipoatrophy. In the recently presented ACTG 5142 study after 96 weeks of 
follow up [172], limb fat had increased from baseline, a median of 18% in 
the ritonavir boosted lopinavir (LPV/r) with efavirenz (EFV) group 
compared with a median gain of 9.8% in the LPV/r with two NRTIs group. 
On the other hand 32% of patients receiving EFV with two NRTIs had 
lipoatrophy, compared with only 17% in the LPV/r with two NRTIs group 
and 9% in the NRTI-sparing LPV/r with EFV group. Although lopinavir and 
efavirenz were randomized, the patients had been preselected with which 
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nucleoside they were going to use. So they either used stavudine (d4T), 
zidovudine (AZT), or tenofovir (TDF). As expected lipoatrophy was more 
common in patients exposed to stavudine (d4T) and the individuals who 
used tenofovir, no matter which arm they were in, had very little 
lipoatrophy. Hence the possibility of channelling bias could not be 
excluded from the results. However, fat wasting of the limb was still more 
likely when participants were also taking EFV along with d4T, compared 
with patients given LPV/r with d4T. The use of tenofovir (TDF) was 
associated with the lowest incidence of lipoatrophy. In a logistic regression 
model, taking EFV along with the NRTIs increased the odds of developing 
lipoatrophy by 2.7-fold. In contrast to lipoatrophy findings, trunk fat 
increased by 12%–16% and did not differ significantly across the 
treatment groups. The results of this study indicate that EFV exacerbates 
the lipoatrophic effects of NRTIs and that thymidine analogues (AZT and 
d4T) produce more lipoatrophy of the extremities than TDF. However, EFV 
did not exert a demonstrable lipoatrophic effect when combined with 
LPV/r, suggesting that either the lipoatrophic effect is dependent on the 
presence of NRTIs or LPV/r has a protective effect against lipoatrophy. 
The ACTG 384 study [264], on the other hand had previously shown that 
patients randomly assigned to receive nelfinavir had a greater percentage 
loss of limb fat than those randomly assigned to the efavirenz arm; limb 
fat in the efavirenz arm also decreased, though to a lesser degree. The 
association of NNRTI with lipoatrophy could be due to the effect of 
nucleoside backbone and appears to be worse than ritonavir boosted PI. 
This could be the fact that ritonavir boosted PI have protective action 
against lipoatrophy but NNRTIs, particularly efavirenz may not have that 
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effect. Further prospective studies might be avle to add more insight in to 
the role of NNRTI on fat loss. 
In essence, both lipoatrophy and lipohypertrophy and fat restribution as a 
whole in individual patients could be the effect of combination of several 
fators including the combined effect of different antiretroviral drugs. Apart 
from thymidine analogues lipoatrophy has not been clearly associated with 
any other antiretrovirals. Fat gain in the early weeks of treatment is 
common with other antiretrovirals and fat gain as a whole is more 
common with regimens containing ritonavir boosted PIs.  
 
1.4.8. Assessment                                                                                      
Different cross-sectional imaging techniques have been used for the 
assessment of fat redistribution. However, there is no gold standard 
method for measuring body fat. Computed tomography (CT) scanning 
provides information about abdominal subcutaneous and visceral fat, but it 
is associated with radiation exposure and should not be used clinically for 
this purpose [25].                                                                             
The dual-energy x-ray absorptiometry (DEXA) scan and magnetic 
resonance imaging (MRI) may have merits but are not used in routine 
clinical practice mostly because of cost and limited availability [265]. A 
clinical case definition, based on physician and patient agreement [241], 
is of limited value for individual patient management, because of lack of 
specificity and is not recommended in routine use [25].  
Anthropometric measurements such as the waist-to-hip ratio have been 
repeatedly shown to correlate with health outcomes [266-268]. The major 
advantages of anthropometry are its safety, portability, and low cost. The 
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lack of specificity of changes in the waist-to-hip ratio limits its use as a 
clinical tool. Although the measurements are standardized, they require 
considerable training and retraining for the results to be reproducible. In 
addition, only gross cut-offs are available for assigning subjects as normal 
or abnormal, and no published data allow translation of waist 
circumference to visceral adipose tissue (VAT). Also very little data are 
available for non-white other ethnic groups.                                                               
Bioelectrical impedance analysis (BIA) estimates whole body composition 
[266], though attempts have been made to modify the measurement for 
regional purposes. To date, methods to use BIA for regional body 
composition have not been validated against criterion methods, and thus 
cannot be recommended for this purpose.                                                        
Theoretically, ultrasound is a better technique than DEXA since it can 
accurately separate adipose and lean compartments and allow 3-
dimensional measurements. The depth of specific adipose tissue 
compartments can be measured, including those on the face, an area that 
has not been measured with cross-sectional imaging to date. However, its 
application to HIV infection has been very limited.                                                                       
1.4.9 Mechanism of fat distribution or lipodystrophy                         
Several pathogenic mechanisms and risk factors for fat redistribution in 
HIV have been postulated (table 1.8). The mechanism appears to be 
different for lipoatrophy and lipohypertrophy. 
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Table 1.8: Potential risk factors and mechanism for Fat distribution in HIV 
infection [189, 213, 221, 223, 269-275] 
 
                                             
 
 
 
 
 
 
 
• Host Factors 
o Male Sex 
o White Ethnicity 
o Older Age 
o Baseline BMI 
o Duration of HIV Illness 
o Effectiveness of viral suppression 
 
• Impairment of adipocyte function 
o Adipocyte apoptosis 
o Adipocyte differentiation 
 
• Mitochondrial toxicity 
o Inhibition of DNA polymerase-γ 
o Decrease in DNA content 
o Mitochondrial dysfunction 
 
 
• Genetic Predisposition 
o Haemochromatosis gene expression (HGE) 
o Association with DNA haplo type J 
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1.4.9.1. Impairment of adipocyte function  
1.4.9.1.1. Adipocyte apoptosis                                                                             
Lipoatrophic tissue from HIV patients showed increased expression of 
TNF-α, a cytokine known to induce apoptosis of adipocytes. A genetic 
case-control study [276] conducted in HIV-positive patients both with     
(n = 61) and without (n = 35) lipodystrophy found a significant difference 
between groups in the frequency of polymorphism -238 in the promoter 
region of the TNF-α gene, suggesting that the -238 polymorphism is a 
determinant in the development of HIV-related lipodystrophy.                                                             
Nolan et al [277], using fat biopsy samples from HIV patients including 
both treatment-naïve and treatment-experienced patients showed 
increased expression of several adipocyte-specific pro-inflammatory 
cytokines (IL-18, IL-6, TNF-α, IL-8, IL-12) and significant correlation with 
increased lipoatrophy. More macrophage infiltration, cytokine expression, 
and mtDNA depletion were noted with stavudine or zidovudine therapy but 
not following initiation of abacavir (tenofovir was not studied in this 
study). Switching from stavudine or zidovudine was associated with 
increased mtDNA content and reduced macrophage numbers and cytokine 
expression, although without improvement in body fat mass. Protease 
inhibitor therapy had no effect. 
1.4.9.1.2. Adipocyte differentiation                                                                           
Bastard et al [278] showed that adipocytes from patients with lipoatrophy 
treated with NRTIs and PIs have higher levels of sterol-regulatory-
element-binding-protein-1 (SREBP1c, an adipocyte transcription factor) 
and higher expression of TNF-α, but the adipocytes were smaller and 
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tended to cluster, suggesting an impairment of differentiation despite the 
increased amount of SREBP1c protein. In other study [279]  using 3T3 
human preadipocytes, efavirenz induced a strong inhibition of the SREBP-
1c-dependent lipogenic pathway that might contribute to adipose tissue 
atrophy and could explain increased lipoatrophy seen in ptients in EFV arm 
in ACTG 5142 study.                                                                                                              
1.4.9.1.3. Mitochondrial toxicity (figure 1.11)                                                                                   
Inhibition of mitochondrial DNA polymerase is associated with nucleoside 
analogues and has been hypothesized to play a role in fat redistribution. 
Initial studies in lipodystrophic patients implicated a reduction in 
mitochondrial DNA [280] caused by interference of nucleoside analogues 
with mitochondrial DNA polymerase [281] and which was correlated to the 
clinical degree of lipoatrophy. Studies performed in vivo [167, 282, 283] 
and in vitro [284, 285] suggest a hierarchical effect of nucleoside 
analogues on mitochondrial DNA (mtDNA) with the dideoxy compounds 
(didanosine and stavudine) having a severe detrimental effect and the 
cytidine analogues (lamivudine, emitricitabine) the least. Zidovudine 
(AZT) and abacavir (ABC) are intermediate and tenofovir (TDF) appears to 
have little effect on adipocyte mtDNA [283].  Substitution of stavudine 
(d4T) with either AZT or ABC increases mtDNA in adipocytes [286]. It 
should be noted that many of the published studies have been performed 
on peripheral blood mononuclear cells (PBMC) which may behave 
differently from subcutaneous fat [287, 288].  
Abnormalities in mitochondrial-encoded respiratory complex genes and 
disturbances in cellular metabolism can also be shown in the absence of 
demonstrable reduction in mtDNA both in HIV-infected treatment-naive 
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patients [289] and in patients with lipodystrophy [290] and may occur 
before demonstrable changes in mtDNA in both HIV-infected patients 
[291] and HIV negative subjects [292] . Adipocyte maturation and 
differentiation is a complex process consisting of sequential activation of 
master transcription factors leading to expression of genes that determine 
adipocyte specific metabolic function [293, 294]. A number of 
transcription factors and co-activators have been shown to be reduced in 
lipodystrophic subjects compared to those without body fat changes 
[294]. While d4T causes lipoatrophy through depletion of adipocyte 
mtDNA depletion [295], AZT produced less, or no, mtDNA loss [283, 288, 
296] and the effect may be predominantly through other mechanisms 
such as interference with both nuclear and mitochondrial-encoded 
mitochondrial respiratory gene expression and oxidative function in the 
adipocyte and muscle and other tissues [292]. Mitochondrial DNA 
depletion has also been shown to correlate poorly with respiratory chain 
activity [297]. Even at low rates of respiratory impairment, increase in 
reactive oxygen species (ROS) can occur [298]  and may be important in 
the early crucial events in HIV related lipodystrophy [187].  
Lower mitochondrial DNA content per adipocyte from subcutaneous 
biopsies was correlated with severity of lipoatrophy and DNA depletion 
was more common in d4T group compared to AZT group. However, some 
studies have shown decrease in mtDNA content but not mitochondrial 
count or mitochondrial deletion, suggesting that a mitochondrial 
dysfunction is the result of reduced DNA content rather than DNA 
deletions. Similarly, Walker et al [281], found that mean mitochondrial 
DNA content was lower in buttock fat biopsies from NRTI-treated patients 
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than in the non-NRTI group, and patients with lipoatrophy had a lower 
mitochondrial DNA content than patients without lipoatrophy. Cherry et al 
[299], on the other hand have shown an increase of mitochondrial DNA 
(copies per adipocyte) 48 weeks after switching from a d4T-containing 
regimen to abacavir- or AZT-based therapy along with some improvement 
in arm, leg, and trunk fat. 
In an extensive study, Nolan et al [300] found mtDNA content to be 
reduced by 85% in patients treated with either zidovudine or stavudine, 
thereby exceeding the threshold for cell function to become impaired 
(Nolan et al. 2003). In another study Nolan et al also identified 
morphological differences within the biopsies consistent with other 
syndromes of mitochondrial depletion [76]. The effect of stavudine was 
consistently greater than that of zidovudine confirming the studies 
reported previously [277]. 
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Figure 1.11: Mitochondrial toxicity. In the normal situation (a) 
mitochondrial DNA (mtDNA) encodes for proteins (blue circles) in the 
respiratory chain, situated at the inner mitochondrial membrane. Most 
respiratory enzymes are encoded by nuclear DNA (nDNA) (red circles). 
Replication of mtDNA is regulated by the enzyme DNA polymerase . In 
inherited mitochondrial diseases (b), parts of mtDNA have been mutated 
or even deleted (green), which results in altered mtDNA-encoded proteins 
(green circles), leading to mitochondrial dysfunction. During NRTI 
treatment (c), DNA polymerase  will be inhibited, leading to 
mitochondrial depletion [280]. 
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1.4.9.1.4. Genetic predisposition                                                                                  
Mitochondrial haplotypes defined by pattern of single nucleotide 
polymorphism in mitochondrial genes and mutation in haemochromatosis 
gene (HFE) may have effect on fat distribution[301]. HIV-infected patients 
with a common mutation in the hemochromatosis gene (HFE), in 
combination with mitochondrial DNA haplogroup J, may be protected from 
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the development of lipoatrophy associated with antiretroviral therapy. In a 
sub study, AIDS Clinical Trials Group [301] assessed relationships 
between HFE gene variants, mitochondrial haplogroups, and peripheral 
lipoatrophy during ART in 96 ART-naive individuals randomized to 
didanosine-stavudine or zidovudine-lamivudine, combined with efavirenz, 
nelfinavir, or both. Patients with the HFE 187C>G polymorphism were less 
apt to develop lipoatrophy during ART. This association was independent 
of other factors including age, CD4 lymphocyte count, and specific 
antiretroviral therapy received [301]. In contrast TNF-α gene -238G/A 
promoter polymorphism were associated with a more rapid onset of 
lipodystrophy [276, 302] and in a sub anlysis of ACTG 5202 study, 
patients with mitochondrial haplotype-I were found to have a tendency 
(p=0.07) to more periphral fat loss compared to non-I haplotypes. 
1.4.9.1.5. Refutation of the Mitochondrial Toxicity hypothesis 
Supporting evidence for NRTIs as a pathogenic factor in lipoatrophy 
remains limited and has been refuted [303, 304]. Some studies failed to 
detect sufficient mtDNA inhibition to induce mitochondrial dysfunction 
[305, 306]. Other studies raised question about the validity of threshold in 
vivo [306, 307]. Arnaudo et al found myopathy with zidovudine use at 
only 22% of mtDNA depletion [308]. In addition, patients with less 
mitochondrial content or impairment were still found to be symptomatic. 
Molecular analysis of mitochondrial depletion in non-HIV inherited 
diseases was unable to substantiate an in-vivo threshold sufficient for 
mtDNA depletion and mitochondrial dysfunction [309, 310].  
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In summary, the underlying mechanisms and specific site(s) of 
dysregulation accounting for the morphologic abnormalities have not been 
identified. NRTIs possibly affect mitochondrial maturation and replication, 
PIs affect preadipocyte differentiation and HIV may have effects on both 
directly or via cytokines. 
 
Section 5: Insulin Resistance and Diabetes 
1.5.1. Overview 
Before the use of highly active antiretroviral therapy (HAART), blood 
glucose abnormalities were infrequently seen in people with HIV. But in 
June 1997, soon after protease inhibitors (PIs) came into widespread 
clinical use, the U.S. Food and Drug Administration (FDA) issued a health 
advisory warning of an association between PIs and hyperglycaemias and 
diabetes mellitus [311]. Since then, there have been continued reports of 
insulin resistance and diabetes in people using HAART (table 1.9).  
1.5.2. Prevalence                                                                                                           
Different studies have yielded widely varying estimates of the prevalence 
of impaired glucose metabolism in people on HAART. The prevalence of 
frank diabetes mellitus (DM) in people with HIV is relatively low, with 
studies reporting rates from 0.5% to 15% [312-315]. Impaired glucose 
tolerance is considerably more common, affecting an estimated 15-25%, 
and some studies suggest that some degree of insulin resistance may 
occur in one-half of patients taking PIs [149, 316, 317]. 
 
 
 
Chapter 1 
 79 
Table 1.9: Overview of key studies describing insulin resistance and diabetes in HIV infection 
Study (Ref) Number Design (comparing arm) Risk factor 
DAD (de Wit et al[318]). 33,389 Observational cohort Thymidine analogues 
MACS  [319] 1288 Prospective Cumulative use of NRTI 
Lo et al[320]. 95 Cross-sectional Cumulative NRTI use 
Visnegarwala et al[321]. 1389 Cross-sectional HCV infection, family history of 
diabetes, BMI, age above 50 
Yoon et al[322]. 147 Case-control BMI, family history and raised liver 
enzyme (ALT) 
Women’s Interagency HIV 
study (Tien et al[323]). 
2088 Prospective Duration of NRTI (d4T), family history, 
BMI, HCV infection, menopause 
Mehta et al[324]. 1230 Retrospective PI use and HCV infection 
Mulligan et al[325]. 29 Retrospective PI use 
Blumer et al[326]. 20 Randomized 
(AZT/3TC/LPV/r vs. LPV/r/NVP) 
AZT/3TC use 
Carr et al[327]. 140 Randomized 
(TVD/LPV/r vs. TVD/TPV/r) 
No difference in LPV/r vs. TPV/r 
Noor et al[328]. 26 Randomized cross-over 
(LPV/r vs. ATV/r) 
Increase in insulin resistance in LPV/r  
 
Noor et al[329]. 30 Randomized double blind cross 
over study (ATV vs. LPV/r)  
Increase in insulin resistance in LPV/r  
Noor et al[330]. 6 Randomized double blind cross 
over study 
(Single dose of IDV use) 
Immediate increase in insulin resistance 
after IDV use 
Brar et al[331]. 9151 Cross-sectional 
General population vs. HIV 
treatment naïve patients 
No difference 
Bedimo et al[332]. 19,424 Cross-sectional HCV co-infection 
Shikuma et al. 838 Cross-sectional HCV co-infection 
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1.5.3. Effect of HIV                                                                                                           
Several risk factors have been proposed as an underlying factor 
responsible for insulin resistance in HIV infection (table 1.10).   Although 
hyperinsulinemia was described in HIV-infected patients in the pre-HAART 
era, HIV infection by itself has not been conclusively implicated as a cause 
of insulin resistance. Potential mechanisms by which HIV infection could 
induce insulin resistance are not confirmed. 
 
Table 1.10: Potential risk factors and mechanism for Insulin resistance in  
HIV infection [320, 321, 333-350] 
 
 
Prevalence of insulin resistance in HIV patients does not appear to be 
higher in treatment naïve cases. Whether the virus itself has any direct 
role on glucose metabolism needs more investigation. In a cross-sectional 
Risk Factors 
• Peripheral lipoatrophy 
• Increased liver / muscle fat 
• Low testosterone 
• Oxidant stress 
• HCV infection 
• Protease Inhibitors 
 
Reduced Glucose uptake 
• Defect in GLUT-4 
• Defect in SREBP 
 
Pancreatic beta cell dysfunction 
 
Defect in adipocytokine 
• Low adiponectin 
• Increased TNF-α, IL-6, IL8 
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survey, Brar et al [331] (CPCRA clinical trial) compared factors associated 
with prevalent diabetes mellitus among HIV-infected antiretroviral-naive 
individuals versus HIV negative individuals in the National Health and 
Nutritional Examination Survey cohort. The prevalence of DM in the 
CPCRA clinical trials versus the NHANES was 3.3% versus 4.8%. The data 
did not suggest an increased prevalence of DM in ART-naive HIV-infected 
patients. The virus as such or the stage of the disease (HIV RNA level and 
CD-4 count) has not been found to have specific effects on the prevalence 
of diabetes mellitus in another study [322]. 
In contrast, during a 4-year follow-up period in the Multicenter AIDS 
Cohort Study (MACS), 24 (10%) of 229 HIV-infected subjects receiving 
HAART developed DM compared with 10 (3%) of 361 HIV-seronegative 
men. After adjustment for BMI and age, this difference represents a 
greater than 4-fold increase in the risk of incident DM among HIV-infected 
subjects receiving HAART [314].  
The recently presented result from D:A:D study [318] showed a lower 
incidence of new-onset diabetes mellitus than in the Multicenter AIDS 
Cohort Study (5.72 vs. 4.7 per 1,000 PYFU) [314]. This difference could 
be related to different size and demographic compositions of both cohorts 
as the MACS involved white males exclusively, who were likely to be 
exposed to the typical North American diet and who were older and had 
higher BMI than the D:A:D participants.   
Tien et al [351] recently reported a relative risk of incident self-reported 
DM of 2.0 (95% CI, 1.0- 4.1) when HIV-infected women receiving a PI 
were compared with an HIV-seronegative subgroup prospectively followed 
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in the Women’s Interagency HIV Study. The higher crude rate of incident 
DM in the HIV-infected, HAART-exposed group in the MACS compared with 
the Women’s Interagency HIV Study (4.7 vs 2.8 [95% CI, 1.6-4.1] cases 
per 100 person-years) may reflect a more sensitive case ascertainment 
method in the MAC cohort [314].  
Antiretroviral medications likely play a causative or permissive role in the 
pathogenesis of hyperglycemia in HIV-infected patients. In MACS cohort 
[314] only ritonavir use was significantly associated with an increased risk 
of a combined end point of DM or hyperglycemia.  
HIV–related non drug factors may be important in the development of 
metabolic abnormalities in HIV-infected patients. Severity of HIV disease, 
as estimated by the nadir CD4 cell count, has been associated with 
increased risk of lipoatrophy, and or lipodystrophy. In the MACS cohort, 
HIV-infected men with lower nadir CD4 cell counts had an increased risk of 
incident glucose abnormalities compared with those with higher nadir CD4 
cell counts. The possibility that confounding factors, such as more 
diabetogenic antiretroviral regimens in the more severely ill patients, 
contributed to this finding cannot be excluded. In contrast, higher CD4 
lymphocyte count was associated with lower insulin concentrations, and 
less evidence of insulin resistance. However, there was no association 
between HIV RNA level or history of prior AIDS diagnoses and measures 
of glucose homeostasis [73].                                                    
1.5.4. Effect of Hepatitis C Virus (HCV)                                                                                                          
Co-infection with the hepatitis C virus (HCV) increases the risk of blood 
glucose abnormalities [344, 352, 353]. Studies have shown that people 
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with chronic HCV infection are more likely to develop insulin resistance 
and type-2 diabetes [321, 324, 354-356]. A study from Johns Hopkins 
University in Baltimore found that people with HCV were four times more 
likely to develop type-2 diabetes than HCV negative people. The same 
study also found that HIV/HCV-co-infected patients were five times more 
likely to develop hyperglycaemia than those with HIV alone [324]. 
Similarly, recent study from USA [357] (Shikuma C et al. Po:931) and 
data from D:A:D group [358] and Veteran Affair (VA) group [359] found 
an increased association of insulin resistance and diabetes in HCV/ HIV 
coinfected patients.  
Although it is not clear how chronic hepatitis promotes blood sugar 
abnormalities, it is believed that liver damage affects the metabolism of 
glycogen and the production of glucose [344, 345]. Hepatic steatosis, iron 
deposition in the liver, and progressive HCV-induced liver damage may 
induce insulin resistance and predispose to DM. Increased hepatic fat 
content has been strongly correlated with elevated fasting insulin levels 
and is associated with impaired glucose tolerance in HIV-infected 
individuals. Chung et al from USA [360] reported that elevated alanine 
transaminase (ALT) liver enzyme levels independently can predict insulin 
resistance in HIV-positive individuals with lipodystrophy whether or not 
they were coinfected with HCV. None of the studies so far has found any 
association with hepatitis B virus (HBV) infection.  
1.5.5. Effect of Protease Inhibitors (PI) 
The use of PI, particularly indinavir appears to be more directly related to 
disorders of glucose metabolism than to other metabolic complications 
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such as body fat gain or loss [361, 362]. A study from Germany [150] 
reported that 46% of PI recipients had impaired glucose tolerance and 
13% had diabetes, compared with 24% and none, respectively, among PI-
naive subjects. Another study from Munich [317] reported that 61% PI-
treated subjects had reduced insulin sensitivity, which was seen in none of 
the treatment-naive HIV controls.  
A study from USA [325] reported development of insulin resistance (IR) 
within an average of 3.4 months after starting treatment with PI; the 
patients did not have any body shape changes. The group treated with 
only NRTIs did not experience similar changes.  
Among the PIs, indinavir has been most strongly associated with impaired 
glucose metabolism [330, 362]. Dube et al [363]  detected signs of IR in 
patients with HIV within eight weeks of starting indinavir. Mustafa Noor et 
al [330] from San Francisco found that insulin resistance without elevated 
lipid levels or body shape changes, developed within four weeks after 
starting indinavir in HIV-negative volunteers. In one of their studies, 
glucose disposal (uptake of glucose by cells) was reduced after a single 
dose of the drug, suggesting that indinavir itself directly triggers insulin 
resistance [364].  
Although most Pls are associated with significant glucose intolerance, 
saquinavir has relatively little effect, and atazanavir has no discernable 
effect [329]. Another study using boosted lopinavir and tipranavir with a 
backbone of tenofovir and lamivudine did not show any evidence of insulin 
resistance at 48 weeks therapy, but was present when used with AZT 
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[327]. Hence insulin resistance could be related more to thymidine 
analogues than to Pls.  
1.5.6. Effect of NRTI 
Use of thymidine analogues is increasingly associated with increase in 
insulin resistance estimated by homeostasis assessment (HOMA) model. 
The recently published Women Interagency HIV Study has shown an 
association of increased risk of diabetes with cumulative exposure of 
NRTIs [323]. Another study using boosted lopinavir and tipranavir with a 
backbone of tenofovir and lamivudine did not show any evidence of insulin 
resistance at 48 weeks therapy [327], but was present when used with 
AZT [326]. Hence insulin resistance could be related more to thymidine 
analogues than to Pls. However, Goebel et al [317] detected evidence of 
insulin resistance in 27% of HIV-positive people treated with NRTIs, 
although the rate in those receiving PIs was twice as high.  
NRTIs especially d4T and AZT (thymidine analogues) may indirectly 
contribute to glucose abnormalities by causing peripheral fat loss. 
However, in the recently presented D:A:D study the incidence of diabetes 
increased with cumulative exposure to HAART, an association that 
remained significant after adjustment for potential risk factors for diabetes 
[318]. The strongest relationship with diabetes was exposure to 
stavudine; exposures to zidovudine and didanosine were also associated 
with an increased risk of diabetes. Although lipodystrophy was 
significantly associated with diabetes, adjustment for this did not modify 
the relationship between HAART and diabetes.  
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1.5.7. Effect of NNRTI                                                                                              
Studies have not implicated non-nucleoside reverse transcriptase 
inhibitors (NNRTIs) in blood glucose abnormalities, although they have 
been linked with other metabolic manifestations in some studies.  
 
Similarly other agents including fusion inhibitors and integrase inhibitors 
have not any influence on glucose metabolism. 
1.5.8. Mechanism of Insulin resistance and Diabetes                                                                       
It is not clear exactly how PIs affect glucose metabolism, but research 
points to a variety of possible mechanisms including, decreased uptake of 
glucose by peripheral cells, decreased insulin production by beta cells in 
the pancreas, and increased glucose production by the liver.  
1.5.8.1. Studies in vitro 
1.5.8.1.1. Reduced glucose uptake by peripheral cells (figure 1.12)                                               
Several laboratory, animal, and clinical studies suggest that PIs may 
directly interfere with the transport of glucose into cells. An insulin-
sensitive glucose transport protein called GLUT-4 plays a key role in 
transporting glucose into fat and muscle cells [342, 343, 362, 365]. The 
insulin signalling pathway within both skeletal and adipose tissue is 
mediated by a series of phosphorylation cascades which can be either 
phosphatidylinositol 3-kinase (PI-3) dependent or independent. Within the 
PI-3 dependent pathway, activation of Akt is an important link in the 
translocation of GLUT-4 to the cell membrane [366]. It involves the 
intracellular translocation of GLUT-4 to the cell surface enabling the 
facilitated diffusion of glucose (figure 1.12).  PI inhibits the glucose uptake 
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through GLUT-4. PIs down regulates the phosphatidyle inositol-3 (PI 3) 
kinase cascade and also impair the intrinsic activity of GLUT-4, leading to 
reduced glucose uptake by cells [367]. In laboratory studies using 3T3-L1 
adipocytes, Haruhiko et al [368] found that indinavir and nelfinavir 
reduced glucose uptake by inhibiting GLUT-4 activity. This inhibition 
occurred within minutes, and was reversed when indinavir was removed.  
Caron et al [190] proposed another mechanism involving the sterol 
regulatory element binding protein (SREBP), a key fat cell messenger that 
triggers stem cells to differentiate into adipocytes. PIs including indinavir, 
nelfinavir, and amprenavir inhibited the production and activity of SREBP 
and also stimulated increased production of peroxisome proliferating 
activation factor gamma (PPAR-gamma), which promotes cellular glucose 
uptake in the presence of insulin. 
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Figure 1.12: The entrance of glucose into cells via GLUT-4 
translocation. PIs block GLUT-4 initiated glucose uptake in fat and 
muscle cells. 
IRS-1: Insulin Receptor Substrate-1; P1 3-kinase: phosphatidyl inositol 3 
kinase; Akt/PKB: protein kinase B.  
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1.5.8.1.2. Beta cell dysfunction                                                                                                                  
 Alternatively, the changes seen in glucose disposal may occur without 
GLUT- 4 blockade. In HIV-negative individuals, impaired glucose 
metabolism is often characterised by up-regulated insulin secretion rates 
(ISR) relative to impaired peripheral insulin sensitivity. Furthermore, 
insulin resistance within the β-cell itself may cause up-regulated insulin 
secretion. Using the hyperglycaemic clamp, Woerle et al [350] showed 
impairment of pancreatic β-cell function following 12 weeks of PI therapy, 
presumably by preferential impairment of first phase insulin secretion 
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[350, 369]. Similar results have also been reported in heavily treated 
NRTI and PI patients with Lipodystrophy [370].                                                               
A related protein, GLUT-2, allows beta cells in the pancreas to take up 
glucose to monitor blood sugar levels and regulate insulin release. Joseph 
Koster J et al from Washington University [371], found that indinavir in 
doses similar to those used in humans and other PIs at higher 
concentrations inhibit the activity of GLUT-2, thus reducing glucose uptake 
by beta cells. 
1.5.8.2. Studies in vivo                                                                                                              
Using the hyperinsulinemic euglycaemic clamp technique, Marc van der 
Valk et al [372] found that hepatic glucose production was 47% higher in 
the PI recipients than in HIV-negative control subjects. In addition, insulin 
induced suppression of glucose production was less in the PI group than in 
controls. Similarly, M  Noor et al [330] found that hepatic glucose 
production in healthy volunteers (both gluconeogenesis and 
glycogenolysis ) increased within four weeks of starting indinavir. Recently 
Noor et al [329] using hyperinsulinemic euglycaemic clamp technique has 
shown that HIV patients taking lopinavir had increased IR, as evidenced 
by increased glucose production and reduced rate of glucose disposal. The 
effect was not found in atazanavir users. However, Jackson et al [373] 
using same technique in HIV patients did not find any difference in IR 
between atazanavir and saquinavir, after 4 weeks of therapy.                                
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1.5.9 Insulin Resistance and Fat distribution                                                                                                        
Much remains to be learned about the relationship between blood glucose 
abnormalities and fat redistribution and lipid abnormalities in HIV patients. 
It is not clear whether all of these result from a common pathogenic 
mechanism.  
Several studies have shown that among patients taking PIs, insulin 
resistance was more common in those with body shape changes, either 
abdominal obesity or peripheral fat loss. Carr et al [374] further reported 
that patients with "buffalo hump" (accumulation of fat at the back of the 
neck) were at higher risk for insulin resistance and diabetes, although 
other studies have yielded conflicting results [244, 269, 374, 375].  
Similarly, Hadigan et al from Boston [376] found that among HIV-positive 
people in the Framingham Offspring Study (a large study of cardiovascular 
risk), those with body fat changes were more likely to have impaired 
glucose tolerance (IGT) and frank diabetes mellitus (DM). The IGT was 
much higher than DM (32% and 9% respectively). In another study, [377] 
insulin levels were most elevated in HIV-positive women with abdominal 
fat accumulation, independent of PI use. The same study group also 
reported insulin resistance in men with AIDS-related wasting syndrome 
who were treated with NRTIs but not PIs, and noted that reduced lean 
body mass and increased abdominal fat were the primary predictors of 
hyperinsulinemia [319].  
Peripheral fat loss leads to increased insulin resistance [378]. Vigouroux 
et al [379] found that among study participants receiving PIs, 11 out of 
14 (79%) with severe facial wasting had either insulin resistance or 
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diabetes, compared with just four out of 20 (20%) without facial fat loss. 
In this study, elevated triglycerides were also more common in the group 
with facial wasting and insulin resistance was greatest in those with fat 
loss. Similarly, Andersen et al [369] from Copenhagen reported that loss 
of limb fat was the strongest predictor of insulin resistance and decreased 
insulin production, independent of the type of antiretroviral therapy used.   
Other studies indicate that blood glucose abnormalities are not directly 
caused by body fat changes or dyslipidaemia. Mulligan et al [325], for 
example, found that blood glucose abnormalities developed just a few 
months after people began taking PIs, well before body shape changes 
occurred. Saint-Marc et al [380] reported that when individuals with 
peripheral fat loss switched from d4T (which is strongly associated with 
lipoatrophy) to either abacavir or AZT, they experienced increased 
subcutaneous fat but no improvement in insulin resistance.  In contrast 
substitution d4T with abacavir (ABC) in ABCDE study [114] showed 
improvement in insulin resistance in the ABC group.                                                                                     
There are not yet enough data to establish the exact relationship between 
blood glucose abnormalities, fat redistribution and lipid abnormalities in 
HIV patients. It is not clear whether all of these results from a common 
pathogenic mechanism, but a link between all these changes are possible. 
The fat cells may play an important role. 
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Section 6:  Fat cells as secretary organs: adipocytokines 
1.6.1. Overview 
It is now recognized that adipose tissue produces multiple bioactive 
peptides, termed adipokines or adipocytokines, which not only influence 
adipocyte function but also affect more than one metabolic pathway 
through the bloodstream [381-385]. So far, many adipokines have been 
identified (figure 1.13). They all integrate in a communication network 
with other tissues and organs such as the skeletal muscle, adrenal cortex, 
brain and sympathetic nervous system and participate in appetite and 
energy balance, immunity, insulin sensitivity, angiogenesis, blood 
pressure, lipid metabolism and haemostasis [384]. Role of different 
adpocytokines, proinflammatory and inflammatory cytokines in lipd 
disroders, fat restribution and insulin resistance in HIV infection have been 
described in different stidies (table 1.11). 
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Table 1.11: Overview of key studies describing role of adiponectin and other cytokines in HIV infection 
 
PAI: plasminogen activator inhibitor-1; sTNFR1: soluble tumour necrosis factor-alpha receptor 1 
 
Study Number Design Changes 
Reeds et al[386] 30 Cross-sectional Low adiponectin and high IL-6 correlated with 
insulin resistance 
Chaparro et 
al[253]. 
34 Cross-sectional PI exposure reduces adiponectin gene expression 
Addy et al[387].  112 Cross-sectional Low adiponectin correlated with raised TG, insulin 
resistance and visceral fat, but negatively with 
peripheral fat loss and low HDL   
Carr et al[327],  140 Prospective Adiponectin increased more with higher dose of 
RTV 
Kosmiski et 
al[388] 
1429 Cross-sectional Adiponectin positively correlated with leg fat, but 
not arm fat 
Jones et al[389]. 
2006 
64 Cross-sectional Adiponectin correlated with peripheral fat loss 
and more common in patients receiving d4T and 
AZT 
Vigouroux et 
al[390]. 2003 
131 Cross-sectional Insulin sensitivity correlated with adiponectin and 
negatively with leptin and IL-6 
Dzwonek et al 
[391]. 
104 Prospective No association of serum leptin with lipodystrophy 
Verkauskiene et 
al[392]. 
130 Cross-sectional Lypodystrophy associated with serum adiponectin 
but not with leptin 
Wunder et 
al[393]. 
97 Case-control  No association of lipoatrophy with serum leptin 
levels 
He et al[394]. 36 Cross-sectional Visceral fat gain assocated with increased plasma 
TNF-alfa, sTNFR1 and PAI-1 
 
Chapter 1 
 94 
1.6.2. Adiponectin                                                                                                                       
Adiponectin is almost exclusively expressed in white adipose tissue [395]. 
Adiponectin sensitises peripheral tissues to insulin [396, 397]. Adiponectin 
appears to be the only adipose-specific protein known to date that is 
negatively regulated in obesity.  In a group of normal weight and obese 
women plasma adiponectin was negatively correlated not only with the 
body mass index and body fat mass, but also with fasting insulin 
concentration and calculated insulin resistance [398].   
Adiponectin activates adenosine monophosphate kinase (AMPK) in skeletal 
muscles and the liver, increasing fatty-acid oxidation and reducing hepatic 
glucose production [399]. Two receptors for adiponectin, Adipo R1 and 
Adipo R2 have been cloned and are expressed predominantly in muscles 
and liver [400].  
In a large number of non diabetic women with dyslipidaemia, Matsubara 
and others [401] have shown that plasma adiponectin is negatively 
correlated with serum triglyceride, atherogenic index, apo-B or apo-E and 
positively correlated with serum HDL cholesterol or apo-A1 levels.  This 
data suggests that existence of a negative feedback mechanism between 
adipose mass and production of adiponectin in humans is possible.                                    
Adiponectin also has antiatherogenic properties, as shown in vitro by its 
inhibition of monocyte adhesion to endothelial cells and macrophage 
transformation to foam cells [402, 403]. High plasma adiponectin was 
associated with reduction of risk of myocardial infarction (MI) in men 
[404].  
A relationship between low circulating levels of adiponectin and 
lipodystrophy in HIV patients has been described [387, 405]. Use of 
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stavudine was associated with low adiponectin level in plasma, and 
increased insulin resistance compared to abacavir [114]. But a 
relationship of adiponectin with lipid metabolism in HIV patients has not 
been delineated, especially in the absence lipoatrophy.   
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Figure 1.13: The adipocyte as a secretary organ [406]  
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Figure 1.14: Peripheral fat loss leads to increased insulin resistance 
(adapted from Van Wijk et al [378].  
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1.6.3. Leptin 
Leptin is perhaps the most intensively studied adipocytokine with reported 
effects on food intake [407, 408], energy expenditure, and lipid 
metabolism, particularly in rodents [409]. In humans, adipocytes secrete 
leptin in direct proportion to the amount of adipose mass, and this 
secretion is greater in subcutaneous tissue relative to visceral adipose 
stores [410]. There is strong evidence showing that the dominant action 
of leptin is to act as a 'starvation signal'. Leptin declines rapidly during 
fasting. In patients with lipodystrophy and leptin deficiency, leptin 
replacement therapy improved glycemic control and decreased triglyceride 
levels [411, 412].  
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1.11.3. Tumour necrosis factor (TNF)-α 
TNF-α is a cytokine involved in systemic inflammation and is a member of 
a group of cytokines that stimulate the acute phase reaction. It is 
produced mainly by macrophages, but they are produced also by a broad 
variety of other cell types including adipose tissue [413]. TNF-α has been 
shown by a number of authors to be over expressed in patients with 
lipodystrophy [250, 252], as well as correlating with markers of insulin 
resistance and hyperlipidemia [250] in patients with subcutaneous 
peripheral wasting. Patients who stop taking PIs have been shown to have 
a significant fall in circulating plasma TNF-α, perhaps indicating a 
pathogenic role for this class of antiretrovirals [414]. Similarly, both 
animal and human studies have indicated that TNF-α can inhibit adipocyte 
differentiation[415], modulate lipid metabolism [416] and enhance 
plasminogen activator inhibitor levels [417, 418], suggesting important 
effects in patients with lipodystrophy [419] and insulin resistance.  
Two cell surface TNF-α receptors were described in humans, TNF-R1 and 
TNF-R2. Soluble forms of those receptors (sTNF-R1 and sTNF-R2) are 
present in plasma and it is supposed that their concentrations might 
reflect local action of TNF-α in tissues [420, 421]. Soluble tumour necrosis 
factor receptors (sTNF-Rs) play a role as modulators of the biological 
function of TNF-α in an agonist/antagonist pattern. It is proposed that 
soluble TNF receptors, particularly sTNF-R2 might serve as the best 
predictor of local TNF-α system activity [421]. In various pathologic states 
the production and release of sTNF-Rs may mediate host response and 
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determine the course and outcome of disease by interacting with TNF-α 
and competing with cell surface receptors. The determination of sTNF-Rs 
in body fluids such as plasma or serum has been showing high accuracy in 
the follow-up and prognosis of various diseases. Endogenous sTNF-Rs 
concentrations appear to reflect the activation state of the TNF-α  /TNF 
receptor system [422]. 
1.6.4. Interleukin-6 (IL-6) 
Interleukin-6 (IL-6) is reported to have multiple effects ranging from 
inflammation to host defence and tissue injury [423]. It is secreted by 
adipose tissue and many other cell types, including immune cells, 
fibroblasts, endothelial cells and skeletal muscle and only about 10% of 
the total IL-6 appears to be produced exclusively by fat cells. Secretion of 
IL-6 varies from different sites, omental fat producing threefold more IL-6 
than subcutaneous adipose tissue [424]. Plasma IL-6 concentrations 
correlate positively with human obesity and insulin resistance, and high 
IL-6 levels are predictive of type 2 diabetes. IL-6 is related to insulin 
resistance in patients with high-grade inflammation. An association with 
increased incidence of CVD has been observed in HIV patients when 
antiretroviral treatment was interrupted [66]. A positive correlation was 
found with viral replication and IL-6 level [66]. Whether IL-6 plays any 
definite role in lipid metabolism in HIV patients has not been established.   
1.6.5. Interleukin-8 (IL- 8) 
Interleukin-8 is produced and released from human subcutaneous and 
visceral adipose tissue, and subcutaneous adipose tissue obtained from 
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HIV-infected people with fat redistribution and insulin resistance [425]. It 
is a member of the chemokine super family [426], enhancing vascular 
smooth muscle cell proliferation, monocyte adhesion to endothelial cells, 
and is believed to have pro-atherogenic properties[427]. Oxidized low-
density lipoprotein, which is well described in the atherosclerotic process, 
stimulates the release of IL-8 from macrophages in the atherosclerotic 
lesion[428]. IL-8 has, besides its implications for atherosclerosis, mostly 
been known for its association with different inflammatory processes.                                                                           
Higher serum IL-8 levels was found in HIV patients with impaired glucose 
tolerance [429], and this is consistent with findings in type 2 diabetes 
mellitus [430], obesity and non-alcoholic fatty liver disease [431]. It is 
possible that the chronic inflammatory state in HIV-infection can be 
associated with elevated fasting serum level of IL-8. Higher serum IL-8 
may also reflect increased production and release from the larger adipose 
depots and may have influence on lipid metabolism along with its effect on 
insulin resistance. The level of IL-8 in blood might change with HAART and 
the effect in lipid metabolism and insulin resistance might change as well.  
1.6.6. Other adipose secretary proteins                                                                                                                
A new adipocytokine termed resistin was identified in 2001 and was found 
to play an important link between insulin resistance and obesity in rodent 
models[432]. In humans, however, studies investigating the link between 
resistin and metabolic disease are conflicting. Resistin in human is 
produced mainly by macrophages rather than adipocytes and has shown 
to have strong association with inflammation and inflammatory 
states[433, 434]. Patients with HIV infection, resitin levels decreased after 
use of rosiglitazone, but correlation between resistin level and insulin 
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resistance or inflammatory markers were found[435]. However, further 
study failed to show any significant difference between mean resistin 
levels of HIV subjects with and without lipodystrophy[436].  
Plasminogen activator inhibitor (PAI-1) is another adipocytokine produced 
mostly by the adipocyte. PAI-1 is a key factor in the regulation of 
fibrinolysis [437]. Both visceral and subcutaneous adipose tissue produce 
PAI-1, but data are controversial as to whether visceral adipose tissue 
produces more, similar amounts of, or less [438-440] PAI-1 than 
subcutaneous adipose tissue.  
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Chapter 2 
Study Rationale 
Antiretroviral treatment of HIV infection is associated with disturbances in 
body fat distribution[180, 224, 441],  dyslipidaemia [150, 180, 224] , 
insulin resistance [150] and diabetes [314, 318]. The exact mechanisms 
of these changes have not been fully understood. At least three different 
processes may contribute: the effect of HIV infection, the effects of some 
antiretroviral drugs and the chronic effects of antiretroviral therapy on 
regional fat distribution.  
HIV infection itself has been reported to increase triglyceride levels [109, 
132], impair triglyceride metabolism and lipoprotein lipase activity [132].  
HIV-infected patients also exhibit reduced plasma cholesterol, low density 
lipoprotein (LDL) cholesterol and apolipoprotein-B 100 [442]. Additionally 
they have reduced high density lipoprotein (HDL) and apo-A1 associated 
with this lipoprotein [132], and higher total cholesterol/HDL cholesterol 
ratio [109]. The changes may be due to direct effect of the virus or may 
be driven by different cytokines generated by the infection.  
Treatment with HIV protease inhibitors for very short periods causes 
hypertriglyceridaemia and impaired insulin sensitivity [363] even in HIV 
negative subjects [194]. Antiretrovirals of nucleoside reverse transcriptase 
inhibitor (NRTI) group cause dyslipidaemia as well [55]. The non-
nucleoside reverse transcriptase (NNRTI) affect lipid metabolism [55] but 
the changes are different from others.  
The fat redistribution, which only becomes apparent after several months 
on treatment, is associated with dyslipidaemia and insulin resistance [264, 
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443] though dyslipidaemia may occur in the absence of obvious 
lipodystrophy [326]. Both the nucleoside reverse transcriptase inhibitor 
(NRTI) and the protease inhibitor (PI) component of highly active 
antiretroviral therapy (HAART) contribute in an as yet undefined way to 
the lipid abnormalities and body fat distribution. The non-nucleoside 
reverse transcriptase inhibitor (NNRTI) component of HAART may also 
contribute to the dyslipidaemia [55, 172] though its relation to the 
lipodystrophy is unclear. 
Fat redistribution with loss or accumulation of excess fat in different 
regions can be associated with changes in adipocytokines. The 
adipocytokines also play key roles in glucose and fat metabolism. 
Hypothesis 
Lipoprotein metabolism takes place in a number of physiological 
compartents and serum levels are a function of two opposing processes of 
either synthesis or catabolism.  
We postulate that lipoprotein catabolism and possibly synthesis may differ 
in patients receiving PIs compared to those taking NNRTIs and perhaps 
aloso between different NRTIs.  
We also postulate that loss of peripheral fat in HIV patients would result in 
decreased plasma adipocytokines, in particular adiponectin, which would be 
associated with changes in VLDL, IDL and LDL apolipoprotein-B (apo-B) 
kinetics.  
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Our key aim is : 
1. To investigate the relationship of apo-B metabolism with 
dyslipidaemia. 
2. To investigate the relationship between apo-B metabolism and fat 
distribution. 
3.  To investigate the relationship of insulin resistance with fat 
distribution and lipid changes. 
4. To investigate the relationship of adiponectin and other cytokines 
with apo-B metabolism, lipid changes, insulin resistance and body 
fat distribution. 
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CHAPTER 3 
Apolipoprotein-B Kinetics in HIV infection 
3.1. Introduction                                                                         
With the advent of highly active antiretroviral therapy (HAART) the 
spectrum of HIV illness has changed remarkably. There has been dramatic 
improvement in the survival rate amongst HIV patients [36]. However, 
metabolic abnormalities including dyslipidaemia in the form of high 
triglycerides (TG), high total cholesterol (TC), low density lipoprotein 
(LDL) -cholesterol and low high density lipoprotein (HDL) -cholesterol 
have been observed more frequently [55, 180]. The mechanisms 
responsible for the changes in different lipoprotein fractions in HIV 
infection and with different treatment regimes are not clear.   
Dyslipidaemia in HIV patients can directly stem from the viral infection. 
Several studies in early 1990s [109, 132] have shown dyslipidaemia in 
treatment naïve HIV patients. Hypertryglyceridaemia due to increased 
very low density lipoproteins (VLDL) has been reported in bacterial, viral 
and other infections [444-446]. Decrease in plasma cholesterol levels 
have also been reported during infection ([447, 448]4-8). Infections other 
than HIV can increase plasma triglyceride (TG) levels by decreasing the 
clearance of circulating lipoproteins, a process thought to be the result of 
reduced lipoprotein lipase (LPL), or by stimulating hepatic lipid synthesis 
through increases in either hepatic fatty acid synthesis or reesterification 
of fatty acids derived from lipolysis [131]. Patients with HIV infection also 
exhibited reduced plasma cholesterol, low density lipoprotein (LDL) 
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cholesterol, apolipoprotein-B 100 (apo-B),  reduced high density 
lipoprotein (HDL) and apolipoprotein-A1 (apo-A1) [109]. The Multicenter 
AIDS Cohort Study (MACS) found that lipids were in the normal range in 
men prior to infection but TC, LDL-C, and HDL-C declined on 
seroconversion [110].  
 
Lipid disorders are more common with antiretrovirals especially with PI 
use. Treatment with ritonavir for very short periods causes 
hypertriglyceridaemia [363]. Both nucleoside reverse transcriptor inhibitor 
(NRTI), particularly thymidine analogues and the protease inhibitor (PI) 
component of highly active antiretroviral therapy (HAART) contribute to 
the lipid abnormalities and both drugs can cause abnormalities of body fat 
distribution. The underlying mechanism is yet to be clealrly defined. The 
non-nucleoside reverse transcriptor inhibitor (NNRTI) component of 
HAART may also cause lipid abnormalities though its relation to body fat 
redistribution is not clear.  
Kinetic studies [103, 449] performed to explore VLDL-TG metabolism in 
type 2 diabetes mellitus patients, have demonstrated an increased VLDL-
TG synthesis and decreased VLDL-TG fractional catabolic rate. Both 
contributed to high plasma TG level in type-2 diabetic patients. However, 
conflicting results have been described about metabolism of apo-B 
containing lipoproteins; either increased synthesis or decreased 
catabolism or both have been described in different studies in HIV patients 
[128, 130, 152, 450]. Increased synthesis of apo-B containing lipoproteins 
has been described in a small number of HIV patients who have significant 
dyslipidaemia [130]. In five patients with ART induced high TG and 
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moderate TC level, a stable isotope tracer kinetic analysis revealed 
reduced transfer rates of VLDL in to denser lipoproteins suggesting a 
lower activity of lipoprotein lipase delipidation activity. The same study in 
addition showed increased synthesis of apo-B. The rate of apo-B transfer 
from more TG rich larger VLDL (VLDL 1) to smaller VLDL (VLDL 2) was 
also reduced. It was noteworthy that all the five patients had significant 
insulin resistance. The discrepancies observed between different results 
concerning VLDL apo-B metabolism in HIV patients may be due to 
differences in patient characteristics and the small numbers of the study 
population [130]. Very little information has been reported on IDL apo-B 
and particularly LDL apo-B metabolism, while LDL apo-B plays an 
important role in lipid metabolism and atherogenesis.  
This study investigated the effect of established antiretroviral therapy, for 
at least one year (1-6 years), on very low density lipoprotein (VLDL), 
intermediate density lipoprotein (IDL) and low density lipoprotein (LDL) 
kinetics. We performed a cross sectional stable isotope tracer kinetic study 
in a large number of subjects including HIV-negative controls, HIV-
infected patients naïve to antiretroviral therapy and patients taking HAART 
including PI, or the NNRTI efavirenz or nevirapine.  
3.2. Objective  
To explore whether the changes in lipid metabolism in HIV patients is 
related to modification of synthesis or catabolism or both in different apo-
B containing lipoprotein fractions.  
 
Chapter 3 
 108 
3.3. Subjects and Methods 
3.3.1. Subjects 
Subjects were 67 individuals which included 41 cases and 26 controls 
(table 3.1). Cases were HIV patients recruited from the HIV clinic in 
University Hospital Birmingham at Selly Oak hospital.  
3.3.2. Cases.  
Cases were HIV infected patients who were taking two nucleoside 
analogues plus either a protease inhibitor (PI, n=15), or the non-
nucleoside reverse transcriptor inhibitors nevirapine (NVP, n=11), or 
efavirenz (EFV, n=14) for between 1 – 6 years. Patients on PI were taking 
nelfinavir (n= 6) lopinavir/ritonavir (n=3), ritonavir alone (n=2) and with 
indinavir (n= 2) or saquinavir (n=1) or indinavir alone (n=1). The most 
common nucleoside analogues were zidovudine (AZT) and lamivudine 
(3TC) used in 28 patients (66.7%, table 3.2). Twenty nine (69%) patients 
were taking AZT containing and 10 (24%) were taking stavudine (d4T) 
containing regimens. Seven patients (16.7%) had previously taken 
another antiretroviral regimen for a median of 17.2 months (range 5-44) 
but had been on the current treatment for a median of 42.9 moths 
(range14-71) at the time of the investigation.  
3.3.3. Controls  
Controls were fifteen HIV infected patients naive to antiretroviral therapy 
(TN) and twelve presumed HIV-negative individuals who were mostly from 
medical students or healthcare professionals in attachment or working in 
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the University Hospital Birmingham. A negative HIV test within the last 
three months was required if history revealed a risk of HIV acquisition. 
Two subjects were identified who subsequently had the HIV antibody test 
and the results were negative. In the others an HIV antibody test was not 
done as unlinked anonymous HIV tests in patients attending sexually 
transmitted disease (STD) clinic in Birmingham between 1994-2001 
showed HIV rates ranging from 0.04 - 0.25% in those without identifiable 
risk factors and there was no identifiable trend. The results were similar to 
those obtained nationally, excluding London and Scotland, in 2002 of 0.2 
% in UK born heterosexual females [451]. 
3.3.4. Medical history 
The following history was obtained: history of cardiovascular disease, 
history of past medical illness and diabetes in first degree relatives, 
smoking, alcohol intake, use of other medication. All patients had a 
thyroid function test performed.  
3.3.5. Exclusion criteria  
The exclusion criteria were fasting glucose more than 6.0 mmol/liter, 
hypothyroidism, serum creatinine more than 150 mmol/liter, alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST), gamma 
glutamyle transferase (GGT) more than five times upper limit of normal, 
clinical anaemia or haemoglobin less than 10 gm% in females and 12 
gm% in males, and more than 10% loss in body weight in the last 6 
months and history of AIDS defining illness in last 3 months, use of 
glucocorticoids, or any other drugs that are known to affect lipid 
metabolism. A minimum of 6 weeks of wash out period was allowed in 
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case any patient was on lipid lowering treatment and patients were 
adviced to restart lipid lowering treatment the day after the study was 
performed.    
 
3.4. Methods and Materials  
3.4.1. Study design  
This is a cross-sectional case control, collaborative study between the 
Department of HIV Medicine, University Hospital Birmingham and Department 
of Diabetes and Endocrinology, St Thomas Hospital, London. The patients and 
all other study participants were recruited by Dr Satyajit Das (SD) and Dr 
Mohsen Shahmanesh (MS) and consent was obtained by SD on the day of the 
test. The Study protocol was written jointly by SD and MS. Samples were 
collected by SD and the nursing staffs of Welcome Research Facility, 
University Hospital Birmingham (UHB). The laboratory work was performed in 
the biochemistry laboratory, St Thomas Hospital, London, under the 
supervision of Dr Margo Umpleby. All the data were collected and analysed by 
SD and final analysis was reviewed by MS and Mr peter Nightingale, 
statistician from Welcome Research facility, UHB.    
3.4.2. Ethics committee approval and patient consent 
Ethical approval was obtained from South Birmingham Local Research 
Ethics Committee. All subjects have been given written information about 
the study and all subjects gave written informed consent before taking 
part into the study.  
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3.4.3. Statistical analyses  
Initial comparison between the four groups was by one-way ANOVA or 
Kruskal-Wallis followed by Bonferroni’s or Dunn’s multiple comparison test 
(SPSS 10.0.7 for Windows; SPSS Inc, Chicago, IL, USA). Fisher’s exact 
test was used for categorical data between groups, and associations were 
analyzed by Spearman’s rank correlation test. A stepwise linear regression 
model examined the effect of variables on VLDL and IDL and LDL 
metabolism. Variables entered were age, sex, ethnicity, smoking, family 
history of diabetes, family history of cardiovascular disease, alcohol 
intake, peripheral fat/ LBM, trunk fat/LBM, glucose, pre-treatment and 
current CD-4, pre-treatment HIV RNA copies amongst HIV positive 
groups, baeline HOMA, and FFA. In a separate model, only patients on 
treatment were included. Assuming a 50% difference between any of the 
patient groups and the controls the study has an 80% power to detect a 
significant difference at the 5% level if 14 patients are recruited for each 
group[130]. 
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3.4.4. Study protocol (figure 3.1): 
Figure 3.1: Clinical protocol for sample collection in the Wellcome trust, 
Queen Elizabeth Hospital, Birmingham, UK 
 
After an overnight fast, subjects were admitted to the Wellcome Trust 
Clinical Research Facility, Queen Elizabeth Hospital, Birmingham. An 
intravenous line was placed in the antecubital vein of each arm; one line 
was used for administration of the isotopic solution and the other for 
drawing blood samples.  An infusion of 13C leucine (13C enrichment 99% 
purity, Cambridge Isotope Laboratory, MA) was administered as a primed 
(1 mg/kg) constant infusion (1mg/kg h-1) for 9 hours.  At the beginning 
of the study, 10ml plasma was collected for measurement of total 
cholesterol (TC), triglycerides (TG), high density lipoprotein-cholesterol 
(HDL-C), free fatty acids (FFA) and glucose.  Five ml of ethylenediamine 
tetraacetate (EDTA) plasma samples were collected for apoB-100 
enrichment determination at minus 0.5, 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 
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7, 8 and 9 hours.  Two ml lithium heparin samples were also taken at 
baseline and after 3, 5, 7 and 9 hours to determine 13C enrichment of α-
ketoisocaproate (α-KIC), the deamination product of leucine, which 
provides a measure of intracellular leucine enrichment.  In addition, 5ml 
EDTA plasma was collected for measurement of very low density 
lipoprotein (VLDL), low density lipoprotein  (LDL) and intermediate density 
lipoprotein (IDL) apolipoprotein-B (apo-B) concentrations and VLDL-TG, 
VLDL-C, IDL-TG, IDL-C, LDL-TG and LDL-C concentrations at 0,3,6, and 9 
hours. Samples were sent by courier, (kept at 4oC for no more than 24 
hours), to St Thomas’ Hospital, London, UK.   
3.4.5. Experimental protocol  
The laboratory analysis was performed in the biochemistry laboratory, St 
Thomas’ Hospital, London, UK.  The laboratory was blinded as to patient 
categories.   A summary of the experimental steps has been shown in the 
figure 3.2. 
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Figure 3.2: Summary of analytical steps (GCMS: gas chromatography and 
mass spectrometry) 
 
                                                                                                                                   
 
 
 
 
EDTA plasma at given time point 
Isolation of VLDL by ultracentrifugation 
Precipitation of VLDL apo-B using tetramethylurea 
Delipidation of VLDL apo-B followed by acid hydrolysis 
Extraction of leucine by ion exchange chromatography 
Derivisation of leucine 
Determination of apoB isotopic enrichment by GCMS analysis 
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3.4.5.1. Isolation and measurement of isotopic enrichment of 
apolipoprotein-B   
VLDL and IDL were separated by sequential floatation ultracentrifugation 
(Beckman Coulter Optima LE80-K ultracentrifuge, High Wycombe, UK).  
Plasma (overlaid with sodium chloride density solution, density = 1.006 
kg/L) was centrifuged at 37,000 rpm for 16 h in a 50.4 Ti Beckman rotor 
to obtain VLDL.  The VLDL fraction was isolated by tube slicing and the 
density of the remaining supernatant was raised to 1.019 kg/L.   This was 
centrifuged at 37,000 rpm for 18 h to isolate IDL. The LDL fraction was 
isolated by adjusting plasma density to 1.063 g/ml and spinning for 
another 20 hours on a Beckman Coulter Optima LE80-K ultracentrifuge 
(High Wycombe, UK). The apolipoprotein B-100 was isolated by 
preparative sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
(SDS-PAGE): the delipidated apo-B containing material was solubilized in 
0.05 mmol/L Tris buffer (pH 8.6) containing 3% SDS, 3% 
mercaptoethanol and 10% glycerol and applied to a 3-mm thick vertical 
slab gel (3% acrylamide). After staining with Coomasie blue R-250, apo-B 
was cut from the gel and hydrolysed in 6M HCL for 24 hour at 115°C . 
Samples were then centrifuged to remove polyacrylamide. Supernatants 
were lyophilized in a Speed Vac (Sevant Instrument, Farmingdale, NY). 
Lyophilized samples were dissolved in 50% acetic acid, applied on AC-50 
W-X8 200-400-mesh cation exchange column (Bio-rad, Richmond, CA), 
and amino acids were recovered by elution with 4 M NH4OH and 
lyophilized.  
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Leucine enrichment of VLDL, IDL and LDL apoB-100 was measured by gas 
chromatography-mass spectrometry (GC-MS, Hewlett Packard 5890 series 
II-5917A MSD, Bracknell, UK) in electron impact ionization mode, 
monitoring ions 302 and 303 representing the [m-57] natural abundance 
and [m-57]+1 enriched fragments of the bis (tert-butyldimethylsilyl) 
derivative.  Plasma α-KIC 13C enrichment was measured as the 
quinoxalinol-trimethylsilyl derivative by monitoring of fragment ions at 
m/z 259 and 260. 
3.4.5.2. Quantification of apo-B and other anylates.  
The apoB-100 VLDL,  IDL and LDL concentrations were determined by an 
in-house specific sandwich Elisa using a polyclonal antibody against apo-B 
(The Binding Site Ltd, Birmingham, UK) as a capture antibody and a 
biotinylated anti apoB-100, 4G3 antibody (Ottawa Heart Institute, Ottawa, 
Canada) as a detection antibody.  Plasma total, VLDL, IDL and LDL 
cholesterol and triglyceride were measured enzymatically (ABX 
Diagnostics, Shefford, UK).  HDL-C was separated by precipitation of apo-
B-containing lipoproteins with dextran sulfate/magnesium chloride and 
measured enzymatically (Boehringer Mannheim, Mannheim, Germany) 
after magnesium phosphotungstate precipitations for HDL-C.  
Enzymatic methods were used to measure serum TC, LDL-C and TG (ABX 
Diagnostics, Shefford, UK) and HDL-C (Roche Diagnostics Ltd, Lewes, UK). 
Serum FFA was measured enzymatically (Wako Chemicals, Neuss, 
Germany) and Lp(a) with an immunoturbidimetric method (Diasorin Ltd., 
Wokingham, UK) using a Cobas Fara II analyzer (Roche 
Diagnostics).Serum insulin was measured by ELISA (Mercodia, Uppsala, 
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Sweden) and glucose concentrations using a glucose analyzer (Roche 
Diagnostics).                                                                                                     
3.4.5.3. Calculation of VLDL, IDL and LDL apo-B secretion and 
clearance rates:   
A multi-compartmental model was used to calculate VLDL, IDL and LDL 
fractional catabolic rate (FCR pools/day).  The fractional catabolic rate 
(FCR)[103] and absolute secretion rate (ASR)[452] of each lipoprotein 
were estimated using a multicompartmental model with an intrahepatic 
delay function as previously described by Duvillard et al [103] using 
Simulation Analysis and Modelling (SAAM II software, SAAM Institute, 
Seattle, WA). The precursor compartment for the incorporation of 13C 
leucine into VLDL (forcing function) is the steady state tracer: tracee ratio 
of αKIC. The absolute secretion (production) rate (ASR mg/kg/day) was 
then calculated from the FCR and apo B pool size. 
Patients were in a steady state in the study as shown by the constant 
VLDL, IDL and LDL apoB concentration (data not shown here). In this 
case, the fractional secretion rate (FSR) equals the fractional catabolic 
rate (FCR). The VLDL, IDL and LDL apoB ASR (mg/kg/day) were 
calculated from the product of the fractional secretion rate (pools/d) and 
the pool size (mg) divided by body weight. The VLDL or IDL or LDL pool 
size was calculated from the product of the mean VLDL or IDL or LDL 
apoB concentration (mean concentration of apoB in four pooled samples) 
and the plasma volume. 
Plasma volume was calculated using the formula of Pearson et al [453]. 
As the experiment was performed in the steady state, fractional synthetic 
rate equalled fractional catabolic rate [454-456]. 
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Because of problems with the sample analysis, it was not possible to 
model IDL data from one subject in the TN group, two subjects in the 
PI group, and five subjects in the NNRTI group. 
3.5. Results 
3.5.1. Patient Characteristics (table 3.1) 
Most of the subjects were male (n=50) and the distribution was similar in 
each group, except the HIV negative control group (table 3.1). Forty-one 
were homosexual and two were in the HIV-negative control group. Most of 
the subjects (n=49) were of white ethnic origin. The median age of the 
subjects was 36 (21-67) years. There was no significant difference 
between groups with regard to age and ethnicity and gender. Daily alcohol 
intake in HIV negative group was higher but not significant statistically. 
Smoking history was similar between all the groups. 
Family histories of ischemic heart disease and strokes were present in 17 
subjects but this was not different between groups (table 3.1). A family 
history of diabetes was present in 6 subjects and was higher in the 
treatment naïve group compared to HIV negative controls (table 3.1).  
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Table 3.1: Baseline characteristics (mean+/-SD) of subjects (n= 67) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                          
 
 
               *Controls vs. TN (Fisher’s exact test, P = 0.012). 
 
Cases (n=55)  Control 
(n=12) TN (n=15) PI (n=15) NNRTI 
(n=25) 
Male sex 
 
5 11 13 21 
Homosexual 
 
2 7 11 21 
White ethnicity 
 
10 7 13 19 
Age (year) 
 
32.8+/-12.2 37.9+/-11 43.6+/-9.3 38.4+/-10.8 
BMI Kg/m2 
 
23.0+/-3.6 24.1+/-2.7 24.4+/-3.6 23.1+/-3.1 
Family history of CVD 
 
4 3 5 5 
Family history of 
Diabetes 
 
0* 3* 2 1 
Smokers 
 
3 5 6 12 
Daily alcohol use 
units/wk 
 
12.3+/-12.9 8.4+/-11 8.8+/-8.7 7.7+/8.4 
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3.5.2. Treatment History (table 3.2) 
The median duration of treatment was 40.5 (12-71) months (table 3.2), 
and was lower in the NNRTI group than the PI group (31 vs. 49, p< 
0.001). There was no history of treatment interruption or change of 
treatment regimen in any of the patients. Four patients who were on lipid 
lowering agents for dyslipidaemia stopped taking the drugs 6 weeks 
before they took part in to this study.  
The commonest nucleoside backbones used were zidovudine (AZT) and 
lamivudine (n=27), stavudine (d4T) and lamivudine (3TC) in 6 patients, 
stavudine (d4T) and didanosine (ddI) in 3 patients and other drugs or 
combinations used were abacavir (ABC) and lamivudine in 2 patients. 
Eleven patients were on nevirapine (NVP) and 14 were on efavirenz (EFV) 
containing regimen. Fifteen patients were on PIs of which 8 were with 
ritonavir (RTV) either as booster (100mg twice daily) or therapeutic dose 
(600mg twice daily). The other PIs were nelfinavir (n=4), indinavir (n=3), 
lopinavir (n=6). None of the patients was on atazanavir or saquinavir. 
 
Table 3.2: Treatment history with HAART (Mean+/-SD) 
Cases (n=55)  Control 
(n=12) TN (n=15) PI (n=15) NNRTI 
(n=25) 
Duration of 
treatment 
(months) 
- - *48.7+/-
14.7 
*30.9+/-2.9 
 
Nucleoside backbone 
AZT/3TC - - 8 19 
d4T/3TC - - 2 4 
d4T/ddI - - 3 1 
Other - - 2 1 
AZT=Zidovudine, 3TC= Lamivudine, d4T= Stavudine, ddI=Didanosine 
*PI vs NNRTI (p=0.001) 
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3.5.3. Laboratory Results (table 3.3) 
Liver function tests (LFT) were within normal limits in all the subjects. 
Serum alkaline phosphatase was lower in the HIV negative controls but 
not statistically significant from the other groups. Serum AST, GGT and 
haemoglobin was similar in all the groups.  
None of the subjects had hepatitis C or was a carrier for hepatitis B virus. 
 
Table 3.3: Mean (+/-SD) baseline laboratory Results 
Cases (n=55)  Control 
(n=12) TN 
(n=15) 
PI (n=15) NNRTI 
(n=25) 
p-value 
between 
groups 
Haemoglobin 
gms% 
13.0 (1.7) 13.8 (1.8) 15.0 (1.2) 14.8 (1.4) NS 
AST 
(mmol/liter) 
22 (2.0) 25 (7.0) 24 (6.0) 26 (13.0) NS 
Alk Phos 
(mmol/liter) 
128 
(27.0) 
179 
(68.0) 
177 
(49.0) 
193 
(33.0) 
NS 
GGT 
mmol/l 
28 (23.0) 34 (26.0) 55 (52.0) 44 (25.0) NS 
 
 
3.5.4. Viral load and CD-4 counts (table 3.4) 
Current CD4 counts of the patients were not different between HIV groups 
(table 3.4), nor were current or pre-treatment viral loads or pre-treatment 
CD4 counts among the treatment groups. Two PI-treated patients on 
HAART had a detectable viral load (800 and 1100 copies/ml) at the time 
of the study. The remaining patients had viral loads below the detection 
limit of the assay (less than 50 copies/ml). 
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Table 3.4: Viral load (VL) and CD-4 counts (mean+/-SD) 
 
Cases (n=55)  Control 
(n=12) TN (n=15) PI (n=15) NNRTI 
(n=25) 
Log Pre-
treatment VL  
(copies/ml) 
- 4.49+/-0.76 5.12 +/- 
0.54 
4.83 +/- 
0.74 
Current VL 
(copies/ml) 
- Log (5.01+/-
5.1) 
Log (2.1+/-
2.5) 
Less than 50 
Pre-
treatment 
CD-4 count 
(cells/dl) 
NA 367+/-222 125+/-122 175+/-128 
Current CD-4 
count 
(cells/dl) 
NA 367+/-222 435 +/- 187 469+/- 265 
 
  
3.5.5. Lipid Profiles (Table 3.5) 
Only five patients had baseline fasting plasma cholesterol levels above 6.0 
mmol/liter (three PI and two NNRTI), and 13 had fasting plasma 
triglyceride levels over 2.3 mmol/liter (two TN, four PI, and seven NNRTI). 
Nine patients (six on PI and three on NNRTI) had calculated LDL-
cholesterol levels above 3.0mmol/l. Severe hyperlipidaemia (cholesterol > 
7 mmol/liter and /or triglyceride > 5 mmol/liter) was observed in only two 
patients and both of them were on PI.  
In the PI group, total cholesterol (table 3.5) and VLDL-cholesterol (table 
3.6) was significantly higher than the TN group (P < 0.03), and plasma 
triglyceride (table 3.5, p<0.01), VLDL-TG (table 3.6, p<0.01), IDL 
triglyceride (table 3.9, p<0.002), were significantly higher than the 
control group.  
Plasma IDL triglyceride was also greater in the TN group than the control 
group (P < 0.05, table 3.9). Plasma HDL cholesterol was lower in TN, PI, 
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and NNRTI group compared with the control group (P < 0.01, table 3.5). 
There was no difference in the lipid profile in the nevirapine- and 
efavirenz-treated patients in the NNRTI group (table 3.7).  
Plasma level of FFA was similar in all the groups (table 3.5), but was 
higher (p<0.003) in antiretroviral-treated patients with dyslipidemia 
(cholesterol ≥ 6 mmol/liter or triglyceride ≥2.3 mmol/liter, n=13) 
compared to those without dyslipidaemia (n=54). 
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              Table 3.5: Baseline lipids and body composition [median (interquartile range)] 
 
 
 
 
 
 
 
 
 
 
 
               1p<0.02 between TN vs. PI, 2p<0.03 between TN & control vs. PI  
               3p<0.01 between control vs. TN, PI and NNRTI 
 
 
Cases (n=55)  Control (n=12) 
TN (n=15) PI (n=15) NNRTI (n=25) 
p-value 
between 
groups 
Total cholesterol 
(mmol/l) 
 
4.6 (4.1–5.2) 4.3 (3.4 –5.1) 15.6 (4.6–6.0) 4.9 (4.1–5.6) 0.03 
Total Triglyceride 
(mmol/l) 
 
 
1.0 (0.7–1.5) 1.1 (0.9 –1.6) 1.8 (1.3–3.4)2 1.5 (0.8 –2.4) 0.02 
LDL cholesterol 
(mmol/l) 
1.7 (1.4-2.4) 1.8 (1.4-2.2) 2.5 (1.8-3.1) 2.2 (1.7-2.7) NS 
HDL cholesterol 
(mmol/l) 
 
1.9 (1.6 –2.2)3 1.1 (0.9 –1.3) 1.1 (1.0 –1.5) 1.2 (1.1–1.4) 0.01 
FFA (mmol/l) 
 
0.46 (0.3–0.7) 0.49 (0.2– 0.6) 0.47 (0.3–0.6) 0.42 (0.2– 0.6) NS 
Plasma volume (l) 
 
2.4 (2.2-2.9) 2.9 (2.6-3.2) 3.0 (2.7-3.2) 2.8 (2.7-3.1) NS 
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3.5.6. Apo-B kinetics (table 3.6-3.14) 
3.5.6.1. VLDL kinetics (table 3.6-3.8) 
3.5.6.1.1. Between the different groups (table 3.6) 
There was no significant difference in VLDL apoB ASR.  The VLDL FCR was 
higher in the HIV-negative control compared to HIV treatment naïve 
(p<0.04) group. In the PI and NNRTI groups, VLDL apo-B FCR were lower 
(P < 0.001) and VLDL residence time were higher than the control group 
(P < 0.01) but were not different from the HIV treatment naive patients. 
The VLDL apoB pool size was higher in the PI group compared to all the 
other groups (p<0.001). The VLDL apoB kinetics, in the HIV treatment 
naive patients otherwise showed a trend in the same direction as the 
antiretroviral treated groups. VLDL-TG was higher in the PI group 
(p<0.01), but VLDL-cholesterol, VLDL apoB/TG and VLDL apoB/cholesterol 
were not different between groups. 
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Table 3.6: VLDL kinetics [median interquartile range (IQR)] 
 
 
 ap<0.04 between HIV-ve control vs. TN,  bp<0.001 between HIV-ve 
control vs. PI and NNRTI, cp<0.01 between HIV-ve control vs. PI and 
NNRTI,  dp< 0.03 between TN vs. PI, ep<0.01 between HIV-ve control & 
TN vs. PI 
Cases (n=55)  Control 
(n=12) TN (n=15) PI 
(n=15) 
NNRTI 
(n=25) 
p-value 
between 
groups 
VLDL ASR 
(mg/kg/d) 
7.7 (3.0 –
10.7) 
6.3 (3.1–
10.6) 
6.4 
(3.7–
11.2) 
5.1 
(3.0-
7.7) 
NS 
VLDL FCR 
(pools/d) 
12.7 
(10.2–
15.9) 
8.3 (4.8 –
14.1)a 
6.1 
(4.3– 
8.5) 
6.3 
(3.4–
8.5) 
0.001 
Pool size mg 51.7(13.5-
73.9) 
57.7 
(23.8-
86.1) 
90.0 
(49.5-
149.5)b 
65.7 
(29.8-
118.8) 
0.001 
Residence time 
hours 
1.9 (1.5-
2.3) 
2.9 (1.7-
4.9) 
3.9(2.8-
5.6)c 
3.8(2.8-
7.0) 
0.01 
VLDL cholesterol 
mmol/l 
0.17 
(0.06-
0.17) 
0.15 
(0.07-0.3) 
0.4 
(0.12-
0.7)d 
0.2 
(0.1-
0.5) 
0.03 
VLDL-
triglyceride 
(mmol/l) 
0.5 (0.2-
0.9) 
0.4 (0.2-
1.4) 
1.1 
(0.7-
1.9)e 
0.7 
(0.4-
1.6) 
0.01 
VLDL 
cholesterol/apoB 
ratio 
3.3 (2.4–
4.1) 
4.4 (2.8–
4.9) 
3.2 (2.9 
–5.6) 
4.2 
(3.2–
5.5) 
NS 
VLDL 
triglyceride/apoB 
ratio 
39.5 (17.0 
–59.1) 
29.4(19.2–
34.9) 
31.7  
(21.1–
59.5) 
30.7  
(27.1– 
45.1) 
NS 
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3.5.6.1.2. In the NNRTI group: Nevirapine vs. Efavirenz (table 3.7) 
There was no difference in VLDL apoB kinetics between the nevirapine- 
and efavirenz-treated patients in the NNRTI group.  
 
Table 3.7: VLDL kinetics [median (IQR)] in patients on antiretroviral 
regimens containing nevirapine and those receiving efavirenz. 
 
 Nevirapine 
N=11 
Efavirenz 
N=14 
P 
value 
VLDL ASR mg/kg/day 5.1 (2.9-8.7) 5.2 (2.8-6.08) NS 
VLDL FCR pools/day 6.3 (5.1-8.2) 6.05 (3.09-10.4) NS 
VLDL residence time hours 3.8 (2.9-4.6) 4.04 (2.3-7.8) NS 
VLDL apoB pool size mg 80.05 (21.6-122.5) 59.3 (29.9-102.5) NS 
VLDL cholesterol mmol/l 0.2 (0.1-0.5) 0.22 (0.13-0.6) NS 
VLDL cholesterol/apoB ratio 4.1 (3.6-5.0) 4.0 (2.6-5.6) NS 
VLDL triglyceride mmol/l 0.78 (0.3-1.7) 0.77 (0.5-1.9) NS 
VLDL triglyceride/apoB ratio 35.7 (25.4-40.4) 30.8 (27.5-59.4) NS 
 
 
3.5.6.1.3. In the PI group: ritonavir vs. non-ritonavir group (table 
3.8) 
Patients on ritonavir-containing regimens had a lower VLDL apoB FCR 
[median, 4.6 pools/d; IQ range, (2.6 –7.0); P < 0.05] and increased 
residence time [5.2 h (3.4–9.2);   P < 0.05] compared to non-ritonavir-
containing PI regimens [8.4 pools/d (6.1–9.4) and 2.86 h (2.5– 4.0), 
respectively]. Antiretroviral-treated patients with dyslipidemia (cholesterol 
≥ 6.0 mmol/liter or triglyceride ≥2.3 mmol/liter, n=11) had lower VLDL 
FCR (P < 0.001), larger VLDL apoB pool size (P < 0.003), increased VLDL 
residence time (P<0.001) compared to the other subjects without 
significant dyslipidaemia (cholesterol <6 mmol/l and or triglyceride <2.3 
mmol/l, n=29). 
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Table 3.8. VLDL kinetics [median (IQR)] in patients on antiretroviral 
regimens containing the protease inhibitor ritonavir and those receiving 
other protease inhibitors. 
 
 
 Ritonavir 
N=8 
Non-Ritonavir 
N=7 
P 
value 
VLDL ASR mg/kg/day 6.51 (3.08-10.3) 6.44 (3.7-13.9) NS 
VLDL FCR pools/day 4.6 (2.6-7.0) 8.48 (6.0-9.4) 0.05 
VLDL residence time hour 5.2 (3.4-9.2) 2.8 (2.4-3.9) 0.05 
VLDL apoB pool size mg 110.8 (56.7-214.9) 53.0 (35.9-127.7) NS 
VLDL cholesterol mmol/l 0.48 (0.4-0.9) 0.25 (0.1-0.3) NS 
VLDL cholesterol/apoB ratio 4.3 (3.0-9.0) 3.0 (2.5-5.4) NS 
VLDL triglyceride mmol/l 1.4 (0.9-2.5) 0.8 (0.3-1.1) NS 
VLDL triglyceride/apoB ratio 34.3 (19.5-58.1) 26.6 (19.1-59.5) NS 
 
3.5.6.2. IDL kinetics (table 3.9-3.11)  
3.5.6.2.1. Between the groups (table 3.9) 
In the PI and NNRTI groups, IDL apo-B FCR were lower (P < 0.002) and 
IDL residence time were higher than the control group (P < 0.002) but 
were not different from the HIV treatment naive patients. There was no 
significant difference in IDL apoB ASR between groups, although IDL apoB 
pool size was higher in the PI-treated patients compared with the HIV-
negative control subjects (P<0.03). The IDL apoB kinetics in the HIV 
treatment naive patients showed a trend in the same direction as the 
antiretroviral treated groups. IDL- TG was lower in the HIV-negative 
controls (0.002), but IDL-cholesterol, IDL apoB/TG and IDL 
apoB/cholesterol were not different between groups. 
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Table 3.9: IDL kinetics (median [IQR]) 
 
 
ap<0.002 between HIV-ve control vs. PI and NNRTI         
bp<0.03 between HIV-ve control vs. PI.  
cp<0.002 between HIV-ve control vs. PI and NNRTI 
dp<0.002 between HIV-ve control vs. PI and p<0.01 between HIV-ve 
control vs. TN   
 
 
 
 
 
Cases (n=55)  Control 
(n=12) TN 
(n=15) 
PI 
(n=15) 
NNRTI 
(n=25) 
p-value 
between 
groups 
IDL ASR 
(mg/kg/day) 
3.9 (2.5-
7.7) 
2.7 (1.7–
5.4) 
3.1 
(1.0–
6.4) 
1.7 (0.7–
3.3) 
NS 
IDL FCR 
(pools/day) 
9.1 (5.9-
11.6)a 
4.1 (2.7–
11.4) 
2.9 (1.0 
–7.2 
2.8 (1.8 –
5.2) 
0.002 
Pool size mg 28.3 
(23.6-
50.6)b 
44.4 
(31.0–
66.5) 
52.7 
(42.6 –
96.7) 
36.2 
(23.3–
70.8) 
0.03 
Residence time 
hours 
2.7 
(2.1– 
4.1)c 
5.8 (2.1–
9.0) 
8.2 (3.4 
–23.1) 
8.5 (4.7–
13.3) 
0.002 
IDL cholesterol 
mmol/l 
0.06 
(0.05– 
0.09) 
0.09 
(0.06–
0.14) 
0.12 
(0.09–
0.21) 
0.12 
(0.06–
0.17) 
NS 
IDL-triglyceride 
(mmol/l) 
0.06 
(0.04–
0.08)d 
0.19 
(0.06–
0.22) 
0.19 
(0.10–
0.24) 
0.09 
(0.04–
0.24) 
0.002 
IDL 
cholesterol/apoB 
ratio 
2.5 (1.4 
–3.6) 
2.6 
2.6 (1.7–
3.5) 
2.7 
(2.3–
2.9) 
3.2 (2.4–
4.5) 
NS 
IDL 
triglyceride/apoB 
ratio 
4.5 (2.4 
–7.5) 
9.2 (3.9 
–11.5) 
6.3 
(4.1–
9.6) 
6.5 (3.7–
7.9) 
NS 
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3.5.6.2.2. In the NNRTI group: nevirapine vs. efavirenz (table 
3.10) 
There was no difference in IDL apoB kinetics between the nevirapine- and 
efavirenz-treated patients in the NNRTI group. 
 
Table 3.10: IDL kinetics [median (IQR)] in patients on antiretroviral 
regimens containing nevirapine and those receiving efavirenz. 
 
 
 Nevirapine 
N=11 
Efavirenz 
N=14 
P 
value 
IDL ASR mg/kg/day 1.02 (0.5-2.9) 1.9 (1.2-3.3) NS 
IDL FCR pools/day 2.67 (1.6-5.1) 3.33 (1.8-5.3) NS 
IDL residence time hour 9.0 (5.0-15.4) 7.2 (4.5-13.3) NS 
IDL apoB pool size mg 32.5 (28.1-58.4) 33.2 (22.4-74.4) NS 
IDL cholesterol mmol/l 0.1 (0.07-0.15) 0.11 (0.06-0.1) NS 
IDL cholesterol/apoB ratio 2.5 (2.0-4.6) 3.1 (2.6-3.7) NS 
IDL triglyceride mmol/l 0.12 (0.05-0.23) 0.17 (0.07-0.2) NS 
IDL triglyceride/apoB ratio 6.6 (3.5-9.3) 5.4 (4.0-7.4) NS 
  
3.5.6.2.3. In the PI group: ritonavir vs. non-ritonavir (table 3.11)  
Patients on ritonavir-containing regimens had a lower IDL apoB FCR (P < 
0.001), increased residence time [5.21 h (3.43–9.2);   P < 0.001] and 
increased pool size (p<0.01) compared with non-ritonavir-containing PI 
regimens. 
Antiretroviral-treated patients with dyslipidaemia (total cholesterol ≥ 6.0 
mmol/liter or triglyceride ≥2.3 mmol/liter, n=11) had larger IDL apoB 
pool size (P < 0.003), but the IDL residence time was not different 
compared to the other subjects without significant dyslipidaemia 
(cholesterol <6 mmol/l and or triglyceride <2.3 mmol/l, n=29). 
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Table 3.11: IDL kinetics [median (IQR)] in patients on antiretroviral 
regimens containing the protease inhibitor ritonavir and those receiving 
other protease inhibitors. 
 
 
 Ritonavir 
N=8 
Non-Ritonavir 
N=7 
P 
value 
IDL ASR mg/kg/day 2.8 (1.4-22.9) 3.4 (0.8-4.8) NS 
IDL FCR pools/day 0.12 (0.06-0.2) 0.2 (0.04-0.3) 0.001 
IDL residence time hour 8.35 (3.7-16.0) 3.8 (3.1-23.2) 0.001 
IDL apoB pool size mg 74.6 (38.7-198.2) 50.2 (36.9-65.7) 0.01 
IDL cholesterol mmol/l 0.1 (0.08-0.5) 0.1 (0.09-0.1) NS 
IDL cholesterol/apoB ratio 2.6 (2.4-2.8) 2.2 (1.61-3.3) NS 
IDL triglyceride mmol/l 0.2 (0.07-0.3) 0.2 (0.1-0.2) NS 
IDL triglyceride/apoB ratio 4.5 (3.7-6.4) 10.4 (7.5-12.5) NS 
  
 
3.5.6.3. LDL kinetics (table 3.12-3.14) 
3.5.6.3.1. Between the groups (table 3.12) 
LDL-cholesterol was not different between groups (table 3.5). LDL apoB 
ASR was higher in the HIV-negative control (p<0.002) and LDL FCR were 
lower (p<0.002) and LDL residence time higher (p<.001, in the PI and 
NNRTI groups than in the control group (p<0.01). In the treatment naïve 
group LDL apoB ASR was lower (p<0.05) and there was a trend for LDL 
apoB FCR to be lower and LDL residence time to be higher (p=0.07) than 
the control subjects. The PI group exhibited a higher LDL apoB pool size 
(p<0.01) compared to controls. LDL- TG, LDL apoB/TG and LDL 
apoB/cholesterol were not different between groups (table 3.12). 
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Table 3.12: LDL kinetics (median [IQR]) 
 
Cases (n=55)  Control 
(n=12) TN 
(n=15) 
PI (n=15) NNRTI 
(n=25) 
+p-
value 
between 
groups 
LDL ASR 
(mg/kg/day) 
9.0 (7.3-9.6)a 5.54 
(3.7-7.0) 
5.12 (4.2-
6.8) 
6.24 
(3.7-
7.5) 
0.002 
LDL FCR 
(pools/d) 
0.48  
(0.3-0.5)b 
0.2 (0.2-
0.3) 
0.2  (0.1-
0.3) 
0.27 
(0.1-
0.4) 
0.002 
Pool size mg 44.0 
(37.0-58.0)c 
49(36-
57) 
71(46-77) 50.0 
(43-
70) 
0.002 
Residence time 
hours 
2.08 
(1.8-2.9)d 
3.71(2.7-
4.0) 
4.11(2.8-
10.5) 
3.6 
(2.3-
6.0) 
0.01 
LDL cholesterol 
mmol/l 
1.7 (1.4-2.4) 1.8 (1.4-
2.2) 
2.5 (1.8-
3.1) 
2.2 
(1.7-
2.7) 
NS 
LDL-triglyceride 
(mmol/l) 
0.14  
(0.09-0.18) 
0.14 
(0.12-
0.18) 
0.20 
(0.13-
0.23) 
0.14 
(0.10-
0.17) 
NS 
LDL 
cholesterol/apoB 
ratio 
1.5  
(1.49-1.6) 
1.5 (1.4-
1.5) 
1.5 (1.4-
1.6) 
1.5 
(1.4-
1.6) 
NS 
LDL 
triglyceride/apoB 
ratio 
0.2 (0.1-0.3) 0.3 (0.2-
0.3) 
0.3 (0.2-
0.35) 
0.2 
(0.19-
0.27) 
NS 
Oxidised LDL 108.9  
(86.9-117.1) 
105.9 
(95.3-
119.8) 
97.2 
(72.3-
112.3) 
91.2 
(72.3-
112.3) 
NS 
 
ap<0.002 between HIV-ve vs. TN, p<0.002, PI, p<0.001, NNRTI, p<0.006 
bp<0.002 between HIV-ve vs. TN, PI and NNRTI,  
cHIV-ve vs. PI, p<0.002. dp<0.01 between HIV-ve vs. TN,PI,NNRTI  
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3.5.6.3.2. In the NNRTI group: nevirapine vs. efavirenz (table 3.13) 
There was no difference in LDL apoB kinetics between the nevirapine- and 
efavirenz-treated patients in the NNRTI group.  
 
Table 3.13: LDL kinetics [median (IQR)] in patients on antiretroviral 
regimens containing nevirapine and those receiving efavirenz. 
 
 Nevirapine 
N=11 
Efavirenz 
N=14 
P 
value 
LDL ASR mg/kg/day 5.63 (3.1-7.6) 6.28 (4.8-7.5) NS 
LDL FCR pools/day 0.26 (0.1-0.4) 0.28 (0.2-0.4) NS 
LDL residence time hour 3.85 (2.4-7.1) 3.48 (2.3-5.1) NS 
LDL apoB pool size mg 5.8 (5.0-6.7) 5.2 (4.3-7.2) NS 
LDL cholesterol mmol/l 2.6 (2.0-2.73) 1.96 (1-5-2.8) NS 
LDL cholesterol/apoB ratio 1.6 (1.5-1.7) 1.5 (1.4-1.5) NS 
LDL triglyceride mmol/l 0.15 (0.12-0.18) 0.14 (0.09-0.1) NS 
LDL triglyceride/apoB ratio 0.27 (0.2-0.27) 0.2 (0.19-0.2) NS 
 
3.5.6.3.3 In the PI group: ritonavir vs. non-ritonavir (table 3.14)  
In the PI group patients on ritonavir-containing regimens had a lower LDL 
apoB ASR (p=0.009) and a trend to a lower LDL apoB FCR and increased 
residence time compared to non-ritonavir containing PI regimens 
(p=0.054). 
Antiretroviral-treated patients with LDL-cholesterol ≥ 3.0 mmol/liter 
(n=11) had lower LDL-FCR (p<0.02), increased LDL apoB pool size (P < 
0.001), increased LDL-TG (p<0.001) compared to LDL-cholesterol to 
those with LDL- cholesterol <3.0mmol/l (n=29). The LDL ASR and LDL-
residence time was not different. 
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Table 3.14: LDL kinetics [median (IQR)] in patients on antiretroviral 
regimens containing the protease inhibitor ritonavir and those receiving 
other protease inhibitors. 
 
 Ritonavir 
N=8 
Non-Ritonavir 
N=7 
P 
value 
LDL ASR mg/kg/day 4.56 (2.5-5.1) 6.87 (5.2-8.47) 0.009 
LDL FCR pools/day 0.15 (0.09-0.2) 0.27 (0.2-0.42) 0.054 
LDL residence time hour 6.86 (3.9-11.6) 3.76 (2.3-4.11) 0.054 
LDL apoB pool size mg 74.0 (49.0-104.0) 61.0 (44.0-73.0) NS 
LDL cholesterol mmol/l 2.95 (1.8-4.0) 2.10 (1.5-3.06) NS 
LDL cholesterol/apoB ratio 1.59 (1.4-1.7) 1.45 (1.3-1.64) NS 
LDL triglyceride mmol/l 0.22 (0.1-0.4) 0.16 (0.1-0.21) NS 
LDL triglyceride/apoB ratio 0.29 (0.2-0.3) 0.29 (0.2-0.30) NS 
 
3.6 Discussion  
This study has investigated VLDL, IDL and LDL apo-B metabolism in HIV-
patients naïve to antiretroviral therapy, HIV-patients taking HAART 
including PI, or the NNRTI efavirenz or nevirapine and compared these 
with HIV negative controls.  
These studies have shown a significant reduction in VLDL, IDL and LDL 
apoB FCR with longer residence time in the three lipoprotein 
compartments in all the HIV positive groups compared to HIV negative 
controls. The HIV positive treatment groups had mild dyslipidaemia. The 
treatment naïve group and the HIV-negative control group did not have 
any difference in serum TG and TC. Compared to the control subjects PI-
treated patients exhibited raised serum triglyceride, LDL cholesterol and 
IDL cholesterol that was not exhibited by NVP or EFV treatment groups; 
this was more marked in patients taking ritonavir containing PI regimen. 
The severity of dyslipidaemia in the patients in our study was less marked 
than in many previous studies of this kind [130, 152, 457]. Only four 
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patients were on lipid lowering treatment who had stopped treatment 6 
weeks before this study.  
Unlike previous studies we were unable to show a significant decrease in 
LDL cholesterol in the treatment naïve patients [135] or an increase in 
LDL cholesterol concentration with PI and NNRTI treatment compared to 
the control subjects [325, 458]. This was particularly surprising in the 
treated patients and may again reflect the exclusion of patients who were 
on lipid lowering drugs. Since LDL cholesterol concentration is determined 
by the LDL ASR and LDL FCR, a normal LDL-cholesterol concentration will 
result if there is a decrease in both LDL ASR and FCR as found in all HIV 
patient groups in our study [78]. The HDL cholesterol was reduced in all 
the HIV positive patient groups and this was similar to what was described 
previously [109, 132]. Nevirapine increases HDL-C, but efavirenz does not 
[176]. In this study there was no difference in the HDL-C level between 
nevirapine and efavirenz group.  
The particle size of different lipoproteins is important. Observational and 
epidemiological studies suggest that subjects having a predominance of 
small, dense particles have increased risk of cardiovascular disease 
(CVD)[459]. Further studies have shown that the number, not the size, of 
LDL- cholesterol particles predicts CVD risk [460, 461].  
The VLDL, IDL and LDL-cholesterol and triglyceride/apoB ratios were not 
different between the controls and HIV treatment groups suggesting that 
there was no change in VLDL, IDL and LDL particle size in contrast with a 
study in patients on PI which reported an increased VLDL 
triglyceride/apoB ratio [462].  
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A decrease in LDL apo-B FCR results in increase of LDL apo-B residence 
time. Previuosly it has been shown that LDL apo-B residence time , 
measured by stable isotope techniques is positively related to surrogate 
markers of LDL apo-B oxidation in healthy subjects and patients with 
familial defective apo-B 100 [463]. In this study oxidised LDL apo-B was 
not different between groups and did not correlate with LDL apo-B FCR.  
The oxidation of LDL is regulated by a complex set of reactions, mainly 
stimulated by the presence of free radicals in the endothelium. Nitric oxide 
down-regulates this oxidation process catalyzed by L-arginine. The activity 
of L-arginine is inhibited by asymmetric dimethylarginine (ADMA) which is  
a metabolic by-product of continual protein modification processes in the 
cytoplasm of all human cells [464]. In this study, L-arginine activity was 
measured but not the ADMA activity which may have influence on the 
result. There is also another possibility that the difference in results of LDL 
apo-B oxidation may be due to the different methods used for measuring 
LDL apo-B oxidation. The previous study measured the oxidation of LDL 
apo-B poline and arginine residue to gamma glutamyl semialdehyde 
[465], where as in our study LDL-apo-B oxidation was measured by an 
ELISA with an antibody to malondialdehyde-LDL.  
Our study demonstrates that the mild dyslipidaemia in the treatment 
groups is due to a decrease in VLDL, IDL and LDL apoB FCR. In all the HIV 
positive groups the VLDL and IDL TG was higher but LDL TG was not.  
In the presence of increased TG rich lipoproteins in the plasma and normal 
levels of activity of the plasma cholesteryl ester transfer protein (CETP), 
TG from VLDL can be exchanged for cholesterolyl esters (CE) in HDL and 
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LDL [106, 466]. The VLDL particles give up TG molecules, donating it to 
the HDL and LDL, in return for more of the cholesteryl ester molecules 
from HDL and LDL.  
There are a number of consequences of elevated TG content in LDL and 
HDL. Both TG rich LDL and HDL become substrate for hepatic lipase (HL) 
which removes much of the TG by hydrolysis making both LDL and HDL 
smaller in size. The TG rich LDL contains a structurally altered apo-B 
whose interaction with LDL receptors are impaired [467]. A cholesterol-
rich VLDL remnant particle is either taken up by hepatic receptors or 
further delipated to cholesterol rich LDL particles and a triglyceride-rich 
cholesterol-depleted HDL particle. The TG-rich HDL particle can undergo 
further modification including hydrolysis of its triglyceride, probably by 
hepatic lipase, which leads to the dissociation of the structurally important 
protein apo A-I [468-470]. The free apo A-I in plasma is cleared more 
rapidly than apo A-I associated with HDL particles. One of the sites of 
clearance is the kidney [471]. In this situation, HDL cholesterol is 
reduced, and the amount of circulating apo A-I and therefore the number 
of HDL particles is also reduced [470]. The prolonged residence time of 
apo-B containing lipoproteins will allow exchange of triglyceride for 
cholesterol esters with HDL through cholesterol ester transfer protein 
(CETP) pathway, which would increase clearance providing a mechanism 
for the reduced HDL-cholesterol seen in both treatment naïve patients and 
those on antiretroviral therapy. 
The changes in VLDL secretion and clearance rate have not been found to 
be uniform in different studies. In a prospective study Carpentier et al 
[129] showed that secretion and clearance of VLDL apo-B were both 
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impaired in HIV patients and treatment with HAART increased the 
secretion but the clearance remaining unchanged. In that study the 
elevation of circulating VLDL early in the course of HAART was caused by 
the combination of impaired VLDL clearance already present in HAART-
naïve HIV- patients and HAART-mediated increase in VLDL secretion. In 
that study, there was a significant reduction of VLDL FCR in HIV-positive 
individuals that was not changed after use of HAART. These changes 
occurred concomitantly with an elevation of plasma free fatty acids before 
significant change in body composition. In contrast, Reeds et al [457] 
showed that HIV patients who had dyslipidaemia, the rate of hepatic 
VLDL-TG secretion during fed and fasted conditions were much greater, 
and clearance of VLDL-TG from plasma was slightly lower, compared to 
healthy men who did not have dyslipidaemia. Therefore, both increased 
VLDL-TG secretion into plasma and decreased plasma VLDL-TG clearance 
contribute to hypertriglyceridaemia. In the present study there appeared 
to be no difference in VLDL and IDL apo-B secretion rate, but the 
clearance rate of both were diminished as was the cases in previous 
studies which found a correlation of increase in serum FFA and VLDL apo-
B secretion rate. However, serum FFA levels, in our study were not 
different between any of the groups.  
There was no significant difference in VLDL and IDL ASR between any 
groups. This contrasts with a previous study which found an increase in 
VLDL ASR in PI treated patients, although all of whom had marked 
abnormalities in serum lipids and the samples were taken in a fed state 
[130, 152]. The same study also reported reduced rates of VLDL transfer 
into denser lipoproteins implying a lower rate of lipoprotein lipase-
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mediated delipidation. The decrease in LDL ASR in our study may be due 
to a reduction in the direct hepatic secretion of LDL and/or reduced 
production of LDL formed as a result of remodelling of IDL and VLDL. The 
reduction in VLDL and IDL apoB FCR in the HIV patient groups might have 
also been played a contributory factor.  
At the time our study was done there was only one study looking at the 
effect of NNRTI on lipoprotein kinetics [152]. The VLDL and IDL apo B 
kinetics in six PI treated patients were compared with five patients treated 
with nevirapine in the fed state. No comparison was made with control 
subjects or HIV treatment naïve patients. Contrary to our study, the VLDL 
and IDL apoB secretion rate were higher in the PI treated patients. This 
difference may be due to small numbers tested or the fed state of the 
subjects.  
Apart from apo-B pool size, the apo-B kinetics was not different in the PI 
and NNRTI group from the TN group in this study. However, when the 
patients in the PI group were subdivided into those treated with ritonavir 
and those treated with other PIs, it was shown that the abnormal apo-B 
kinetics was exacerbated by ritonavir treatment.  Apo-B FCR in the 
ritonavir group was extremely low, particularly in VLDL and IDL 
compartment. The LDL FCR was reduced but not to that extent. The LDL 
ASR was reduced as well.  This was similar to levels reported in patients 
with familial defective apolipoprotein B-100 in which binding of LDL to the 
LDL receptor is impaired [472, 473]. LDL cholesterol was not significantly 
increased by ritonavir since there was a decrease in LDL ASR along with 
some decrease LDL FCR.  
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This study together with the previous studies suggests [130, 152, 457] 
that a primary abnormality in HAART treated patients is a decrease in 
apo-B clearance which leads to mild dyslipidaemia whereas severe 
dyslipidaemia is the result of both a decrease in apo-B clearance and an 
increase in VLDL ASR.   
In conclusion this study suggests that in patients with mild dyslipidaemia 
reduced apo apoB FCR and consequently an increased apo-B residence 
time may be a primary abnormality in lipoprotein kinetics in HIV infection. 
The same abnormalities were also found in patients treated with either a 
protease inhibitor, or NNRTI containing HAART regimens, with more 
marked changes in apo-B kinetics in the patients treated with the PI, 
ritonavir.  
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CHAPTER 4 
Relation of Fat Redistribution, insulin resistance and 
apolipoprotein-B kinetics 
4.1. Introduction                                                                                                            
Abnormalities in body fat distribution have been reported in 40 to 50 
percent of ambulatory HIV-infected patients and the proportion is greater 
in those receiving combination antiretroviral therapies [212, 214, 228]. 
Prevalence rates vary widely, from 11 to 83 percent, in cross-sectional 
studies [224, 225].  A systematic study that attempted to provide a 
unifying definition suggested that peripheral fat wasting was associated 
with abdominal visceral adiposity, dyslipidaemia and insulin resistance and 
the condition was called lipodystrophy syndrome [180]. The vast majority 
of patients were on PI at that time and the condition was thought to be 
related to PI use. However, further studies revealed that lipoatrophy is a 
separate phenomenon and mostly associated with use of thymidine 
analogues and lipohypertrophy with PI use [77].  
Adipose tissue demonstrates extreme plasticity in its capacity to vary both 
in volume and cell number. The adipocyte cells have the capacity to 
increase its diameter 20 fold and volume by 1000 fold when required to 
store extra energy in the form fat vacuoles [474]. An increase in adipose 
mass or size may be the result of both hypertrophy of existing adipocytes, 
increased adipocyte differentiation from preadipocytes from the stromal 
vascular fraction, or an impairment of apoptosis. In contrast a decrease in 
adipose mass or size may be the result of atrophy of existing adipocytes 
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or defect in adipocyte differentiation and that may lead to impairment of 
several metabolic functions. 
4.2. Regional Differences in adipocyte function 
Several studies with obese individuals have clearly indicated that excess 
adiposity is linked to metabolic abnormalities [474-477]. Excess intra-
abdominal, particularly visceral rather than peripheral or subcutaneous fat 
is more strongly associated with diabetes, hypertension and 
cardiovascular disease, indicating wider metabolic differences within the 
different adipose tissue regions [478]. Intra-abdominal fat can be further 
divided into an intraperitoneal depot (omental [0.5-3 kg] and mesenteric 
[0.5-2 kg]) and retroperitoneal, i.e. perirenal fat (0.5-2 kg) [479](147). 
Omental and mesenteric fat depots are also referred to as visceral fat 
since their venous drainage is mainly through the portal vein. However, 
subcutaneous fat is the largest abdominal fat depot with an estimated 
weight of 1-20 kg [479]. Of the whole body adipose tissue mass, 
subcutaneous fat constitutes at least 80% in both lean and obese subjects 
[478]. In addition, isotopic tracer studies have shown that the TG 
synthesis, breakdown and lipid turnover as a whole is substantially higher 
in the visceral in contrast to the subcutaneous depot [480].  
 
4.3. Fat distribution and Dyslipidaemia                                                              
Dyslipidaemia associated with PI therapy is characterised by high levels of 
triglyceride rich lipoproteins [363] with increased abdominal adiposity, but 
with thymidine analogues the dyslipidaemia is associated more with 
lipoatrophy [208]. Lipohypertrophy is more common with PI use [481] 
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and lipoatrophy with thymidine analogues [482] and a role of NNRTI has 
become debatable since ACTG 5142 [172] showed an association of 
lipoatrophy with use of efavirenz as described in chapter 1. Both 
lipoatrophy and lypohypertrophy can be associated with dyslipidaemia and 
insulin resistance [483, 484]. While switching from thymidine analogues 
to non-thymidine analogous are associated with improvement in 
lipoatrophy and dyslipidaemia [166], lipohypertrophy does not improve 
with switching of PIs to non-PI regimens [209, 485]. However, 
dyslipidaemia improves in switching PI regimen to a non-PI regimen [144] 
or switching to newer PIs like atazanavir [486]. 
While lipoatrophy is less common in patients on nucleoside sparing NNRTI 
and ritonavir boosted PI regimen, lipid disturbance in the form of raised 
TC and TG are more common in the same regimen [172, 487].  
4.4. Fat distribution, Dyslipidaemia and Insulin resistance                                        
There is strong evidence from in vivo [329, 488] and in vitro [336, 368] 
studies that PI therapy is associated with insulin resistance. A single dose 
of indinavir in HIV negative volunteers has been associated with 
significant reduction of glucose disposal [330]. Hence PI induced insulin 
resistance can develop rapidly and is not necessarily secondary to body fat 
changes. However, the same may not happen in HIV patients. Noor et al 
[329] showed significant differences in rate of glucose disposal in HIV 
negative patients when using atazanavir and lopinavir with ritonavir. A 
recent study by Jackson et al [489] did not show any difference when 
atazanavir was compared with saquinavir in HIV patients.  
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The recently published Women Interagency HIV Study [323] has shown 
an association of increased risk of diabetes with cumulative exposure of 
NRTIs. Another study using boosted lopinavir and tipranavir with a 
backbone of tenofovir and lamivudine did not show any evidence of insulin 
resistance at 48 weeks therapy [327], but was present when used with 
AZT [327]. Hence insulin resistance could be related more to thymidine 
analogues than to Pls. 
In the recently published D:A:D study the incidence of diabetes increased 
with cumulative exposure to HAART. The strongest relationship with 
diabetes was exposure to thymidine analogue including stavudine and 
then zidovudine. Time-updated measurements of total cholesterol, HDL 
cholesterol, and triglycerides were all associated with diabetes. Adjusting 
for each of these variables separately reduced the relationship between 
HAART and diabetes slightly. Although lipodystrophy was significantly 
associated with diabetes, adjustment for this did not modify the 
relationship between HAART and diabetes.  
4.5. Adipocentric model (figure 4.1) 
The available evidence implicates both PIs and NRTIs in the pathogenesis 
of lipodystrophy and dyslipidaemia and insulin resistance.  In an attempt 
to bring together the mixed findings of both mitochondrial dysfunction in 
relation to NRTI therapy and PI related insulin resistance plus impaired 
maturation of adipocytes an ‘adipocentric’ model of lipodystrophy has 
been proposed [76].  The clinical appearance of this syndrome is 
purported to be related to the dominance of the drug class, whereby 
greater NRTI toxicity would lead to lipoatrophy, whilst the combination of 
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PI induced insulin resistance as well as NRTI toxicity would lead to a 
mixed morphological appearance. The divergent effects upon the 
adipocyte by the different classes of drugs could therefore combine to 
produce a greater risk of firstly developing lipodystrophy as well as 
dictating the severity of this condition, a suggestion that has been 
supported by clinical findings [490, 491]. 
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Fig. 4.1:  A multifactorial Adipocentric model of lipodystrophy 
syndrome(s); a collection of abnormalities with partially overlapping risk 
factors (PI and NRTI) adapted from Nolan et al, 2001[76]. d4T = 
stavudine; NRTI – nucleoside reverse transcriptase inhibitor; PI = 
protease inhibitor; AZT = zidovudine 
 
 
 
The exact mechanisms of these changes have yet to be determined but 
may be related to the effect of HIV infection, the adverse effects of some 
antiretroviral drugs and the long term consequence of antiretroviral 
therapy on regional fat distribution and insulin resistance. A recent study 
of treated and untreated HIV patients with and without lipodystrophy 
showed that lipodystrophy in HIV was associated with a lower expression 
of LDL receptors [193].  
Chapter 4 
 147 
It was hypothesised that the reported increase in LDL cholesterol in PI and 
NNRTI treated patients may be due to a decrease in LDL clearance and 
that this may be related to changes in body fat distribution.  
The study in the previous chapter has shown that patients treated with 
protease inhibitors or non-nucleoside reverse transcriptase inhibitors with 
mild dyslipidaemia have a decreased clearance of apo-B containing 
lipoproteins. This study will describe the fat distribution of the same 
subjects and investigate the relation of the apo-B kinetics with fat 
distribution and insulin resistance.  
4.6. Objective. 
To find out the relation between fat distribution, insulin resistance and 
apo-B kinetics in HIV patients.  
4.7. Subjects and Methods 
4.7.1. Subjects 
The subjects were same as described in the previous chapter. One patient 
on treatment with the PI, nelfinavir was unable to attend for the dexa 
scan.  
Exclusion criteria were the same as used for apo-B kinetics.  
4.7.2. Experimental design:  
A cross-sectional case control study. 
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4.7.3. Ethics committee approval and patient consent 
Ethical approval was obtained from South Birmingham Local Research 
Ethics Committee and all subjects have been given written information 
about the study and all subjects gave written informed consent before 
taking part into the study. 
4.7.4. Study protocol 
Following the day of admission in the Wellcome Trust Clinical Research 
Facility, Queen Elizabeth Hospital, Birmingham, the subjects attended the 
Department of Nuclear Medicine in the same Hospital either on the same 
day or any other day within seven days of the admission for the 
measurement of their body fat distribution.    
4.7.5. Measurement of body fat distribution   
Body fat distribution was measured by whole-body dual-energy x-ray 
absorptiometry (DEXA) scan within seven days of the leucine infusion. The 
trunk was defined as the region including the chest, abdomen and pelvis, 
excluding head and neck. The proximal limit of the leg regions were 
placed through the hip joints at an angle of approximately 45 degree and 
for the arm regions vertically through the shoulder joints. The area 
between horizontal lines at the level of xiphoid process and the iliac crest 
was denoted abdominal region. 
Peripheral fat mass was defined as the sum of arm and leg masses. The 
precision of DEXA scan in this department was 3% for total fat mass, 4% 
for trunk fat mass and 5% for extremity fat mass. The DEXA scan was 
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performed and reported in random order and the operator who performed 
the analysis were not aware of any treatment or any history details of the 
subjects. The inter-observer error was eliminated by having a single 
investigator to perform all measurements. The coefficient of variation of 
repeated skinfold measurements by the same trained observer is 
approximately only 5%, but it rises to 10-20% between different 
observers [492]. 
A total of 57 subjects were scanned using a Hologic QDR 4500A (version 
11.2:3, Hologic Inc., Waltham, MA) and 9 subjects using a Lunar DPX-L 
(version1.3 g, GE Medical Systems, Waukesha, WI). Results are presented 
as leg fat, peripheral fat (arm plus leg), or trunk fat (Kg), divided by the 
lean body mass (bone plus muscles) Kg. 
4.7.6. Insulin Resistance  
The fasting glucose and fasting insulin concentration were utilised to 
estimate insulin resistance. The fasting insulin concentration is dependent 
on fasting glucose level [493]. Fasting glucose and insulin levels are 
determined by a simple feedback loop between the liver and the beta cells 
of pancreas. Decreased insulin levels allow increased gluconeogenesis, 
until plasma glucose level rises to a level that stimulates an optimal 
insulin response from beta cells. 
Homeostasis model assessment (HOMA) is a mathematical model of the 
glucose and insulin interaction that enables an interpretation of the 
feedback loop [494]. This model was based on the assumption that 
normal weighed healthy subject aged less than 35 years have insulin 
resistance of 1 and beta cell function of 100%. The model estimates a 
unique combination of beta cell function and insulin sensitivity which 
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produced the given glucose and insulin values. The main advantage of 
HOMA is that it is a simple method that can estimate relative beta cell 
function and insulin resistance (IR).  
The accuracy and precision of the estimate have been determined by 
comparison with independent measures of insulin resistance and beta-cell 
function using hyperglycaemic and euglycaemic clamps and an 
intravenous glucose tolerance test. As a method for assessing insulin 
resistance, HOMA correlates well with the euglycaemic clamp (r=0.8, 
p<0.0001), but its estimate of beta cell function appears to be less 
accurate, when compared with hyperglycaemic clamp (r=0.6, p<0.01) 
and with the estimate from the intravenous glucose tolerance test (r = 
0.6, p < 0.05). There was no correlation with any aspect of insulin-
receptor binding. The coefficient of variation is high, about 30% for both 
insulin resistance and beta cell function [494].  
The formula represents an approximation to the HOMA where HOMAIR  
stays for Insulin Resistance and HOMAsecr for beta cell function.  
 
We used the HOMAIR for calculation of Insulin Resistance (IR) :        
                   fasting plasma Insulin  x fasting plasma Glucose)/ 22.5 
                  (Units: insulin in U/ml and fasting plasma glucose in mmol/L) 
4.7.7. Statistical analyses 
Initial comparison between the four groups was by one-way ANOVA or 
Kruskal-Wallis followed by Bonferroni’s or Dunn’s multiple comparison 
tests (SPSS 10.0.7 for Windows; SPSS Inc, Chicago, IL, USA). Fisher’s 
exact test was used for categorical data between groups, and associations 
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were analyzed by Spearman’s rank correlation test. A stepwise linear 
regression model examined the effect of variables on VLDL and IDL and 
LDL metabolism. Variables entered were age, sex, ethnicity, smoking, 
family history of diabetes, family history of cardiovascular disease, alcohol 
intake, peripheral fat/ LBM, trunk fat/LBM, glucose, HOMA, and FFA. Pre-
treatment CD-4 count, HIV RNA copies and current CD-4 counts were 
included when HIV positive groups were analysed separately and in a 
separate model, only patients on antiretroviral treatment and their 
duration of treatment were included. 
4.8. Results 
4.8.1. Patient Characteristics, treatment history and lab results 
were similar to what has already been described in the previous chapter 
(table 3.1-3.3).  
4.8.2. Viral load and CD-4 counts (table 3.4) 
Current CD4 counts of the patients were not different between HIV 
positive groups, nor were current or pre-treatment viral loads or pre-
treatment CD-4 counts among the treatment groups. Two PI-treated 
patients on HAART had a detectable viral load (800 and 1100 copies/ml). 
The remaining patients had viral loads below the detection limit of the 
assay (less than 50 copies/ml).  
 
4.8.3. Fat distribution (table 4.1- 4.3) 
Only four patients had clinical evidence of lipodystrophy, one in the PI 
group and three in the NNRTI group. Three of them had both lipoatrophy 
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and visceral adiposity and one had lipoatrophy only.  All those four 
patients were on thymidine analogue based nucleoside backbones. 
A lipodystrophy score was not applied on the patients because not all the 
information was available to perform the scoring and besides the scoring 
has not been validated in clinical practice because of lack of specificity (as 
discussed in chapter 1).  
DEXA results were available in 66 subjects (table 3.1). Peripheral fat/lean 
body mass (LBM) and leg fat/LBM were significantly reduced in the PI and 
NNRTI groups compared with the control group (P < 0.05). Lean body 
mass, total fat (Kg) and trunk fat (Kg) were similar in all the groups. Total 
peripheral fat (p<0.01), arm fat (p<0.01), leg fat (p<0.01), peripheral 
fat/LBM (p<0.01), leg fat/LBM (p<0.001) were lower in the PI and NNRTI 
group, but not different between the two control groups. 
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Table 4.1: Median (IQR) Body fat distribution by DEXA scan of all subjects 
(n=64) 
 
Cases (n=54)  Control 
(n=12) TN (n=15) PI (n=14) NNRTI 
(n=25) 
p-value 
between 
groups 
Total fat Kg 17.4 (11.3-
20.3) 
16.3 (10.4-
17.8) 
14.7 (9.7-
17.2) 
11.5 (8.0-
16.2) 
 
NS 
Trunk fat Kg 7.9 (4.3-
9.2) 
7.3 (5.9-
9.1) 
9.0 (4.9-
10.3) 
6.5 (4.4-
9.4) 
 
NS 
Total 
peripheral fat 
Kg 
9.4 (6.3-
11.0)a 
8.0 (51-9.2) 5.5 (3.7-
8.2) 
4.3 (2.8-
6.6) 
0.01 
Lean body 
mass Kg 
40.6 (33.8-
53.7) 
47.5 (45.0-
59.2) 
54.8 (45.6-
61.5) 
53.0 (45.5-
56.7) 
 
NS 
Arm fat Kg 1.9 (1.3-
2.5)b 
1.6 (1.4-
2.2) 
1.5 (1.1-
2.0) 
0.9 (0.7-
1.7) 
0.01 
Leg fat Kg 7.5 (5.0-
8.0)c 
5.9 (3.6-
7.1) 
4.0 (2.5-
6.0) 
3.4 (2.1-
5.1) 
0.01 
Trunk 
fat/peripheral 
fat ratio 
0.8 (0.6-
1.0) 
1.0 (0.6-
1.2) 
1.6 (0.9-
2.0) 
1.3 (1.0-
1.9) 
NS 
Trunk fat 
(kg)/LBM 
(Kg) 
0.16 (0.11-
0.21) 
0.16 (0.09-
0.19) 
0.14 (0.11-
0.19) 
0.14 (0.08-
0.20) 
NS 
Limb fat 
(Kg)/LBM(kg) 
0.2(0.1-
0.3)d 
0.1 (0.09-
0.21) 
0.09 (0.07-
0.15) 
0.08 (0.06-
0.14) 
0.001 
Leg fat 
(Kg)/LBM(Kg) 
0.05 (0.03-
0.05)e 
0.04 (0.02-
0.05) 
0.03 (0.02-
0.04) 
0.02 (0.01-
0.04) 
0.001 
 
ap-value between control vs. PI& NNRTI and TN vs. PI & NNRTI 
bp-value between control vs. PI& NNRTI  
cp-value between control vs. PI& NNRTI  
dp-value between control vs. PI& NNRTI  
ep-value between control vs. PI& NNRTI  
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Distribution of fat was not different between AZT and d4T users (table 
4.2).  
 
Table 4.2: Median (IQR) Body fat distribution by DEXA scan amongst  
thymidine analogue user (d4t vs. AZT) 
 
 AZT (n=27) d4T (n=10) p-value 
Total fat (Kg) 14.0 (10.0-20.0) 10.2 (8.0-13.7) NS 
Trunk fat (Kg) 8.2 (5.7-11.6) 6.3 (4.4-8.8) NS 
Total peripheral 
fat (arm + leg) 
Kg 
5.4 (4.0-7.8) 3.7 (2.7-6.2) 
NS 
Lean body mass 
= bone plus 
muscle (Kg) 
55.3 (47.8-61.8) 50.7 (40.2-55.7) 
NS 
Arm fat (Kg) 1.5 (0.8-1.9) 1.0 (0.7-1.6) NS 
Leg fat (Kg) 4.0 (3.0-6.1) 2.6 (1.9-4.5) NS 
Total fat (Kg)/ 
lean body mass 
(Kg) 
0.2 (0.160.34) 0.20 (0.1-0.3) 
NS 
Limb fat Kg/Lean 
body mass Kg 
0.03 (0.01-0.04) 0.02 (0.01-0.04) 
NS 
 
Amongst the group using PI, fat distribution was similar between ritonavir 
user and non-user (table 4.3).  
There was no significant difference in regional body fat changes in 
patients with significant dyslipidaemia (cholesterol ≥6 mmol/l and or 
triglyceride ≥2.3 mmol/l, n=13) compared to the other subjects without 
significant dyslipidaemia(cholesterol <6 mmol/l and or triglyceride <2.3 
mmol/l, n=53). 
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Table 4.3: Median (IQR) Body fat distribution by DEXA scan amongst 
ritonavir as PI booster or non -ritonavir user 
 
 Ritonavir as PI 
or booster (n=8) 
Non-ritonavir PI 
(n=7) 
p-value 
Total fat (Kg) 14.8 (9.1-19.0) 13.0 (9.1-19.1) NS 
Trunk fat (Kg) 9.1 (5.5-10.0) 7.3 (3.6-13.7) NS 
Total peripheral 
fat (arm + leg) 
Kg 
5.2 (3.1-8.8) 5.5 (4.2-7.2) 
NS 
Lean body mass 
= bone plus 
muscle (Kg) 
53.7 (42.3-58.7) 58.1 (44.4-63.3) 
NS 
Arm fat (Kg) 1.7 (0.9-2.0) 1.4 (1.0-1.9) NS 
Leg fat (Kg) 3.5 (2.1-6.7) 4.0 (2.9-5.6) NS 
Total fat (Kg)/ 
lean body mass 
(Kg) 
0.24 (0.16-0.33) 0.26 (0.19-0.33) 
NS 
Limb fat Kg/Lean 
body mass Kg 
0.08 (0.06-0.16) 0.10 (0.07-0.15) 
NS 
  
4.8.4. Insulin Resistance [HOMAIR] (table 4.4, 4.5) 
Median fasting blood sugar was 5.1 (range: 3.9-6.1) mmol/l, and was not 
different amongst the groups (two subjects having fasting blood sugar 6.0 
and 6.1mmol/l, one with PI and one with NNRTI).   
Fasting plasma insulin level was higher in PI group compared to HIV-
negative controls (p<0.01). Compared to HIV-negative controls, HOMAIR 
was higher in PI group but not in others (p<0.01). There was no 
difference in HOMAIR amongst the HIV positive groups (table 4.4). 
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Table 4.4: Baseline plasma glucose, insulin and HOMAIR [median 
(interquartile range)] 
Cases (n=66)  Control 
(n=12) TN (n=14) PI (n=15) NNRTI 
(n=25) 
p-
value 
betwee
n 
groups 
Glucose 
mmol/l 
4.9 (4.7–
5.2) 
4.9 (4.7–
5.0) 
5.2 (4.9 –
5.4) 
5.1 (4.5–5.5) NS 
Insulin 
(pmol/l) 
30.0 
(20.0–
40.3) 
37.5 
(28.1–
56.2) 
42.3 
(31.1–
114.2) 
37.0 (18.7– 
64.8) 
NS 
HOMAIR 0.9 (0.6 –
1.3) 
1.3 (0.9 –
1.9) 
1.4 (1.0 –
3.3)1 
1.3 (0.5–2.0) 0.01 
 
1P <0.01 Between PI and control 
HOMAIR was not different amongst the HIV patients who had significant 
dyslipidaemia (cholesterol ≥6 mmol/l and or triglyceride ≥2.3 mmol/l, 
n=14) compared to the other subjects without significant dyslipidaemia 
(cholesterol <6 mmol/l and or triglyceride <2.3 mmol/l, n=40). 
However, in the antiretroviral-treated patients with dyslipidemia 
(cholesterol ≥ 6 mmol/liter or triglyceride ≥2.3 mmol/liter, n=11) had 
lower VLDL FCR (P < 0.001), larger VLDL apoB pool size (P < 0.003), 
increased VLDL residence time (P<0.001), increased trunk fat/BMI (P< 
0.04), HOMA (P < 0.04), and FFA     (P < 0.003) compared with those 
without dyslipidemia (n=28). 
 
4.8.5. Correlation of fat distribution, HOMAIR and apo-B kinetics 
Duration of treatment was negatively correlated with total fat/LBM (r=0.4, 
p< 0.001) and leg fat/LBM (0.54, p<0.0001), but not with trunk fat / LBM 
(table 4.5).  
 
 
 
 
 
Chapter 4 
 157 
 
Table 4.5: Correlations between duration of treatment and fat distribution 
 
   
Total fat 
(g)/ lean 
mass (g) 
Limb fat 
(g) / lean 
mass (g) 
Trunk fat 
(g) / lean 
mass (g) 
Total duration of 
treatment 
Correlation 
Coefficient (r) 
-.40(**) -.54(**) -.19 
  Sig. (2-tailed) .001 .000 .116 
** Correlation is significant at the 0.01 level (2-tailed). 
     LBM: lean body mass 
 
Peripheral fat/LBM was positively correlated with trunk fat/LBM 
(r=0.6,p<0.0001, table 4.6). Peripheral fat/LBM was positively correlated 
with VLDL apoB FCR (r=0.38, p<0.002), IDL apo-B FCR (r=0.4,p<0.002) 
and LDL apo-b FCR (r=0.3, p<0.01, table 4.6, figure 4.2, 4.3 and 4.4). 
HOMAIR correlated with trunk fat/LBM (r=0.3, p=0.01) but not with limb 
fat/LBM (table 4.6).  
HOMAIR correlated positively with serum TG (r=0.37, p<0.002, table 4.7) 
and negatively with HDL-cholesterol (r=0.4, p<0.001, table 4.7). 
HOMAIR correlated negatively with VLDL apo-B FCR (r=0.29, p<0.01, table 
4.8), IDL apo-B FCR (r=0.29, p<0.02, table 4.9) and LDL apo-B FCR 
(r=0.33, p<0.008, table 4.10) and LDL ASR (r=0.32, p<0.008, table 
4.10) respectively. 
HOMAIR correlated positively with VLDL apo-B pool size, VLDL residence 
time, VLDL-TG, VLDL-C (r=0.36, 0.3, 0.42, 0.44, p< 0.003, 0.01, 0.0001, 
0.0001, respectively, table 4.7), and IDL residence time (r=0.3, p<0.02, 
table 4.9) and also with LDL pool size and residence time(r=0.31, 0.33, 
p<0.01, 0.007, table 4.10 respectively) but not with IDL-TG and IDL-C 
(table 4.9) and LDL-TG, LDL-C (table 4.10).
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Table 4.6: Correlations between HOMA, apo-B FCR and fat distribution 
  
HOMA 
(insulin.glu
cose/22.5) 
VLDL FCR 
pools/day 
IDL 
FCR/day 
LDL FCR 
pools/day 
Trunk fat (g) / 
lean body mass 
(g) 
Peripheral Fat / 
lean body mass 
Correlation 
Coefficient (r) 
-.290(*) -.299(*) -.334(**) .385(**) .013 
HOMA 
(insulin.glucose
/22.5) Sig. (2-tailed) 
 
.018 .022 .008 .002 .921 
Correlation 
Coefficient (r) 
-.290(*) 
.746(**
) 
.700(**) -.078 .382(**) 
VLDL FCR 
pools/day 
Sig. (2-tailed) .018 
 
.000 .000 .536 .002 
Correlation 
Coefficient (r) 
-.299(*) .746(**) .557(**) -.143 .405(**) 
IDL FCR/day 
Sig. (2-tailed) .022 .000 
 
.000 .283 .002 
Correlation 
Coefficient (r) 
-.334(**) .700(**) 
.557(**
) 
-.111 .309(*) 
LDL FCR 
pools/day 
Sig. (2-tailed) .008 .000 .000 
 
.385 .014 
Correlation 
Coefficient (r) 
.385(**) -.078 -.143 -.111 .665(**) 
Trunk fat (g) / 
lean body mass 
(g) Sig. (2-tailed) .002 .536 .283 .385 
 
.000 
Correlation 
Coefficient (r) 
.013 .382(**) 
.405(**
) 
.309(*) .665(**) 
Peripheral fat / 
lean body mass 
Sig. (2-tailed) .921 .002 .002 .014 .000 
 
 
*  Correlation is significant at the 0.05 level (2-tailed). **  Correlation is significant at the 0.01 level (2-tailed). 
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Table 4.7: Correlations between HOMAIR, lipids and FFA 
 
  
total 
cholesterol 
(mmol/L) 
HDL 
cholesterol 
total 
triglyceride 
Free fatty 
acids mmol/l 
LDL cholesterol 
mmol/l 
Correlation 
Coefficient (r) 
.193 -.413(**) .373(**) -.086 .128 
HOMAIR 
(insulin.glucose 
/22.5) 
 
 
Sig. (2-tailed) 
.120 .001 .002 .495 .316 
 
** Correlation is significant at the 0.01 level (2-tailed).  *  Correlation is significant at the 0.05 level (2-tailed). 
 
 
Table 4.8: Correlations of HOMAIR and VLDL fractions 
 
   
VLDL FCR 
(pools/day) 
VLDL 
ASR 
(mg/kg/
day) 
ApoB 
pool size 
mg 
VLDL 
chol 
(mmol/l) 
VLDL 
triglyceride 
(mmol/l) 
VLDL residence 
time (h) 
Correlation 
Coefficient (r) 
-.290(*) .070 .365(**) .442(**) .428(**) .3(*) 
HOMAIR 
(insulin.glucose 
/22.5) 
  
Sig. (2-tailed) 
.018 .576 .003 .000 .000 .018 
** Correlation is significant at the 0.01 level (2-tailed). * Correlation is significant at the 0.05 level (2-tailed). 
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Table 4.9: Correlations of HOMAIR and IDL fractions 
 
  
IDL FCR 
pools/day 
IDL ASR 
(mg/kg/
day) 
IDL Apo-B 
pool size 
(mg) 
IDL 
cholesterol 
(mmol/l) 
IDL 
triglyceride 
(mmol/l) 
IDL 
residence 
time (h) 
Correlation 
Coefficient (r) 
-.299(*) -.233 .135 .154 .044 .304(*) 
HOMAIR 
(insulin.glucose 
/22.5) 
 
Sig. (2-tailed) 
.022 .079 .279 .218 .725 .020 
** Correlation is significant at the 0.01 level (2-tailed).  *  Correlation is significant at the 0.05 level (2-tailed). 
 
 
 
 
Table 4.10: Correlations of HOMAIR and LDL fractions 
  
LDL FCR 
pools/day LDL ASR 
LDL apoB 
g 
LDL 
cholesterol 
g/l 
LDL 
triglyceride 
mmol/l 
LDL residence 
time (h) 
Correlation 
Coefficient (r) 
-.334(**) -.329(**) .314(*) .127 .028 .335(**) 
HOMAIR 
(insulin.glucose 
/22.5) Sig. (2-tailed) .008 .008 .012 .323 .827 .007 
** Correlation is significant at the 0.01 level (2-tailed). * Correlation is significant at the 0.05 level (2-tailed). 
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Figure 4.2: Correlation between peripheral fat and VLDL apo-B FCR 
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Figure 4.3: Correlation between peripheral fat and IDL apo-B FCR 
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Figure 4.4: Correlation between peripheral fat and LDL apo-B FCR 
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4.8.6. Linear regression analysis 
In a linear regression model HOMA predicted VLDL apoB residence time 
(P<0.005), VLDL cholesterol (P < 0.006), VLDL triglyceride (P < 0.008), 
LDL residence time (0.01) and FCR (0.01) and inversely predicted VLDL 
apoB FCR (P < 0.005) and IDL ASR (P < 0.02) and LDL ASR (p=0.005).  
Peripheral fat predicted VLDL apoB FCR (P < 0.001) and IDL apoB FCR (P 
< 0.001) but inversely predicted IDL cholesterol (P < 0.001). Trunk fat 
predicted VLDL apoB pool size (P <0.006), VLDL cholesterol (P < 0.001), 
and IDL residence time (P < 0.001), LDL apoB pool size (p<0.019), 
negatively IDL apoB FCR (P < 0.001) and LDL FCR (p=0.016). FFA 
concentration predicted LDL apoB pool size (p=0.012), LDL cholesterol 
(p=0.044) and LDL TG (p<0.001). 
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4.8. Discussion                                                                                                   
This study has shown that HIV patients on treatment had more loss of 
peripheral fat compared to treatment naïve HIV patients and HIV negative 
controls and this was associated with impaired apo-B clearance rate, but 
not with insulin resistance. Insulin resistance was associated with 
increased trunk fat and increased VLDL and LDL-apo-B pool size, but not 
with IDL pool size. Patients on longer duration of treatment had more loss 
of peripheral fat, but their insulin resistance was not different from the 
other patients. Amongst the group using PI, fat distribution was similar 
between ritonavir user and non-user. Distribution of fat was not different 
between AZT and d4T users. However, this is likely to be the effct of 
sample size as such a difference has been previously well established[495, 
496].    
Insulin resistance decreases delipidation of lipoproteins [497] derived 
from liver or from gut (chylomicrons) through lipoprotein lipase which is 
produced and secreted by adipocytes under the influence of insulin [498]. 
Increased FFA liberated from lipolysis, and increased chylomicron 
remnants can stimulate more synthesis of hepatic VLDL [499-501]. 
Increased VLDL production leads to increased production of LDL that is 
then cleared by LDL receptors. However, altered TG enriched VLDL 
producesTG rich LDL which then leads to formation of smaller dense LDL 
that is less effectively cleared by the LDL receptors and is more 
susceptible to oxidative modification (figure 4.4). Alternatively TG rich 
VLDL can also produce IDL [502] with the help of endothelial lipase [97, 
502, 503] (figure 4.4). The TG rich IDL can either be taken up by liver 
receptors or transformed further to TG rich LDL. 
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The larger apo-B containing lipoproteins (VLDL) rich in triglyceride are 
metabolised by sequential delipidation through a transient IDL to 
cholesterol-rich LDL.  Several components contribute to the regulation of 
this process, including the lipolytic enzymes lipoprotein lipase and hepatic 
lipase, apolipoproteins CII, CIII and E, and the apolipoprotein B/E or LDL 
receptor [504]. Clearance of IDL to LDL is dependent on plasma hepatic 
lipase activity [504-506]. Lipoprotein lipase acts primarily on large VLDL. 
Hepatic lipase on the other hand seems to be critical for the conversion of 
smaller particles. In our study HOMAIR correlated with VLDL and LDL-apo-
B pool size but not with IDL-apoB pool size.  While LPA activity is reduced 
in insulin resistance, the activity of hepatic lipase increases [505]. This 
could explain the lack of association of insulin resistance with IDL apo-B 
pool size. Insulin resistance has influence on the activities of lipase 
systems. Influence of other factors including adipocytokines is possible. 
 
 
Chapter 4 
 167 
Fig. 4.5: Insulin resistance and lipid metabolism: Insulin resistance lowers delipidation of different lipoproteins through LPL 
system resulting increased production of TG rich VLDL-C.  These are cleared either by IDL pathway or by LDL pathway 
exchanging TG load with cholesterol with HDL-C (adapted from Nolan et al[76].  Apo B100 = apolipoprotein B100; B48 = 
apolipoprotein B48; CETP – cholesterol ester transfer protein; FFA = free fatty acid; HDL = high density lipoprotein; IDL = 
intermediate density lipoprotein 
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In contrast to many previous studies, this study did not show a significant 
change in insulin resistance in any of the treatment group. 
However, in a regression model insulin resistance predicted VLDL apo-B 
FCR, apo-B concentration, and cholesterol and triglyceride content, 
possibly through the control of insulin on lipoprotein lipase activity [507]. 
Central obesity and increased visceral fat is strongly associated with 
insulin resistance [508]. The failure to find a significant change in insulin 
resistance between groups in the present study may be explained by the 
lack of a significant change in trunk fat and also could be due to small 
sample size as a correlation between trunk fat and HOMA became evident 
when the subjects were combined. Interestingly trunk fat, FFA and HOMA 
were significantly higher in patients with dyslipidaemia (cholesterol ≥6 
mmol/l and or triglyceride ≥2.3 mmol/l) compared to those without. The 
association between visceral fat and insulin resistance and dyslipidaemia 
is well-documented [475]. 
Several studies have shown that PI induced insulin resistance and TG rich 
dyslipidaemia have a common association with abnormal fatty acid 
metabolism. The increased production of FFA from breakdown of fat or 
decreased clearance of FFA from the plasma by adipocytes and muscles 
acts as a fuel for the synthesis of increased VLDL in the liver [509]. 
Increased FFA in the plasma can also act as a fuel for increased 
gluconeogenesis in the liver [510], impair the uptake of glucose in the 
muscle or fat and can induce beta cell dysfunction in the pancreas 
(discussed in chapter 1, figure 1.14) [378]. This association was not 
present in our study, but an association was found only in patients who 
had severe dyslipidaemia. The patients who had severe dyslipidaemia had 
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higher HOMA and higher FFA, along with decreased apo-B FCR and 
increased apo-B pool size and increased trunk fat. It is possible that in 
HIV patients insulin resistance may not have any direct influence on apo-B 
kinetics and fat distribution in the absence of significant dyslipidaemia. 
Although insulin resistance in HIV infection can develop earlier in the 
absence of lipodystrophy [326], factors other than insulin resistance may 
play an important role in the impairment of apo-B kinetics and may have 
association with peripheral fat loss.   
Our data suggests that in patients with mild dyslipidaemia reduced VLDL, 
IDL and LDL-apoB FCR may be a primary abnormality in lipoprotein 
kinetics in HIV infection, possibly in consequence to the peripheral fat 
loss, which is further exacerbated by treatment with either a protease 
inhibitor, or nevirapine or efavirenz-containing regimen. The association of 
VLDL, IDL and LDL apoB FCR with regional fat distribution suggests that 
the mechanism for decrease in this parameter may be related to a 
decrease in lipoprotein lipase and or a possible change in hepatic lipase 
activity. Interestingly the patients with significant dyslipidaemia in our 
study did not have any difference in the peripheral fat distribution, but 
their HOMA and FFA were higher along with decreased apo-B FCR, and 
increased trunk fat.  
Insulin resistance has been described more with PI use and visceral 
adiposity. Association with peripheral fat loss has not been well described 
till recently when a few studies pointed to the influence of thymidine 
analogues [318, 323, 326], but the mechanisms have yet to be defined. A 
role of adiponectin has been supported by some other studies [387, 511]. 
In diabetic patients insulin resistance plays an important role in VLDL apo-
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B clearance [103, 129, 512, 513]. The absence of association of insulin 
resistance or HOMA with VLDL apo-B FCR in our study possibly indicates 
the role of some other factors in the clearance of apo-B in HIV patients. In 
healthy subjects adiponectin has been found to increase the insulin 
sensitivity in different tissues including liver and skeletal muscles [514]. 
The inter relationship of adiponectin, other cytokines, apo-B kinetics and 
body fat distribution will be investigated in the next chapter. 
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CHAPTER 5 
Adipocytokines and Dyslipidaemia in HIV patients                                                             
5.1. Introduction  
Adipose tissue is a hormonally active system [515] involved in the control 
of intermediary metabolism and not merely a storehouse of excess energy 
[385]. The term adipocytokines has been used to refer to a series of 
adipocyte-derived biologically active molecules which may influence the 
function as well as the structural integrity of other tissues. It has now 
become clear that the adipocytes release free fatty acids and several 
cytokines and hormones, including tumour necrosis factor alpha        
(TNF-α) , interleukins, plasminogen activator inhibitor type 1, leptin, 
adiponectin and resistin.  These secretary products have paracrine and 
endocrine actions and allow the adipocyte to have an important role in the 
regulation of metabolism, including insulin resistance and to participate in 
the atherogenic processes [381].  
5.1.1. Adiponectin 
The most abundant protein within the adipocyte is adiponectin [396].  
There seems to be a clear relationship between adiponectin and fat mass 
in humans [516].  Adiponectin is the only adipose-specific protein known 
to date that is negatively regulated in obesity [396]. The relationships 
between adiponectin and serum lipid concentrations have recently been 
studied [517-520].  Plasma adiponectin has been found to be correlated 
negatively with serum triglyceride and positively with serum HDL 
cholesterol in female non diabetic subjects [401].  
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The mechanisms responsible for the control of the production of 
adiponectin have not been determined so far.  The only hormone 
implicated in the regulation of adiponectin expression has been insulin 
[521].  But the mechanism regulating the decreased adiponectin 
concentration in insulin resistance remains obscure.  TNF-α 
 is one of the candidate molecules responsible for causing insulin 
resistance [522].  The expression and secretion of adiponectin from 
adipocytes are significantly reduced by TNF-α [523-525] and therefore 
increased TNF- α might be partially responsible for the decreased 
adiponectin production in obesity or in insulin resistance. 
5.1.2. Adiponectin, Dyslipidaemia and Lipodystrophy 
Several authors have investigated the potential role of adiponectin in the 
pathogenesis of PI associated lipodystrophy [347, 387, 425, 526]. 
Patients with HIV associated lipoatrophy have a reduction in both mRNA 
and plasma concentrations of adiponectin which correlate with markers of 
insulin resistance and lipolysis [387].  However, it is difficult to assess 
whether this is the effect or cause of the lipoatrophy and whether the 
change in adiponectin is due to HIV or the drugs used in the HAART 
regimen.  In particular, the extensive use of PIs within these studies has 
led to suggestions that this class is responsible for the reductions in 
adiponectin witnessed in patients with lipodystrophy [527, 528]. Using a 
murine cell line Xu et al [529], demonstrated that indinavir (IDV), 
nelfinavir (NFV) and ritonavir (RTV) could decrease adiponectin mRNA and 
adiponectin secretion, with RTV having the most profound effect. A few 
recent studies on the other hand have suggested that NRTI use rather PI 
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use has greater effect on the reduction of plasma adiponectin in HIV 
patients [387, 390, 526].  
Furthermore the lack of prospective studies makes it difficult to asses 
whether hypoadiponectaemia is simply a reflection of reduced adipocyte 
size rather than a specific drug induced effect. In support of that, patients 
with non-HIV congenital lipodystrophy have lower amounts of plasma 
adiponectin than patients with only partial lipodystrophy [530].  
5.1.3. Leptin, Dyslipidaemia and Lipodystrophy 
Leptin is synthesized and released from fat cells in response to changes in 
body fat mass [531]. Leptin reduces intracellular lipid levels in skeletal 
muscle, liver and pancreatic beta cells, and thereby improves insulin 
sensitivity [409]. These changes are partially mediated by central 
sympathetic activation of adrenergic receptors [532]. Leptin deficiency is 
a rare monogenic disorder and thus confined to only a few patients, but 
that in simple obesity leptin resistance prevails[533]. Thus leptin 
treatment does not appear to be a suitable option for obesity or 
lipodystrophy in the general population[534]. In patients with 
lipodystrophy and leptin deficiency, leptin replacement therapy improved 
glycaemic control and decreased triglyceride levels, but no change in 
lipodystrophy. However, the role of leptin in HIV infection and its response 
to HAART has not been established [411]. 
5.1.4. Tumour Necrosis Factor (TNF)-α  
TNF-α, is a multipotential cytokine. It has been proposed as a molecular 
link between obesity and insulin resistance [535]. Studies in obese rats 
with blockade or neutralization of TNF-α have shown improvement in 
insulin resistance [418, 420]. In humans TNF-α is synthesized and 
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secreted by different tissues including adipocytes and stroma of vascular 
cells [536, 537]. Adipose tissue TNF-α mRNA correlates with body mass 
index, percentage of body fat and hyperinsulinaemia [538]. Several 
mechanisms could account for the effect of TNF-α on obesity-related 
insulin resistance that include increased release of FFA by adipocytes, 
reduced adiponectin synthesis and impaired insulin signalling.  
The role of TNF- α in HIV can be complex as plasma levels can vary with 
different stages of infection. TNF-α has been shown by a number of 
authors to be over expressed in patients with lipodystrophy [250, 252], as 
well as correlating with markers of insulin resistance and hyperlipidaemia 
[250] in patients with subcutaneous peripheral wasting. Both animal and 
human studies have indicated that TNF-α can inhibit adipocyte 
differentiation [539, 540], 2000), modulate lipid metabolism [416] and 
enhance plasminogen activator inhibitor levels [541]; effects that are 
typically evident in patients with lipodystrophy [419]. 
In humans two cell surface TNF-α receptors, TNF-R1 and TNF-R2 have 
been described. Soluble forms of those receptors (sTNF-R1 and sTNF-R2) 
are present in plasma and their concentrations might reflect local action of 
TNF-α in diffent tissues [420, 421]. Mynarcik et al [250] found 
relationship between the degree of insulin resistance and sTNFR2 levels 
and suggested an inflammatory stimulus is contributing to the 
development of HIV-associated lipodystrophy. Levels of sTNFR2 were 
elevated in all HIV-infected subjects, but they were significantly higher in 
those with lipodystrophy than without, and sTNFR2 levels strongly 
correlated with the reduction in insulin sensitivity.  
 
Chapter 5 
 175 
5.1.5. Interleukin-6 (IL-6) 
IL-6 is a circulating cytokine with multiple effects ranging from 
inflammation to host defence and tissue injury. It is secreted by adipose 
tissue and many other cell types [540, 542, 543]. There is a positive 
correlations between plasma IL-6 concentrations with human obesity and 
insulin resistance [544], and high IL-6 levels are predictive of type 2 
diabetes and myocardial infarction [545-547].  In the recently presented 
SMARTY study IL-6 was associated with high plasma HIV RNA level and 
also associated with increased risk CVD. The role of IL-6 in fat distribution 
and dyslipidaemia in HIV patients, have not been established. 
5.1.6. Interleukin-8 (IL-8)                                                                 
It is possible that the chronic inflammatory state associated with HIV 
infection, and reflected as elevated fasting serum IL-8 levels, may 
contribute to abnormalities in glucose metabolism. IL-8 has possible effect 
on atherogenesis [426, 548]. IL-8 is produced and released from human 
subcutaneous and visceral adipose tissue [549] and subcutaneous adipose 
tissue obtained from HIV-infected individuals with fat redistribution and 
insulin resistance [425]. Serum IL-8 levels are increased in diabetic 
patients, and IL-8 has been suggested to be involved in the pathogenesis 
of atherosclerosis. Enhanced mRNA levels of TNF-α, IL-6, and IL-8 and low 
adiponectin were found in subcutaneous adipose tissue of patients who 
have HIV associated lipodystrophy [425]. Increased adipocytokine 
expression might play a role for the reduced levels of adiponectin found in 
HIV associated LD patients. 
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5.1.7. Other cytokines                                                                       
A host of other cytokines [540, 550, 551] have been proposed to have 
effects on lipid and insulin metabolism and this can vary with the 
disposition of fat distribution while the fat cells of different region have 
different actions.  
Resistin was found to have influence on glucose metabolism possibly 
though insulin resistance [432] [552]. But subsequent studies have 
conflicting results and various authors have failed to associate the 
adipocyte as being a key secretor of resistin [434].  
Cytokines including IL-1α and β, IL-12 have been found to have effects on 
lipid metabolism and insulin resistance [553]. These cytokines have 
effects on the secretion of other cytokines including adiponectin. 
Macrophage related involution of fat cells have been described in HIV 
negative individuals [554]. Adipose tissue from patients with HIV-related 
lipodystrophy presents a state of chronic inflammation. Altered expression 
of cytokines or adipokines and macrophage infiltration could be involved in 
patients' insulin resistance and lipoatrophy. Increased chemokine or 
cytokine production by adipocytes and macrophages could be involved in 
macrophage recruitment and participate in lipoatrophy and insulin 
resistance [553, 555, 556]. 
As discussed in the previous chapter the available evidence implicates 
both PIs and NRTIs in the pathogenesis of lipodystrophy.  The adipocentric 
model of lipodystrophy proposed by Nolan, attempted to  bring together 
the mixed findings of both NRTI therapy related mitochondrial dysfunction 
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and PI related insulin resistance plus impairment of adipocyte maturation 
[76]. The divergent effects upon the adipocyte by the different classes of 
drugs and the virus might be responsible for secretion of different 
cytokines that could be the mediator of different metabolic disturbances 
seen in HIV patients.  
In the previous chapters we demonstrated in HIV patients, a significant 
reduction in VLDL, IDL and LDL apoB fractional catabolic rate [6, 7] which 
was inversely related to peripheral fat, without any significant difference 
in insulin resistance. The underlying cause for the altered lipid metabolism 
and consequent dyslipidaemia may be due to loss of peripheral fat but the 
mechanism is not understood.  
In this study it was hypothesised that loss of peripheral fat in HIV patients 
would result in decreased plasma adipocytokines, in particular 
adiponectin, which would be associated with changes in VLDL, IDL and 
LDL apolipoprotein-B (apo-B) kinetics. 
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5.2. Objective 
To find out the relationship between plasma adipocytokines and apo-B 
kinetics and fat distribution in HIV patients  
5.3. Subjects and Methods 
5.3.1. Subjects 
The subjects were same as described in the previous chapter. One patient 
on treatment with PI, nelfinavir was unable to attend for the dexa scan.  
Exclusion criteria were the same as used for apo-B kinetics.  
5.2.2. Experimental design:  
A cross-sectional case control study. 
5.2.3. Ethics committee approval and patient consent 
Ethical approval was obtained from South Birmingham Local Research 
Ethics Committee and all subjects have been given written information 
about the study and all subjects gave written informed consent before 
taking part into the study. 
5.2.4. Study protocol 
The fasting plasma samples were taken at the same time as other 
samples were taken for apo-B kinetics.  
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5.2.5. Adiponectin and Leptin assay 
Plasma adiponectin and plasma leptin were measured by 
radioimmunoassay assay using Linco Research, St Louis, MO, USA .  The 
LINCO Research, Inc. adiponectin RIA assay utilizes 125I-labeled murine 
adiponectin and a multispecies adiponectin rabbit antiserum to determine 
the level of adiponectin in serum, plasma or tissue culture media by the 
double antibody/PEG technique. The adiponectin standards were prepared 
using recombinant mouse adiponectin and were used to determine the 
circulating levels of adiponectin in mouse or rat serum/plasma samples.  
Human adiponectin sensitivity is at 1ng/ml when using a 100micro lit 
sample size. Assay range is 1-200 ng /ml. Specificity is <0.01% for 
human C1q and 400% for mouse adiponectin. Interassay % CV (variance) 
is 9.25 on a sample concentration of 1.5 ug/l with intra-assay CV 
(variance) of 3.59%.  
 
5.2.6. Cytokines assay  
The following cytokines were measured in fasting blood sample: TNF-α 
including TNF-soluble receptor 1 and TNF-soluble receptor-2, interleukin-1 
beta (IL-1b), IL-6, IL8, IL-10 and IL-12p70. We used the Becton 
Dickinson Human Inflammation Cytometric Bead Array to measure the 
cytokines on a dual-laser FACS Calibur flow cytometer. The detection limit 
of the assay was 3 pg/ml.  
5.2.7. Statistical analyses 
Initial comparison between the five groups was by one-way ANOVA or 
Kruskal-Wallis followed by Bonferroni’s or Dunn’s multiple comparison test 
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(SPSS 10.0.7 for Windows; SPSS Inc, Chicago, IL, USA). Fisher’s exact 
test was used for categorical data between groups, and associations were 
analyzed by Spearman’s rank correlation test.  
A stepwise linear regression model examined the effect of variables on 
VLDL and IDL and LDL metabolism. Variables entered were age, sex, 
ethnicity, smoking, family history of diabetes, family history of 
cardiovascular disease, alcohol intake, peripheral fat/ LBM, trunk fat/LBM, 
glucose, HOMA, FFA, cytokines including adiponectin, leptin, TNF-α, TNFR-
1, TNFR-2,  IL-8. Pre-teatment and current CD-4 count and pretreatment 
HIV RNA copies were included when compared between the HIV positive 
groups. In a separate model, only patients on treatment were included. All 
the variables entered in to the multivariate model were log transformed.   
 
5.3. Results 
5.3.1. Patient Characteristics, treatment history and lab results 
were similar to what has already been described in the previous chapter 
(table 3.1-3.3)  
5.3.2. Viral load and CD-4 counts were similar to what has already 
been described in the previous chapter. has been described in the 
previous chapter (table 3.4). 
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5.3.3. Adipocytokines  
5.3.3.1. Adiponectin (table 5.1)  
Adiponectin was lower in all HIV patients, including TN patients compared 
to controls (p<0.003) but was not different between the three HIV groups. 
Adiponectin was lower (p<0.01) in patients with dyslipidaemia (cholesterol 
≥6 mmol/l and or triglyceride ≥2.3 mmol/l) compared to those without 
dyslipidaemia (3.3 µg/ml [2.4-5.1] (n=14) v 5.4 µg/ml [4.7-7.9], n=41).   
5.3.3.2. Leptin (table 5.1)  
Leptin levels were lower in HIV positive groups (p<0.006).  
Amongst the HIV positive groups leptin level was lower in NNRTI group 
compared to the others (p<0.05).  
There was no significant difference in leptin level in patients with 
significant dyslipidaemia (cholesterol ≥6 mmol/l and or triglyceride ≥2.3 
mmol/l, n=14) compared to those without dyslipidaemia (n=41).  
5.3.3.3. TNF- α and other cytokines (table 5.1)   
Serum TNF-α was lower in HIV-ve controls (<0.0001) compared to HIV 
positive groups. Among the HIV+ve groups TNF-α was higher in the 
treatment naïve group (0.01) but there was no difference between the PI 
and NNRTI group.  
Serum TNF-R1 was lower in TN (p<0.03) compared to other groups, but 
was not different amongst HIV-ve control, PI and NNRTI group. TNF-R2 
was higher in PI compared to all other groups (p< 0.01) and was lower in 
TN (p<0.05) compared to HIV-ve control (p<0.05) and NNRTI (p<0.01).  
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Serum IL-8 was higher (p<0.01) in TN and PI group, but not in NNRTI and 
HIV-negative controls.  
IL-1 was lower in all HIV positive groups (p<0.01) compared to HIV-ve 
controls, but was not different between the HIV positive groups.  
IL-1β, IL-6, IL-10 and IL-12p70 were below the detection limit of the 
assay for most samples and hence were excluded from statistical analysis. 
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Table 5.1: Median (IQR) adipocytokines and other cytokines  
Cases (n=55)  Control 
(n=12) TN (n=15) PI (n=15) NNRTI 
(n=25) 
p-value 
between 
groups 
Adiponectin 
µg/ml 
a9.7 (6.9-
13.3) 
5.4 (4.7-
8.5) 
5.0 (3.3-
6.4) 
5.0 (3.1-
6.7) 
0.003 
Leptin 
ng/ml 
b8.7 (3.4-
13.5) 
4.4 (2.5-
7.5) 
4.1 (3.3-
6.2) 
c2.1(1.1-
4.9) 
0.006 
TNF- α 
pg/ml 
d0.75 
(0.5-
0.9)* 
e3.7 (2.6-
4.2) 
1.5 (1.3-
4.7) 
1.1 (1.0-
2.1) 
0.0001 
TNF soluble 
receptor I 
pg/ml 
752.1 
(720.3-
1012.2) 
f431.7 
(312.7-
758.9) 
936.6 
(723.2-
1132.1) 
873.9 
(569.7-
1033.7) 
0.03 
TNF soluble 
receptor II 
pg/ml 
2544.0 
(2133.7-
3086.9) 
g75.0 
(37.9-
5324.0) 
h8830.9 
(818.8-
9446.5) 
5551.9 
(2736.0-
8343.6) 
0.015 
IL-1 α 
  pg/ml 
i34.1 
(8.7-00)d 
14.7 (5.3-
00) 
18.7 
(17.4-00) 
14.7 (7.9-
33.6) 
0.01 
IL-1 beta 
pg/ml 
- - - - - 
IL-6 pg/ml - - - - - 
IL-8 pg/ml j4.0 (3.3-
4.2) 
6.0 (4.2-
7.5) 
5.8 (4.7-
6.4) 
4.9 (3.9-
7.6) 
0.015 
IL-10 
pg/ml 
0.4 (0.3-
0.6) 
0.5 (0.4-
0.6) 
0.4 (0.4-
0.5) 
0.4 (0.3-
0.5) 
NS 
IL-12 
pg/ml 
- 18 (0-
88.0) 
2.5 (0-
5.7) 
3.0 (0-
16.2) 
- 
 
ap<0.003 between HIV-ve control vs. TN, PI & NNRTI;  
bp<0.006 between HIV-ve control vs. TN, PI & NNRTI; cp<0.05 between 
NNRTI vs. TN & PI   
dp<0.0001 between HIV-ve controls vs. HIV positive groups; ep<0.01 
between TN vs.  PI and NNRTI group.  
fP<0.03 between TN vs. control, PI & NNRTI gp<0.01 between PI vs. HIV-
ve control, TN & NNRTI and hp<0.001 between TN vs. HIV-ve control.  
iP<0.01 between HIV-ve control vs. TN, PI & NNRTI;  jp<0.01 between PI 
vs. HIV-ve control & NNRTI  and  TN VS. HIV-ve control & NNRTI   
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5.3.4. Relation between apo-B kinetics, body fat distribution, 
HOMAIR and adipocytokines (table 5.2- 5.8) 
There was a negative correlation of adiponectin with HOMAIR (r=0.4, 
p<0.0001) and positive correlation with limb fat/LBM (r=0.6, p<0.0001, 
figure 5.1 and table 5.2) and with total fat/LBM (r=0.4, p<0.003, figure 
5.2 and table 5.2). Leptin correlated with total fat/LBM (r=0.87, 
p<0.0001) and limb fat/LBM (r=0.79, p<0.0001, table 5.2).  
Adiponectin correlated positively with serum HDL-cholesterol (r=0.6, 
p<0.0001, table 5.3), VLDL, IDL and LDL apo-B FCR (r=0.5, 0.5, 0.4, 
p<0.0001, 0.0001 and 0.004 respectively, table 5.4 and figure 5.3, 5.4, 
5.6 respectively) and negatively with serum TG [(r=0.53,p<0.0001) table 
5.3], VLDL, IDL and LDL  apo-B pool size (r=0.46, 0.3, 0.42, 
p<0.001,0.01 and 0.001, table 5.5, 5.6 and 5.7 respectively) , VLDL TG, 
VLDL-C, VLDL residence time (r=0.48, 0.5, 0.46 p<0.0001, table 5.5), 
IDL-C, IDL residence time (r=0.44, 0.5, p<0.0001 table 5.6 ), LDL-C, 
LDL-RT (r=0.25, 0.36, p<0.04, 0.004 respectively, table 5.7).  
Adiponectin correlated positively with leptin (r=0.26, p<0.01), negatively 
with IL-8 [(r=0.3, p<0.01, table 5.2) and TNF-R1 (r=0.3, p<0.03, table 
5.8).  
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Table 5.2: Correlations between adiponectin, HOMA, leptin, IL-8 and fat distribution (Spearman) 
 
  
Serum 
adiponectin 
(ug/ml) 
HOMAIR  
(insulin.glucose
/22.5) 
Leptin 
(ng/ml) 
IL-8 
(pg/ml) 
Total fat / 
lean mass 
Limb fat / lean 
mass 
Correlation 
Coefficient (r) 
-.43(**) .26(*) -.30(*) .40(**) .60(**) 
Serum adiponectin 
(ug/ml) 
 
 
Sig. (2-tailed) 
 
.000 .032 .017 .003 .000 
Correlation 
Coefficient (r) 
-.43(**) .293(*) -.079 .199 .013 
HOMAIR 
(insulin.glucose/22.
5) Sig. (2-tailed) .000 
 
.017 .545 .112 .921 
Correlation 
Coefficient (r) 
.26(*) .29(*) 
-
.328(**) 
.874(**) .787(**) 
Leptin (ng/ml) 
Sig. (2-tailed) .032 .017 
 
.009 .000 .000 
Correlation 
Coefficient (r) 
-.30(*) -.07 
-
.328(**) 
-.323(*) -.398(**) 
IL-8 (pg/ml) 
Sig. (2-tailed) .017 .54 .009 
 
.011 .001 
Correlation 
Coefficient (r) 
.40(**) .2 .874(**) -.323(*) .913(**) 
Total fat / lean 
mass 
Sig. (2-tailed) .003 .112 .000 .011 
 
.000 
Correlation 
Coefficient (r) 
.60(**) .013 .787(**) 
-
.398(**) 
.913(**) 
Limb fat / lean 
mass 
  Sig. (2-tailed) .000 .921 .000 .001 .000 
 
 
** Correlation is significant at the 0.01 level (2-tailed).    *  Correlation is significant at the 0.05 level (2-tailed). 
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Table 5.3: Correlations between adiponectin, HOMAIR, lipids and FFA 
 
  
Total 
cholesterol 
(mmol/L) 
HDL 
cholesterol 
Total 
triglyceride 
Free fatty 
acids mmol/l 
LDL cholesterol 
mmol/l 
Correlation 
Coefficient (r) 
-.251(*) .60(**) -.532(**) .093 -.255(*) 
Serum 
adiponectin 
ug/ml 
 
 
Sig. (2-tailed) 
.043 .000 .000 .458 .044 
Correlation 
Coefficient (r) 
.193 -.413(**) .373(**) -.086 .128 
HOMAIR 
(insulin.glucos
e /22.5) 
 
 
Sig. (2-tailed) 
.120 .001 .002 .495 .316 
 
** Correlation is significant at the 0.01 level (2-tailed).  *  Correlation is significant at the 0.05 level (2-tailed). 
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Table 5.4: Correlations between adiponectin, HOMAIR, apo-B FCR and fat distribution 
 
  
Serum 
adiponectin 
(ug/ml) 
HOMAIR  
(insulin.glucose
/22.5) 
VLDL FCR 
(pools/day) 
IDL FCR 
(pools/day) 
LDL FCR 
(pools/day) 
Correlation 
Coefficient(r) 
-.432(**) .50(**) .50(**) .40(**) 
Serum adiponectin 
(ug/ml) 
 Sig. (2-tailed) 
 
.000 .000 .000 .004 
Correlation 
Coefficient(r) 
-.432(**) -.290(*) -.299(*) -.334(**) 
HOMAIR 
(insulin.glucose 
/22.5) 
 
Sig. (2-tailed) 
.000 
 
.018 .022 .008 
Correlation 
Coefficient(r) 
.50(**) -.290(*) .746(**) .700(**) 
VLDL FCR 
(pools/day) 
 Sig. (2-tailed) .000 .018 
 
.000 .000 
Correlation 
Coefficient(r) 
.50(**) -.299(*) .746(**) .557(**) 
IDL FCR (pools 
/day) 
 Sig. (2-tailed) .000 .022 .000 
 
.000 
Correlation 
Coefficient(r) 
.40(**) -.334(**) .700(**) .557(**) 
LDL FCR 
(pools/day) 
 Sig. (2-tailed) .004 .008 .000 .000 
 
 
** Correlation is significant at the 0.01 level (2-tailed).   * Correlation is significant at the 0.05 level (2-tailed). 
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Table 5.5: Correlations of adiponectin, HOMAIR and VLDL fractions 
 
  
VLDL FCR 
(pools/day) 
VLDL ASR 
(mg/kg/day) 
ApoB 
pool size 
mg 
VLDL chol 
(mmol/l) 
VLDL 
triglyceride 
(mmol/l) 
VLDL residence 
time (h) 
Correlation 
Coefficient (r) 
.465(**) -.182 
-
.461(**) 
-.500(**) -.484(**) -.464(**) 
Serum 
adiponectin 
(ug/ml) 
 
Sig. (2-tailed) 
.000 .143 .000 .000 .000 .000 
Correlation 
Coefficient (r) 
-.290(*) .070 .365(**) .442(**) .428(**) .290(*) 
HOMAIR 
(insulin.glucose 
/22.5) 
 
Sig. (2-tailed) 
.018 .576 .003 .000 .000 .018 
** Correlation is significant at the 0.01 level (2-tailed). *  Correlation is significant at the 0.05 level (2-tailed). 
 
 
Table 5.6: Correlations of adiponectin, HOMAIR and IDL fractions 
  
IDL FCR 
pools/day 
IDL ASR 
(mg/kg/
day) 
IDL Apo-B 
pool size 
(mg) 
IDL 
cholesterol 
(mmol/l) 
IDL 
triglyceride 
(mmol/l) 
IDL residence 
time (h) 
Correlation 
Coefficient (r) 
.499(**) .345(**) -.307(*) -.441(**) -.154 -.500(**) 
Serum adiponectin 
(ug/ml) 
 Sig. (2-tailed) .000 .008 .012 .000 .216 .000 
Correlation 
Coefficient (r) 
-.299(*) -.233 .135 .154 .044 .304(*) 
HOMAIR 
(insulin.glucose 
/22.5) 
 
Sig. (2-tailed) 
.022 .079 .279 .218 .725 .020 
** Correlation is significant at the 0.01 level (2-tailed).  *  Correlation is significant at the 0.05 level (2-tailed). 
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Table 5.7: Correlations of adiponectin, HOMAIR and LDL fractions 
  
LDL FCR 
pools/day 
LDL ASR 
(mg/kg/
day) 
LDL apoB 
g 
LDL 
cholesterol 
g/l 
LDL 
triglyceride 
mmol/l 
LDL 
residence 
time (h) 
Correlation 
Coefficient (r) 
.361(**) .225 
-
.426(**) 
-.250(*) -.205 -.361(**) 
Serum adiponectin 
ug/ml 
Sig. (2-tailed) .004 .076 .001 .048 .107 .004 
Correlation 
Coefficient (r) 
-.334(**) 
-
.329(**) 
.314(*) .127 .028 .335(**) 
HOMAIR 
(insulin.glucose 
/22.5) Sig. (2-tailed) .008 .008 .012 .323 .827 .007 
**  Correlation is significant at the 0.01 level (2-tailed). *  Correlation is significant at the 0.05 level (2-tailed). 
 
 
 
Table 5.8: Spearman’s Correlations between adipocytokines and HOMA 
 
  
TNF-α 
(pg/ml) 
TNF 
soluble 
receptor I 
(pg/ml) 
TNF soluble 
receptor II 
(pg/ml) IL-8 (pg/ml) Leptin (ng/ml) 
Correlation 
Coefficient (r) 
-.159 -.271(*) -.063 -.306(*) .264(*) 
Serum adiponectin 
ug/ml 
 Sig. (2-tailed) .207 .035 .653 .017 .032 
Correlation 
Coefficient (r) 
.043 .062 .043 -.079 .293(*) 
HOMAIR 
(insulin.glucose 
/22.5) 
 
Sig. (2-tailed) 
.734 .636 .759 .545 .017 
**  Correlation is significant at the 0.01 level (2-tailed).  * Correlation is significant at the 0.05 level (2-tailed). 
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Figure 5.1: Correlation of adiponectin with limb fat / LBM (LBM: lean body mass) 
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Figure 5.3: Correlation of adiponectin with VLDL apo-B FCR 
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Figure 5.4: Correlation of adiponectin with IDL apo-B FCR 
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                                              Figure 5.5: Correlation of adiponectin with LDL apo-B FCR 
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5.3.5. Linear regression analysis 
In a linear regression model adiponectin predicted VLDL, IDL and LDL 
apo-B FCR (p= 0.01, p<0.001, p=0.02 respectively) and HDL cholesterol 
(p<0.001) and negatively predicted VLDL triglyceride (p=0.004),  
IDL apo-B pool size (p=0.04), LDL apoB pool size (p=0.01) and total 
triglyceride (p<0.001). HOMAIR predicted VLDL apoB concentration 
(p=0.02), VLDL cholesterol (p=0.002) and LDL apoB pool size (p=0.04) 
and negatively predicted LDL ASR (p=0.02).  Leptin predicted VLDL 
triglyceride (p=0.002), IDL apo-B pool size (p=0.004), and LDL 
cholesterol (p=0.02). TNF-α negatively predicted LDL ASR (p=0.01) and 
HDL cholesterol (p=0.002).  IL-8 predicted VLDL triglyceride (p=0.042), 
VLDL apo-B pool size (p=0.02) and LDL triglyceride (p<0.001). The IL-8, 
TNF-α and the soluble receptors TNF-R1 and TNF-R2 did not 
independently predict any of the outcomes tested. 
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5.4. Discussion 
This study has shown that compared to HIV negative controls, HIV 
infected patients taking antiretroviral medication with PI or NNRTI 
containing regimens, as well as treatment naïve patients, show a 
significant reduction in plasma adiponectin level. There was a correlation 
between adiponectin and limb fat loss and also with VLDL, IDL and LDL 
apo-B FCR. Although adiponectin levels correlated inversely with insulin 
resistance, measured by HOMAIR, in a linear regression model which 
included HOMAIR, adiponectin was an independent predictor of VLDL, IDL 
and LDL FCR and HDL cholesterol.  
The decrease in adiponectin in HIV patients in the present study is in 
agreement with previous studies in HIV patients with lipodystrophy [387] 
although to our knowledge reduced adiponectin levels have not been 
previously reported in HIV treatment-naïve patients without lipoatrophy. 
It has been suggested that low adiponectin levels may lead to insulin 
resistance and the insulin resistance may cause the abnormalities in lipid 
metabolism in HIV lipodystrophy [387]. However we were unable to 
demonstrate a significant change in insulin resistance, as measured by 
HOMAIR, in any of the treatment groups. Moreover, although HOMAIR 
correlated with VLDL FCR, the effect was less striking than adiponectin 
and disappeared in the regression model when adiponectin was added. 
Leptin levels, which correlated closely with limb and total fat/LBM, did not 
correlate with VLDL, IDL or LDL apoB FCR. Adiponectin levels were 
significantly lower in the dyslipidaemic patients than patients with normal 
lipid levels, whereas HOMAIR and leptin levels were not different. Our 
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results suggest a role for adiponectin in VLDL, IDL and LDL metabolism 
which could be independent of insulin action.  
In this study peripheral fat loss was associated with low plasma 
adiponectin level. Atrophic adipose tissue contains poorly developed 
adipocytes with marked alteration in gene expression including 
adiponectin [290, 557]. Lihn et al [425] investigated the implications of 
cytokines for adiponectin levels by determining circulating levels of TNF-α, 
IL-6 and IL-8 as well as gene expression of these cytokines in 
lipodyststrophic adipose tissue. Patients with lipodystrophy exhibited 
reduced plasma adiponectin levels and correspondingly, adiponectin mRNA 
levels in adipose tissue were reduced by more than 50%. The patients 
were insulin resistant, and a positive correlation was found between 
plasma adiponectin and insulin sensitivity and percent limb fat. Adipose 
tissue mRNA of TNF-α, IL-6 and IL-8 was increased in lipodystrophic 
subjects and both adipose tissue TNF-α mRNA and plasma TNF-α were 
negatively correlated to plasma adiponectin. In our study, TNF-α and IL-8 
had negative correlation with adiponectin confirming previous studies 
[425, 558, 559]. Both TNF- α and IL-8 were higher in HIV treatment naïve 
patients but returned to control levels, reflecting the reduced immune 
activation after initiation of antiviral therapy. We were not able to 
comment on IL-6 as it was undetectable in most of the samples. This 
could be due to the assay we have used for the estimation of IL-6. 
Cross-sectional studies [555, 560] revealed correlation of increased 
cytokine expression with current use of antiretroviral therapy, greater 
severity of lipoatrophy, and a greater degree of macrophage infiltration in 
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adipose tissue. More macrophage infiltration, cytokine expression, and 
mtDNA depletion were noted with stavudine or zidovudine therapy but not 
following initiation of abacavir [561]. No significant effect of protease 
inhibitor therapy was detected. Switching from stavudine or zidovudine 
was associated with increased mtDNA content and reduced macrophage 
numbers and cytokine expression, although without improvement in body 
fat mass. The inflammatory cytokines produced by macrophages, which 
are likely to be present to phagocytose dead or dying adipocytes, may 
exacerbate lipoatrophy[561].  
Since VLDL, IDL and LDL apo-B fractional clearance rate correlated with 
limb fat this suggests that the primary abnormality may be lipoatrophy. It 
is likely that lipoatrophy leads to reduced gene expression of adiponectin. 
Reduced plasma adiponectin may lead to reduced clearance of VLDL, IDL 
and LDL apo-B by inhibiting lipoprotein lipase. Lipoprotein lipase mRNA 
has also been shown to be lower in HIV patients with lipodystrophy 
compared to patients without lipodystrophy [290] suggesting regulation 
may be at the level of transcription. Using real time PCR from fat biopsies 
Boothby et al [562] showed decrease in 11β-HSD1 mRNA and LPL gene 
expression in HIV patients but increase after ARV treatment alongside 
markers of adipocyte differentiation, lipid and glucose metabolism. The 
subjects did not have any lipodystrophy. 
The association of LDL apoB FCR with adiponectin may also indicate a role 
for adiponectin in the control of LDL receptor number. By increasing the 
number of LDL receptors, adiponectin can increase LDL uptake by the liver 
and can cause increased clearance of LDL apo-B from the circulation. 
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Adiponectin has been found to have a positive correlation with serum HDL 
level [387, 563, 564]. Low adiponectin can be associated with increased 
hepatic lipase (HL) activity which causes breakdown of TG-rich HDL in to 
smaller HDL with rapid clearance from circulation. Low adiponectin in our 
study was associated with delayed clearance of apo-B containing 
lipoproteins including VLDL, IDL and LDL apo-B with a prolonged residence 
time resulting in low HDL level. This suggests again that adiponectin may 
have an important role in HDL metabolism independent of insulin 
resistance.  
In summary we were able to demonstrate that loss of peripheral fat in HIV 
patients resulted in decreased plasma adiponectin and leptin but not other 
measured adipocytokines. Decreased adiponectin but not leptin was 
associated with changes in VLDL, IDL and LDL apo-B kinetics. The effect 
of adiponectin on apo-B kinetics was independent of insulin resistance and 
other cytokines.  
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Chapter 6 
Concluding Discussion 
6.1. Overall Summary 
This study, to our knowledge the largest of its kind, has investigated the 
apo-B metabolism in different lipoprotein components including VLDL, IDL 
and LDL and further investigated the relation between apo-B metabolism, 
regional body fat distribution, insulin resistance and adipocytokines in HIV 
infected-treatment naïve patients and those on established triple antiviral 
treatment and compared these with HIV negative controls. 
In the current study, four groups of subjects were included. The cases 
included HIV positive treatment naïve and HIV positive treatment groups 
which again was divided in to PI and NNRTI group. The NNRTI group was 
divided further in to nevirapine and efavirenz group. The controls were 
HIV negative individuals.  This gave the opportunity of comparing the 
results in different groups and also gave the opportunity of observing the 
effect of HIV and antiretroviral drugs on different metabolic functions 
including fat distribution. This is important, since a chronic HIV infection 
itself induces expression of inflammatory cytokines [131, 132]. It has 
been shown that human preadipocytes express CD4, CXCR4 and CCR5 
receptors, which are necessary for entry of HIV into inflammatory host 
cells viruses [22, 23]. Adipocytes at least in vitro, can actually express 
viral proteins [565]. Therefore the mere presence of HIV may influence 
gene expression in adipocytes and influence on fat distribution and 
metabolism as well. When results were compared between HIV-infected 
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groups and two different HAART-treated groups, these potential 
interferences have been avoided. 
The subjects were matched for age, ethnicity, BMI, and also for gender 
with the exception of the control group where number of female subjects 
was higher. However, the results of the study did not change when gender 
was included as a covariate in the analyses. 
We have shown that HIV infected patients taking antiretroviral medication 
with PI or NNRTI containing regimens, with mild dyslipidaemia, show a 
significant reduction in VLDL, IDL and LDL apoB FCR and consequently a 
longer residence time compared to HIV negative controls. Moreover these 
studies have shown that patients on antiretroviral treatment had a 
significantly lower peripheral fat content than HIV negative and HIV 
positive treatment naïve controls. In all subjects there was a positive 
correlation between VLDL, IDL and LDL apoB FCR and peripheral fat. 
While treatment naive patients were not significantly different from the 
control subjects in terms of serum triglyceride and total cholesterol, the 
apoB kinetics, or regional fat distribution they exhibited, had a trend in 
the same direction as the antiretroviral treated patients in almost all the 
variables measured. There were no significant differences between PI and 
NVP or EFV groups when compared to one another. However, compared to 
the control subjects PI-treated patients exhibited raised serum 
triglyceride, VLDL-TG and IDL TG and IDL-cholesterol but not exhibited by 
NVP or EFV treatment groups.  
This study has further shown that HIV infected patients taking 
antiretroviral medication with PI or NNRTI containing regimens, as well as 
treatment naïve patients, had a significant reduction in adiponectin 
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compared to HIV negative controls. There was a strong correlation 
between adiponectin and limb fat loss and also with VLDL, IDL and LDL 
apo-B FCR and serum HDL-cholesterol.  
6.2. Fat distribution  
The change in fat distribution which follows antiretroviral treatment is a 
complex interrelation between peripheral fat loss and visceral fat 
accumulation [76, 205, 566, 567]. Some host related risk factors for fat 
distribution apart from antiretroviral therapy have been identified in 
different studies [221, 223, 245]. In this study we did not find any effect 
of host related fators including gender, age, ethnicity, body mass index 
when they were used as covariates. 
There is also evidence that HIV infection itself may cause some 
subcutaneous fat loss [250-252]. The baseline viral load or viral 
suppression, baseline CD-4 count or change of CD-4 count after treatment 
did not have any effect on our result. Pro-inflammatory cytokines 
including TNF-α may have effect on fat loss [277]. In our study the 
cytokines including TNF-α, IL-8 did not have any correlation with fat loss 
in the periphery or fat accumulation in the trunk. Our study showed 
peripheral fat was reduced to a similar extent in all the HIV treatment 
groups including patients on NNRTI-containing antiretroviral regimens 
despite different time exposure to anti-retroviral therapy. Although PI use 
has been shown to contribute to the central fat accumulation, results from 
our study did not show any difference in trunk fat between different 
groups. The fat loss due to antiretroviral therapy is thought to be mainly 
the result of the NRTI backbone of HAART regimens through their 
interference with mitochondrial DNA polymerase-gamma[213, 223, 568]. 
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In the ACTG 5142 study [172] patients on NNRTI arm had more 
peripheral fat loss and PI had less. Further analysis of the same study 
[202] however, showed that the fat loss was predicted by thymidine 
analogues, baseline CD 4 count and probably not by NNRTIs. In another 
study [203] compared to ritonavir boosted PI monotherapy, lipoatrophy 
was significantly higher in the efavirenz, zidovudine and lamivudine 
combination treatment arm. However, the increased lipoatrophy could be 
due to the effect of zidovudine in the efavirenz arm. On the other hand 
the ritonavir boosted PI may have protective effect on fat loss [327]. In 
relation to body fat changes the interaction of NRTIs and PIs and recently 
NNRTIs is considered to be the dominant predictor of subcutaneous fat 
loss and visceral fat accumulation [569]. Nolan et al [76] suggested that 
interaction of different classes of antiretrovirals have more effct in fat 
distribution than any single class. Most of the patients in our study were 
on thymidine analogue as nucleoside backbone and the absence of 
changes in fat distribution in the treatment group might be a combined 
effect of the thymidine and non-thymidine analogues with PI and NNRTI.  
 
6.3. Dyslipidaemia 
The dyslipidaemia in the patients in our study was less marked than in 
many previous studies, many of which had been performed in patients 
taking PI-containing medication. Efavirenz containing HAART regimens are 
also reported to raise serum cholesterol and triglyceride levels while NVP 
containing regimens appear to have a better lipid profile than PI and EFV 
[176]. In this study PI-containing regimens found to have a greater 
dyslipidaemic effect compared to NNRTI in particular causing an increase 
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in serum total TG, and TG containing apo-b lipoproteins including VLDL 
and IDL -TG and LDL-TG concentration. The effect becomes more obvious 
in ritonavir containing PI regimens. 
The nature of the apo-B containing particle secreted from the liver is 
related to the plasma FFA and triglyceride level. At low levels of plasma 
triglyceride (<1.0 mmol/l) a substantial portion (up to 50%) of apoB is 
released as VLDL of smaller size, also known as VLDL2 and directly as IDL 
or LDL [102] but at high normal levels of TG more than 90% of apoB is 
secreted in the form of TG rich VLDL, also known as VLDL1. 
Figure 6.1: Two metabolically distinct pools in LDL (α  and ß) arise from 
different sources (adapted from Packard et al [570]).  
PL: phospholipid; CE: cholesteryl ester; TG: triglyceride; HE: hepatic 
lipase; LPL: lipoprotein lipase; CETP: cholesteryl ester transfer protein; 
RT: residence time; CIII: apolipoprotein CIII. 
 
 
Kinetic evidence suggests that there are two distinct metabolic LDL pool in 
plasma (α and ß) and the two pools arise from different sources. The two 
LDL species have substantially differing residence times (RT) in the 
circulation [570]). Pool α is the major species detected by 
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multicompartmental modelling of subjects with low normal plasma 
triglyceride levels and is rapidly cleared by receptors. The LDL with the 
kinetic properties of longlived pool ß has been shown to be the product of 
larger VLDL (VLDL1) delipidation [570]. Hence generation of LDL of 
smaller particle size is favoured when plasma triglyceride is high and 
hepatic lipase (HL) is in the normal range. When plasma TG levels are 
high larger VLDL (VLDL 1) are the main species and they are catabolised 
either to smaller VLDL (or VLDL 2), IDL and LDL by the action of LPL and 
the pathway leads to the formation of TG rich LDL (pool B, figure 6.1). 
The TG rich LDL becomes smaller by the action of HL  taking longer time 
in the clearance, leaving with time an increasing proportion of long-lived 
pool ß, a species with a relatively low affinity for receptors [571].  
In our study PI-containing regimens had higher serum total TG including 
VLDL-TG, and IDL -TG and LDL-TG concentration compared to NNRTI. 
However, the LDL-C concentration was similar and also the particle size of 
different apo-B containing lipoproteins was similar. The particle size was 
different in another study [462]. The apo-b containing lipoprotein particle 
size can be measured directly by other techniques that could give a more 
accurate estimation than the indirect method we have used in our study. 
Using nuclear magnetic resonance (NMR) method Riddler et al [572] 
measured the size of LDL particles and has shown that the LDL particle 
size can be different in HIV patients compared to HIV negative patients 
and patients on ART have more smaller LDL particles.   
The dyslipidaemic effect was more marked in patients using ritonavir 
containing PI regimen with more delay in clearance of VLDL, IDL and LDL-
apo-B and increase in VLDL, IDl and LDL apo-B pool size. This has already 
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been described in other studies [130]. Delayed clearance of apo-B or 
prolonged residence time exposes the apo-B for oxidation [463], but in 
our study the oxidised LDL-apoB was similar in all the groups. This again 
could be different assay we have used in our study. 
This study, demonstrates that the mild dyslipidaemia in the treatment 
groups is due to a decrease in VLDL, IDL and LDL apo-B FCR. The 
resulting increased residence time will allow increased exchange of 
triglyceride from apoB containing lipoproteins with HDL and LDL 
cholesterol (figure 1.6b, 6.2). This could explain the reduced HDL 
cholesterol seen in all our HIV groups. 
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Figure 6.2: HDL metabolism thorugh cholesterol ester transfer 
protein(CETP) exchange [104]. CE: cholesteryl ester; HL: hepatic lipase; 
LCAT: lecithine cholesterol acyle transferase 
 
  
 
6.4. Relation of Fat Distribution and Dyslipidaemia  
Association of metabolic abnormalities with excess adiposity has been 
demonstrated in several previous studies [474-477]. Excess intra-
abdominal, particularly visceral rather than peripheral or subcutaneous fat 
is more strongly associated with diabetes, hypertension and 
cardiovascular disease, indicating wider metabolic differences within the 
different adipose tissue regions. In our study the decrease in VLDL, IDL 
and LDL apoB FCR was strongly associated with peripheral fat loss. In a 
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regression model, regional fat changes including the peripheral fat losses 
predicted VLDL, IDL and LDL apoB FCR and VLDL, IDL and LDL cholesterol 
concentrations. These findings suggest that there may be common 
mechanisms shared between the regional fat redistribution and the 
metabolism of apoB-containing lipoproteins. This may be related to an 
interference of antiretroviral treatment with lipoprotein lipase which is or 
may be closely linked to the lipodystrophy through yet undefined 
mechanism. This is supported by the finding in another study [290] that 
lipoprotein lipase mRNA was lower in HIV patients with lipodystrophy 
compared to patients with no lipodystrophy.  HIV infection itself has also 
been reported to reduce lipoprotein lipase and impair hepatic lipase 
activity [132]. The trend towards a reduction in VLDL, IDL and LDL apoB 
FCR and in crease in VLDL, IDL and LDL residence time and a significant 
increase in VLDL and IDL triglyceride in HIV treatment naive patients 
compared to controls would be in keeping with these reports. While short 
term exposure of healthy volunteers to PI has no effect on lipoprotein 
lipase activity it has been shown to reduce hepatic lipase [194]. Longer 
treatment with PI-containing HAART regimens is reported to result in 
reduced lipoprotein lipase activity [573]. PI treatment and lipodystrophy 
has been previously shown to be associated with insulin resistance [154]. 
This too may result in impairment in lipoprotein lipase activity. However, 
the activity of hepatic lipase could be altered rather than diminished as it 
has reciprocal relationship with lipoprotein lipase activity as discussed 
earlier in this chapter.   
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6.5. Insulin Resistance 
Prevalence of insulin resistance in HIV patients is higher compared to age 
and sex matched non-HIV population [312]. Insulin resistance is higher in 
patients on PIs [488]. We were unable to demonstrate a significant 
change in insulin resistance as measured by HOMAIR in any of the 
treatment groups. However, in a regression model insulin sensitivity 
predicted VLDL apoB FCR, while insulin resistance predicted apo-B pool 
size, cholesterol and triglyceride content and IDL ASR. This could possibly 
be mediated by the action of insulin on lipoprotein lipase activity. Central 
obesity and increased visceral fat is strongly associated with insulin 
resistance [574-576]. The failure to find a significant change in insulin 
resistance between groups in the present study may be explained by the 
lack of a significant change in trunk fat or the relatively small numbers in 
our study. However, when the groups were combined there was a highly 
significant negative correlation between trunk fat and HOMA. In the 
present study the visceral fat was not measured separately from trunk fat. 
Visceral adiposity is a better predictor of insulin resistance than trunk fat 
and subcutaneous adipose tissue in the abdominal wall may not have any 
association with insulin resistance. Interestingly trunk fat, VLDL apoB FCR 
and apoB concentration, FFA, and HOMA were significantly higher in 
patients with dyslipidaemia (cholesterol ≥6 mmol/l or triglyceride ≥2.3 
mmol/l) compared to those without. The association between visceral fat 
and insulin resistance and dyslipidaemia is well-documented [475]. 
Dyslipidaemia is associated with insulin resistance and trunk fat 
accumulation. However, mild dyslipidaemia in the absence of significant 
insulin resistance may not be affected by trunk fat accumulation. 
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The LDL concentration was not increased in the treatment arm or not 
decreased in the treatment naïve arm or decreased compared to control 
subjects. This is dissimilar to many other studies and could be due to the 
fact that we have excluded patients who were unable to stop lipid lowering 
treatment at the time of the study. However, the variation in LDL 
concentration is not as common as in the other lipid parameters in HIV 
patients.  The LDL cholesterol concentration is determined by the 
synthesis and clearance of LDL-cholesterol and a decrease in both LDL 
ASR and LDL FCR will result a normal concentration as we found in our 
study in all HIV patient groups.  
The decrease in LDL apoB ASR and FCR was greater in the PI group, 
particularly in patients treated with ritonavir.  This has already been well 
documented in previous studies which have shown ritonavir to have a 
greater lipodystrophic and dyslipidaemic effect than other PIs [577]. In 
our study, the LDL kinetics were not different in the PI and NNRTI group 
compared to treatment naïve (TN) group. But when the patients in the PI 
group were subdivided into those treated with ritonavir and those treated 
with other PIs, the abnormal LDL kinetics were exacerbated in the 
ritonavir treatment arm.  The low level of LDL apo-b FCR in ritonavir 
treated arm may be due to defective binding of LDL to the LDL receptor 
[473] or reduction of LDL receptor number in the patient group.  
However, a study of treated and untreated HIV patients with and without 
lipodystrophy showed that HIV-lipodystrophy was associated with a lower 
expression of LDL receptors and was not related to PI treatment [193].  
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Hence other mechanisms may also play a role. While hepatic lipase 
contributes to the remodelling of apo-B containing lipoproteins it also 
participates with surface proteoglycans and LDL receptor like protein 
(LRP) as a ligand for the hepatic uptake of apo-B containing remnant 
lipoproteins and LDL[578]. Decreased hepatic lipase activity may thus 
contribute to the decrease in LDL FCR.  It has also been suggested that 
protease inhibitors may inhibit LRP since the catalytic region of HIV-1 
protease, to which protease inhibitors bind, has approximately 60% 
homology to regions within LRP [181], but this theory has been 
subsequently challenged and probably not tenable any more. Since LDL 
FCR was not different in the PI treated patients from NNRTI or the 
treatment naïve group this is unlikely to be the major mechanism for the 
decrease in LDL FCR seen in the present study.  
The LDL receptor is regulated by the cholesterol content of cells but is also 
under hormonal control both directly and indirectly by altering cholesterol 
content and metabolism. There is evidence that insulin up regulates the 
LDL receptor [579]. A previous study [580] has shown that the expression 
of LDL receptors is reduced in patients with type 2 diabetes with poor 
metabolic control and expression is increased after insulin treatment 
[581]. This provides an explanation for the decrease in LDL FCR observed 
in poorly controlled type 2 diabetic subjects and its normalisation in 
insulin-treated patients [580]. Although steady state insulin resistance 
measured by HOMAIR was not significantly different between groups in the 
present study, HOMAIR values within each group were very variable. The 
negative correlation between HOMAIR and LDL FCR in the current study 
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suggests that insulin resistance, which may down regulate LDL receptors, 
may be one mechanism for the observed decrease in LDL FCR.  
6.6. Adipocytokines 
Association of different cytokines with insulin resistance in HIV patients 
has already been described in previous studies. Some studies have shown 
association of low adiponectin with lipodystrophy in HIV patients [233, 
387, 405, 582, 583], but to our knowledge, low diponectin in the absence 
of lipoatrophy in treatment naïve HIV patients have not been described. 
However, treatment naïve patients may have fat accumulation in the liver 
[584] which can cause low adiponectin and we were not unable to 
comment on fat accumulation in the different visceral cmpartments. In 
this study we were able to show that low adiponectin had strong 
correlation with peripheral fat loss and with clearance of apo-B containing 
lipoproteins independent of insulin resistance. Like adiponectin, leptin was 
low in HIV patients and had correlation with fat loss and insulin resistance, 
but not apo-B clearance rates. Adiponectin levels were significantly lower 
in subjects with dyslipidaemia compared to those whose with normal lipid 
levels, whereas leptin level and levels of other measured cytokines and 
HOMAIR were not different. 
Adiponectin gene expression can be impaired in atrophic adipose tissue 
[425]. In our study the strong correlation of VLDL, IDL and LDL apoB 
fractional catabolic rate (FCR) with limb fat suggests that the primary 
abnormality could be lipoatrophy that leads to reduction of adiponectin 
gene expression resulting low adiponectin level in plasma. Previous 
studies have shown an association of decreased lipoprotein lipase (LPL) 
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activity with low plasma adiponectin. The association was independent of 
systemic inflammation and insulin resistance, suggesting that LPL may 
represent a link between low adiponectin levels and dyslipidemia [520, 
585]. The relation of adiponectin with hepatic lipase is different and a 
significant inverse association between adiponectin and plasma hepatic 
lipase (HL) activity has been demonstated in other study [520]. Lipases 
regulate the flow of the lipoprotein particles through the VLDL-IDL-LDL 
delipidation cascade. Large VLDL are converted to LDL by LPL and hepatic 
lipase (HL) operate at the opposite end of the pathway to transform IDL to 
LDL whereas both LPL and HL enzymes participate in the delipidation of 
smaller VLDL [586]. LPL and HL also facilitate receptor mediated uptake of 
TG rich lipoprpoteins [587]. Low adiponectin level may help HL to act on 
IDL and LDL and also their uptake by hepatic receptor [587-589]. The 
normal level of LDL in our study in all HIV patient groups inspite of having 
significant impairment of catabolism could be explained by the improved 
activity of hepatic lipase (HL) which is invesrsely related to adiponectin 
level. 
 
Reduced plasma adiponectin may lead to reduced clearance of VLDL, IDL 
and LDL apo-B by inhibiting lipoprotein lipase. Lipoprotein lipase mRNA 
has also been shown to be lower in HIV patients with lipodystrophy 
compared to patients without lipodystrophy suggesting regulation may be 
at the level of transcription [290].  
The association of LDL apoB FCR with adiponectin may indicate a role for 
adiponectin in the control of LDL receptor number. In contrast low 
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adiponectin level may increase the activity of hepatic lipase and help 
increased uptake of LDL by the available receptors.  
All the patient groups in our study had low HDL-cholesterol (HDL). The 
metabolism of HDL-cholesterol is complex.  The catabolism of HDL varies 
with its apolipoprotein composition and also the triglyceride (TG) or 
cholesterol ester (CE) content. The liver and the intestine produce nascent 
HDLs. Free cholesterol is acquired from macrophages and other peripheral 
cells and esterified by lecithin-cholesterol acyltransferase (LCAT), forming 
mature HDLs that can be selectively taken up by the liver via scavenger 
receptor class BI (SR-BI). Alternatively, HDL cholesteryl ester can be 
transferred by cholesteryl ester transfer protein (CETP) from HDLs to 
VLDLs and chylomicrons, which can then be taken up by the liver [505, 
570].  
The half life of TG rich HDL are shorter as this is broken down to smaller 
HDL and the individual apolipoproteins like A1 can catabolised to amino 
acids in the liver or can be excreted through kidney [590]. 
Low plasma adiponectin may lead to increased hepatic lipase activity 
[520] which may cause increased breakdown of TG rich HDL into smaller 
HDL which is cleared from circulation rapidly [591]. The TG rich apo-B 
containing will allow exchange of triglyceride for cholesterol esters with 
HDL, which would increase clearance providing a mechanism for the 
reduced HDL-cholesterol seen in both treatment naïve patients and those 
on antiretroviral therapy and may explain the strong correlation of 
adiponectin with HDL-cholesterol.  
Other mechanism can be responsible for low HDL in HIV patients including 
patients in our study. Role of ATP-binding cassette transporter A1 
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(ABCA1) has been shown in patients with low HDL. Free cholesterol from 
from the arterial wall and cell membrane are transferred to apo-A1 by 
ABCA1. The viral protein (nef gene protein [7]) impairs ABCA1-dependent 
cholesterol efflux from human macrophages ABC-A1 seems to play an 
important [201].  
 
6.7. Limitations of the study  
The sample size may have impact on the outcome of different results. 
However, this was the largest study of this kind where apo-B kinetics were 
compared with subjects different groups. 
As opposed to longitudinal or prospective study this was a crosss-sectional 
study and the results have to be looked with some caution. 
The control group had more females compared to other groups. The fat 
distribution in females may have over emphasized the difference in 
peripheral fat distribution compared to HIV positive groups. Only two 
subjects in the control arm had HIV test , others did not and this could be 
regarded as a limitation. 
Body composition was measured using DEXA scan which can measure 
total truncal fat, but not separate the two depots.  In contrast MRI and CT 
imaging allow depot-specific quantification of abdominal subcutaneous vs. 
intra-abdominal fat [492, 592].  Abdominal subcutaneous and intra-
abdominal fat depots are most commonly measured using a single CT or 
MRI scan at the level of L4-L5.  
Lack of MRI and CT imaging due to limited funding should be considered a 
limitation of the current study, since CT and MRI would have provided an 
additional measure of fat mass in the different visceral compartment, 
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even though a good correlation has been shown between the fat mass 
measured in the different regions including the total fat mass in the 
abdomen.  
 The use of different machines for DEXA scan may have some influence on 
the results as well. The use of Hologic and Lunar DEXA scan in different 
patient groups might have added to some heterogeneity of the result as 
the precission of the two different sacns are not same. However, using the 
data separately did not show any effect on the outcome of the results. 
Fifty five subjects used the same machine and the results did not have 
any difference with the overall result.  
We were unable to measure the other apolipoproteins, particularly apo-CI, 
CII and CIII which may have effect on the results. Our study did not look 
at the reverse cholesterol transport which may have some effect on the 
result as well. We measured HDL-cholesterol, but not the different 
fractions of HDL or the apolipoproteins namely apo-A1. 
We measured adiponectin whole molecule and the effect of different 
fractions or dimmers and trimmers have different actions or the whole 
molecular assay may not reveal the function of adiponectin as a whole.  
However, this study in spite of these limitations describes some important 
findings which may have some important impact on the understanding of 
the mechanism of dyslipidaemia and fat distribution in HIV patients with 
all these limitations  
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6.8 Conclusion 
In conclusion our data suggests that in patients with mild dyslipidaemia 
reduced VLDL, IDL and LDL apoB FCR and consequently an increased 
residence time may be a primary abnormality in lipoprotein kinetics in HIV 
infection, possibly consequent to body fat redistribution. Similar 
abnormalities were found in patients treated with either a protease 
inhibitor, or NNRTI containing HAART regimens. The association of apoB 
FCR with regional fat distribution suggests a common mechanism for 
lipodystrophy and abnormal VLDL, IDL and LDL metabolism. The latter 
may be due to a decrease in hepatic lipase, down regulation of the LDL 
receptor or LDL related receptor or a combination of all these. The 
increased residence time will lead to increased LDL oxidation and 
atherogenesis thus contributing to the increased risk for CHD reported in 
these patients.   
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Chapter 7 
FUTURE DIRECTIONS 
In our study we have shown that antiretroviral treatment significantly 
reduced VLDL, IDL and LDL apoB FCR compared to HIV negative controls. 
This suggests an impairment of lipoprotein lipase and hepatic lipase by 
antiretroviral therapy. This appears to be an accentuation of the trend 
seen in treatment naïve HIV-infected patients. 
Cytokines may also affect lipid metabolism [131, 132, 200, 593]. TNF-α 
secreted by fat cells, has important local regulatory effects on the 
adipocyte [594, 595]. Interferon-α has also been shown to down regulate 
the activities of hepatic and lipoprotein lipase and cholesterol ester 
transfer proteins[131].  
The exact role of adiponectin and other adipocyte secretary products 
remains to be determined, but is likely to be important. This study 
complements others highlighting the important role played by the 
adipocyte in the metabolic abnormalities in HIV infection. Previously Nolan 
proposed an adipocentric model [76] to explain both the lipodystrophy 
and metabolic abnormalities seen in antiretroviral therapy where the most 
powerful determinant is peripheral fat wasting, and where NRTI-induced 
mitochondrial toxicity interacts with PI-induced insulin resistance and 
impaired adipocyte maturation.  
Lamivudine (3TC), emtricitabine (FTC) and the nucleotide analogue 
tenofovir have a less toxic effect on mtDNA, produce less dyslipidaemia 
[167, 170, 596] and would be expected to result in less lipodystrophy 
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than the thymidine analogues d4T and AZT. Similarly abacavir (ABC) 
causes less lipodystrophy [163, 208] and FTC may have less effect on 
DNA polymerase-γ than 3TC. Thus if the lipoatrophy is an important 
mechanism underlying the metabolic abnormalities of HIV which is 
accelerated and accentuated by some ART regimens then ART regimens 
with the least lipoatrophic effect would be expected to cause the least long 
term disturbance in lipid and glucose metabolism.  
A recent study [179] has shown that HIV replication alone without any 
influence of antiretroviral drugs enhances production of free fatty acids, 
low density lipoproteins and many key proteins associated in lipid 
synthesis, transport and metabolism. Further studies with these proteins 
may now shed light on how some of these proteins may be useful for early 
diagnosis of individuals who might be at high risk for developing lipid 
related disorders. 
 
Longitudinal studies have shown that peripheral fat loss is progressive in 
the first two years but slows thereafter in a non linear fashion [205]. 
Further studies should be done to find out the changes in mitochondrial 
DNA and nuclear DNA ratio, mtDNA oxidative phosphorylation enzyme 
activity, mitochondrial uncoupling proteins (UCP) and genes involved in 
lipid and glucose metabolism in subcutaneous fat in patients taking AZT 
containing regimen compared to tenofovir or abacavir containing regimen. 
   
Finally, the majority of studies in dyslipidaemia have examined patients 
with long treatment histories, making it difficult to attribute causation of 
metabolic abnormalities to individual drugs. It is therefore necessary for 
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future studies to be conducted prospectively in treatment naive patients, 
which will aid in the understanding of the timeframe of the development 
of this syndrome, as well as providing in-vivo support for the work 
conducted in-vitro. Further work needs to examine the role that genetic 
factors play in the development of dyslipidaemia using large and ethnically 
diverse populations.   
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